• Principal Investigator
  • Male

Prof. dr. L. de Haan

Position: Professor
Main activities: Research, Teaching, Patient care
Specialisation: Psychotic disorders
foto L. de Haan is one of the AMC Principal Investigators
Focus of research:

Early Psychosis and Schizophrenia

AMC themes: Neurological & Psychiatric Disorders
Departments: Psychiatry: Adult Psychiatry
de Wit IE, van Dijk FA, Meijer CJ, van Tricht MJ, de Haan L, Dopamine D-2-receptor affinity of antipsychotics in relation to subjective well-being in patients with a psychotic disorder. INT CLIN PSYCHOPHARM 2017;32 (5):249-255 [PubMed]
Doedens P, Maaskant JM, Latour CHM, Meijel BKGv, Koeter MWJ, Storosum JG, Barkhof E, de Haan L, Nursing Staff Factors Contributing to Seclusion in Acute Mental Health Care - An Explorative Cohort Study. ISSUES MENT HEALTH N 2017;38 (7):584-589 [PubMed]
Frissen A, van Os J, Habets P, Gronenschild E, Marcelis M [Contributors: de Haan L, Meijer CJ, et al -]] , No Evidence of Association between Childhood Urban Environment and Cortical Thinning in Psychotic Disorder. PLOS ONE 2017;12 (1):e0166651 [PubMed]
Grech A, van Os J [Contributors: de Haan L, Meijer CJ, Schirmbeck F, et al -]] , Evidence That the Urban Environment Moderates the Level of Familial Clustering of Positive Psychotic Symptoms. SCHIZOPHRENIA BULL 2017;43 (2):325-331 [PubMed]
Hagen JM, Sutterland AL, Koeter MW, Lutter R, Cohen D, de Haan L, Advanced Glycation End Products in Recent-Onset Psychosis Indicate Early Onset of Cardiovascular Risk. J CLIN PSYCHIAT 2017;-:- [PubMed]
Hartmann JA, McGorry PD, Schmidt SJ, Amminger GP, Yuen HP, Markulev C, Berger GE, Chen EYH, de Haan L, Hickie IB, Lavoie S, McHugh MJ, Mossaheb N, Nieman DH, Nordentoft M, Riecher-Rössler A, Schäfer MR, Schlögelhofer M, Smesny S, Thompson A, Verma SK, Yung AR, Nelson B, Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis. PSYCHOTHER PSYCHOSOM 2017;86 (5):292-299 [PubMed]
Islam MA, Khan MFH, Quee PJ, Snieder H, van den Heuvel ER, Bruggeman R, Alizadeh BZ [Contributors: Bartels-Velthuis AA, van Beveren NJ, Cahn W, de Haan L, Delespaul P, Meijer CJ, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, van Haren NE, van Os J, van Winkel R]] , Familial liability to psychosis is a risk factor for multimorbidity in people with psychotic disorders and their unaffected siblings. EUR PSYCHIAT 2017;45:81-89 [PubMed]
Koenders L, Lorenzetti V, de Haan L, Suo C, Vingerhoets W, van den Brink W, Wiers RW, Meijer CJ, Machielsen M, Goudriaan AE, Veltman DJ, Yücel M, Cousijn J, Longitudinal study of hippocampal volumes in heavy cannabis users. J PSYCHOPHARMACOL 2017;31 (8):1027-1034 [PubMed]
Kraan TC. Environmental risk factors in the ultra high risk stage of psychosis. S.l.: s.n.; 2017. 185p. ISBN 978-90-826049-8-6 Proefschrift Free University, Human movement sciences. (Promotor(s): van der Gaag M, de Haan L; copromotor(s): Velthorst E)
Kraan TC, Ising HK, Fokkema M, Velthorst E, van den Berg DPG, Kerkhoven M, Veling W, Smit F, Linszen DH, Nieman DH, Wunderink L, Boonstra N, Klaassen RMC, Dragt S, Rietdijk J, de Haan L, van der Gaag M, The effect of childhood adversity on 4-year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. PSYCHIAT RES 2017;247:55-62 [PubMed]
Kraan TC, Velthorst E, Themmen M, Valmaggia L, Kempton MJ, McGuire P, van Os J, Rutten BPF, Smit F, de Haan L, van der Gaag M, Child Maltreatment and Clinical Outcome in Individuals at Ultra-High Risk for Psychosis in the EU-GEI High Risk Study. SCHIZOPHRENIA BULL 2017;ahead of print [PubMed]
Linscott RJ, Morton SE [Contributors: Alizadeh BZ, Bartels-Velthuis AA, van Beveren NJ, Bruggeman R, Cahn W, de Haan L, Delespaul P, Meijer CJ, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, van Haren NE, van Os J, van Winkel R]] , The Latent Taxonicity of Schizotypy in Biological Siblings of Probands With Schizophrenia. SCHIZOPHRENIA BULL 2017;ahead of print [PubMed]
Machielsen MWJ, Veltman DJ, van den Brink W, de Haan L, Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. SCHIZOPHR RES 2017;ahead of print [PubMed]
Mansueto G, van Nierop M, Schruers K, Alizadeh BZ, Bartels-Velthuis AA, van Beveren NJ, Bruggeman R, Cahn W, de Haan L, Delespaul P, Meijer CJ, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, van Haren NEM, van Os J, van Winkel R, The role of cognitive functioning in the relationship between childhood trauma and a mixed phenotype of affective-anxious-psychotic symptoms in psychotic disorders. SCHIZOPHR RES 2017;ahead of print [PubMed]
Markulev C, McGorry PD, Nelson B, Yuen HP, Schaefer M, Yung AR, Thompson A, Berger G, Mossaheb N, Schlögelhofer M, Smesny S, de Haan L, Riecher-Rössler A, Nordentoft M, Chen EYH, Verma S, Hickie I, Amminger GP, NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. EARLY INTERV PSYCHIA 2017;11 (5):418-428 [PubMed]
Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, Antaki D, Shetty A, Holmans PA, Pinto D, Gujral M, Brandler WM, Malhotra D, Wang Z, Fajarado KVF, Maile MS, Ripke S, Agartz I, Albus M, Alexander M, Amin F, Atkins J, Bacanu SA, Belliveau RA Jr, Bergen SE, Bertalan M, Bevilacqua E, Bigdeli TB, Black DW, Bruggeman R, Buccola NG, Buckner RL, Bulik-Sullivan B, Byerley W, Cahn W, Cai G, Cairns MJ, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Cheng W, Cloninger CR, Cohen D, Cormican P, Craddock N, Crespo-Facorro B, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, del Favero J, DeLisi LE, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farh KH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedman JI, Forstner AJ, Fromer M, Genovese G, Georgieva L, Gershon ES, Giegling I, Giusti-Rodríguez P, Godard S, Goldstein JI, Gratten J, de Haan L, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms S, Hirschhorn JN, Hoffmann P, Hofman A, Huang H, Ikeda M, Joa I, Kähler AK, Kahn RS, Kalaydjieva L, Karjalainen J, Kavanagh D, Keller MC, Kelly BJ, Kennedy JL, Kim Y, Knowles JA, Konte B, Laurent C, Lee P, Lee SH, Legge SE, Lerer B, Levy DL, Liang KY, Lieberman J, Lönnqvist J, Loughland CM, Magnusson PKE, Maher BS, Maier W, Mallet J, Mattheisen M, Mattingsdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Müller-Myhsok B, Murphy KC, Murray RM, Myin-Germeys I, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nisenbaum L, Nordin A, O'Callaghan E, O'Dushlaine C, Oh SY, Olincy A, Olsen L, O'Neill FA, van Os J, Pantelis C, Papadimitriou GN, Parkhomenko E, Pato MT, Paunio T, Perkins DO, Pers TH, Pietiläinen O, Pimm J, Pocklington AJ, Powell J, Price A, Pulver AE, Purcell SM, Quested D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Savitz A, Schall U, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Silverman JM, Smoller JW, Söderman E, Spencer CCA, Stahl EA, Strengman E, Strohmaier J, Stroup TS, Suvisaari J, Svrakic DM, Szatkiewicz JP, Thirumalai S, Tooney PA, Veijola J, Visscher PM, Waddington J, Walsh D, Webb BT, Weiser M, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wormley BK, Wray NR, Wu JQ, Zai CC, Adolfsson R, Andreassen OA, Blackwood DHR, Bramon E, Buxbaum JD, Cichon S, Collier DA, Corvin A, Daly MJ, Darvasi A, Domenici E, Esko T, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jönsson EG, Kendler KS, Kirov G, Knight J, Levinson DF, Li QS, McCarroll SA, McQuillin A, Moran JL, Mowry BJ, Nöthen MM, Ophoff RA, Owen MJ, Palotie A, Pato CN, Petryshen TL, Posthuma D, Rietschel M, Riley BP, Rujescu D, Sklar P, St Clair D, Walters JTR, Werge T, Sullivan PF, O'Donovan MC, Scherer SW, Neale BM, Sebat J, Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. NAT GENET 2017;49 (1):27-35 [PubMed]
McGorry PD, Nelson B, Markulev C, Yuen HP, Schäfer MR, Mossaheb N, Schlögelhofer M, Smesny S, Hickie IB, Berger GE, Chen EYH, de Haan L, Nieman DH, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung AR, Amminger GP, Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial. JAMA PSYCHIAT 2017;74 (1):19-27 [PubMed]
McHugh MJ, McGorry PD, Yuen HP, Hickie IB, Thompson A, de Haan L, Mossaheb N, Smesny S, Lin A, Markulev C, Schloegelhofer M, Wood SJ, Nieman D, Hartmann JA, Nordentoft M, Schäfer M, Amminger GP, Yung A, Nelson B, The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo. SCHIZOPHR RES 2017;ahead of print [PubMed]
McLaughlin RL, Schijven D, van Rheenen W, van Eijk KR, O'Brien M, Kahn RS, Ophoff RA, Goris A, Bradley DG, Al-Chalabi A, van den Berg LH, Luykx JJ, Hardiman O, Veldink JH [Contributors: Shatunov A, Dekker AM, Diekstra FP, Pulit SL, van der Spek RAA, van Doormaal PTC, Sproviero W, Jones AR, Nicholson GA, Rowe DB, Pamphlett R, Kiernan MC, Bauer D, Kahlke T, Williams K, Eftimov F, Fogh I, Ticozzi N, Lin K, Millecamps S, Salachas F, Meininger V, de Carvalho M, Pinto S, Mora JS, Rojas-García R, Polak M, Chandran S, Colville S, Swingler R, Morrison KE, Shaw PJ, Hardy J, Orrell RW, Pittman A, Sidle K, Fratta P, Malaspina A, Petri S, Abdulla S, Drepper C, Sendtner M, Meyer T, Wiedau-Pazos M, Lomen-Hoerth C, van Deerlin VM, Trojanowski JQ, Elman L, McCluskey L, Basak N, Meitinger T, Lichtner P, Blagojevic-Radivojkov M, Andres CR, Maurel C, Bensimon G, Landwehrmeyer B, Brice A, Payan CAM, Saker-Delye S, Dürr A, Wood N, Tittmann L, Lieb W, Franke A, Rietschel M, Cichon S, Nöuthen MM, Amouyel P, Tzourio C, Dartigues JF, Uitterlinden AG, Rivadeneira F, Estrada K, Hofman A, Curtis C, van der Kooi AJ, de Visser M, Weber M , Shaw CE, Smith BN, Pansarasa O, Cereda C, del Bo R, Comi GP, D'alfonso S, Bertolin C, Sorarù G, Mazzini L, Pensato V, Gellera C, Tiloca C, Ratti A, Calvo A, Moglia C, Brunetti M, Arcuti S, Capozzo R, Zecca C, Lunetta C, Penco S, Riva N, Padovani A, Filosto M, Blair I, Leigh PN, Casale F, Chio A, Beghi E, Pupillo E, Tortelli R, Logroscino G, Powell J, Ludolph AC, Weishaupt JH, Robberecht W, van Damme P, Brown RH, Glass J, Landers JE, Andersen PM, Corcia P, Vourc'h P, Silani V, van Es MA, Pasterkamp RJ, Lewis CM, Breen G, Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, Lee P, Bulik-Sullivan B, Collier DA, Huang H, Pers TH, Agartz I, Agerbo E, Albus M, Alexander M, Amin F, Bacanu SA, Begemann M, Belliveau RA, Bene J, Bergen SE, Bevilacqua E, Bigdeli TB, Black DW, Bruggeman R, Buccola NG, Buckner RL, Byerley W, Cahn W, Cai G, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Chan RCK, Chan RYL, Chen EYH, Cheng W, Cheung EFC, Chong SA, Cloninger CR, Cohen D, Cohen N, Cormican P, Craddock N, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, del Favero J, Demontis D, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Durmishi N, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedl M, Friedman JI, Fromer M, Genovese G, Georgieva L, Giegling I, Giusti-Rodríguez P, Godard S, Goldstein JI, Golimbet V, Gopal S, Gratten J, de Haan L, Hammer C, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms S, Hirschhorn JN, Hoffmann P, Hofman A, Hollegaard MV, Hougaard DM, Ikeda M, Joa I, Julià A, Kalaydjieva L, Karachanak-Yankova S, Karjalainen J, Kavanagh D, Keller MC, Kennedy JL, Khrunin A, Kim Y, Klovins J, Knowles JA, Konte B, Kucinskas V, Kucinskiene ZA, Kuzelova-Ptackova H, Kähler AK, Laurent C, Lee J, Lee SH, Legge SE, Lerer B, Li M, Li T, Liang KY, Lieberman J, Limborska S, Loughland CM, Lubinski J, Lönnqvist J, Macek M, Magnusson PKE, Maher BS, Maier W, Mallet J, Marsal S, Mattheisen M, Mattingsdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Mors O, Murphy KC, Murray RM, Myin-Germeys I, Müller-Myhsok B, Nelis M, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nikitina-Zake L, Nisenbaum L, Nordin A, O'Callaghan E, O'Dushlaine C, O'Neill FA, Oh SY, Olincy A, Olsen L, van Os J, Pantelis C, Papadimitriou GN, Papiol S, Parkhomenko E, Pato MT, Paunio T, Pejovic-Milovancevic M, Perkins DO, Pietiläinen O, Pimm J, Pocklington AJ, Price A, Pulver AE, Purcell SM, Quested D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Schall U, Schubert CR, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Sigurdsson E, Silagadze T, Silverman JM, Sim K, Slominsky P, Smoller JW, So HC, Spencer CCA, Stahl EA, Stefansson H, Steinberg S, Stogmann E, Straub RE, Strengman E, Strohmaier J, Stroup TS, Subramaniam M, Suvisaari J, Svrakic DM, Szatkiewicz JP, Söderman E, Thirumalai S, Toncheva D, Tosato S, Veijola J, Waddington J, Walsh D, Wang D, Wang Q, Webb BT, Weiser M, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wong EHM, Wormley BK, Xi HS, Zai CC, Zheng X, Zimprich F, Wray NR, Stefansson K, Visscher PM, Adolfsson R, Andreassen OA, Blackwood DHR, Bramon E, Buxbaum JD, Børglum AD, Darvasi A, Domenici E, Ehrenreich H, Esko T, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jönsson EG, Kendler KS, Kirov G, Knight J, Lencz T, Levinson DF, Li QS, Liu J, Malhotra AK, McCarroll SA, McQuillin A, Moran JL, Mortensen PB, Mowry BJ, Owen MJ, Palotie A, Pato CN, Petryshen TL, Posthuma D, Riley BP, Rujescu D, Sham PC, Sklar P, St Clair D, Weinberger DR, Wendland JR, Werge T, Daly MJ, Sullivan PF, O'Donovan MC]] , Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. NAT COMMUN 2017;8:14774 [PubMed]
Muller DP, de Haan L, Stoppen met roken en schizofrenie. TIJDSCHR PSYCHIATR 2017;59 (5):297-301 [PubMed]
Pos K, de Wit IE, van Dijk FA, Bartels-Velthuis AA, Bruggeman R, Meijer CJ, de Haan L, Alizadeh BZ, van Beveren NJ, Cahn W, Delespaul P, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, van Haren NE, van Os J, van Winkel R, An experience sampling study on the ecological validity of the SWN-20: Indication that subjective well-being is associated with momentary affective states above and beyond psychosis susceptibility. PSYCHIAT RES 2017;ahead of print [PubMed]
Pos K, Meijer CJ, Verkerk O, Ackema O, Krabbendam L, de Haan L, Metacognitive training in patients recovering from a first psychosis: an experience sampling study testing treatment effects. EUR ARCH PSY CLIN N 2017;ahead of print [PubMed]
Schipper R, Dekker M, de Haan L, van den Brink W, Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series. J PSYCHOPHARMACOL 2017;ahead of print [PubMed]
Schreuder MJ, Schirmbeck F, Meijer C, de Haan L, The associations between childhood trauma, neuroticism and comorbid obsessive-compulsive symptoms in patients with psychotic disorders. PSYCHIAT RES 2017;254:48-53 [PubMed]
Tedja A, Velthorst E, van Tricht M, de Haan L, Preliminary validation of a clinical staging model in schizophrenia and related disorders. CLIN SCHIZOPHR RELAT PSYCHOSES 2017;ahead of print [PubMed]
van Dam DS. Untangling pathways between childhood trauma and psychosis. S.l.: s.n.; 2017. 202p. ISBN 978-94-6295-536-3 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L; copromotor(s): Meijer CJ, Velthorst E)
van Dijk F, de Wit I, Blankers M, Sommer I, de Haan L, The Personal Antipsychotic Choice Index. PHARMACOPSYCHIATRY 2017;ahead of print [PubMed]
van Eck RM, Burger TJ, Vellinga A, Schirmbeck F, de Haan L, The Relationship Between Clinical and Personal Recovery in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-analysis. SCHIZOPHRENIA BULL 2017;ahead of print [PubMed]
van Rooijen G, Isvoranu AM, Kruijt OH, van Borkulo CD, Meijer CJ, Wigman JTW, Ruhé HG , de Haan L [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer C, Myin-Germeys I, van Os J, Bartels-Velthuis AA]] , A state-independent network of depressive, negative and positive symptoms in male patients with schizophrenia spectrum disorders. SCHIZOPHR RES 2017;ahead of print [PubMed]
van Rooijen G, Isvoranu AM, Meijer CJ, van Borkulo CD, Ruhé HG , de Haan L, A symptom network structure of the psychosis spectrum. SCHIZOPHR RES 2017;ahead of print [PubMed]
van Rooijen G, Vermeulen JM, Ruhé HG, de Haan L, Treating depressive episodes or symptoms in patients with schizophrenia. CNS SPECTRUMS 2017;ahead of print [PubMed]
Veerman SRT, Schulte PFJ, de Haan L, Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review. DRUGS 2017;77 (13):1423-1459 [PubMed]
Veerman SRT, Schulte PFJ, Deijen JB, de Haan L, Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. PSYCHOL MED 2017;47 (2):363-375 [PubMed]
Veerman S, Schulte P, de Haan L, Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia. PSYCHOPHARMACOLOGY 2017;ahead of print [PubMed]
Velthorst E, Smith L, Bello G, Austin C, Gennings C, Modabbernia A, Franke N, Frangou S, Wright R, de Haan L, Reichenberg A, Arora M, New Research Strategy for Measuring Pre- and Postnatal Metal Dysregulation in Psychotic Disorders. SCHIZOPHRENIA BULL 2017;43 (6):1153-1157 [PubMed]
Vermeulen JM, Schirmbeck NF, Van Tricht MJ, de Haan L, Satisfaction of psychotic patients with care and its value to predict outcomes. EUR PSYCHIAT 2017;47:60-66 [PubMed]
Vermeulen J, van Rooijen G, Doedens P, Numminen E, van Tricht M, de Haan L, Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. PSYCHOL MED 2017;47 (13):2217-2228 [PubMed]
Bakker G, Caan MWA, Schluter RS, Bloemen OJN, da Silva-Alves F, de Koning MB, Boot E, Vingerhoets WAM, Nieman DH, de Haan L, Booij J, van Amelsvoort TAMJ, Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosis. PSYCHOL MED 2016;46 (11):2299-2311 [PubMed]
Bakker G, Caan MWA, Vingerhoets WAM, da Silva-Alves F, de Koning M, Boot E, Nieman DH, de Haan L, Bloemen OJ, Booij J, van Amelsvoort TAMJ, Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. PLOS ONE 2016;11 (11):e0159928 [PubMed]
Bigdeli TB, Ripke S, Bacanu SA, Lee SH, Wray NR, Gejman PV, Rietschel M, Cichon S, St Clair D, Corvin A, Kirov G, McQuillin A, Gurling H, Rujescu D, Andreassen OA, Werge T, Blackwood DHR, Pato CN, Pato MT, Malhotra AK, O'Donovan MC, Kendler KS, Fanous AH [Contributors: Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, Lee P, Bulik-Sullivan B, Collier DA, Huang H, Pers TH, Agartz I, Agerbo E, Albus M, Alexander M, Amin F, Bacanu SA, Begemann M, Belliveau RA Jr, Bene J, Bergen SE, Bevilacqua E, Bigdeli TB, Black DW, Bruggeman R, Buccola NG, Buckner RL, Byerley W, Cahn W, Cai G, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Chan RCK, Chan RYL, Chen EYH, Cheng W, Cheung EFC, Chong SA, Cloninger CR, Cohen D, Cohen N, Cormican P, Craddock N, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, del Favero J, Demontis D, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Durmishi N, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedl M, Friedman JI, Fromer M, Genovese G, Georgieva L, Giegling I, Giusti-Rodríguez P, Godard S, Goldstein JI, Golimbet V, Gopal S, Gratten J, de Haan L, Hammer C, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms S, Hirschhorn JN, Hoffmann P, Hofman A, Hollegaard MV, Ikeda M, Joa I, Julià A, Kahn RS, Kalaydjieva L, Karachanak-Yankova S, Karjalainen J, Kavanagh D, Keller MC, Kennedy JL, Khrunin A, Kim Y, Klovins J, Knowles JA, Konte B, Kucinskas V, Kucinskiene ZA, Kuzelova-Ptackova H, Kähler AK, Laurent C, Lee J, Lee SH, Legge SE, Lerer B, Li M, Li T, Liang KY, Lieberman J, Limborska S, Loughland CM, Lubinski J, Lönnqvist J, Macek M, Magnusson PKE, Maher BS, Maier W, Mallet J, Marsal S, Mattheisen M, Mattingsdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Mors O, Murphy KC, Murray RM, Myin-Germeys I, Müller-Myhsok B, Nelis M, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nikitina-Zake L, Nisenbaum L, Nordin A, O'Callaghan E, O'Dushlaine C, O'Neill FA, Oh SY, Olincy A, Olsen L, van J, Pantelis C, Papadimitriou GN, Papiol S, Parkhomenko E, Pato MT, Paunio T, Pejovic-Milovancevic M, Perkins DO, Pietiläinen O, Pimm J, Pocklington AJ, Posthuma D, Powell J, Price A, Pulver AE, Purcell S, Quested D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Schall U, Schubert CR, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Sigurdsson E, Silagadze T, Silverman JM, Sim K, Slominsky P, Smoller JW, Spencer CCA, Stahl EA, Stefansson H, Steinberg S, Stogmann E, Straub RE, Strengman E, Strohmaier J, Stroup TS, Subramaniam M, Suvisaari J, Svrakic DM, Szatkiewicz JP, Söderman E, Thirumalai S, Toncheva D, Tosato S, Veijola J, Visscher PM, Waddington J, Walsh D, Wang D, Wang Q, Webb BT, Weiser M, Wiersma D, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wong EHM, Wormley BK, Simon H, Zai CC, Zheng X, Zimprich F, Wray NR, Stefansson K, Adolfsson R, Andreassen OA, Blackwood DHR, Bramon E, Buxbaum JD, Børglum AD, Cichon S, Darvasi A, Domenici E, Ehrenreich H, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jönsson EG, Kendler KS, Kirov G, Knight J, Lencz T, Levinson DF, Li QS, Liu J, Malhotra AK, McCarroll SA, McQuillin A, Moran JL, Mortensen PB, Mowry BJ, Nöthen MM, Ophoff RA, Owen MJ, Pato CN, Petryshen TL, Rietschel M, Riley BP, Rujescu D, Sham PC, Sklar P, Clair DS, Weinberger DR, Wendland JR, Werge T, Daly MJ, Sullivan PF, O'Donovan MC]] , Genome-wide association study reveals greater polygenic loading for schizophrenia in cases with a family history of illness. AM J MED GENET B 2016;171BB (2):276-289 [PubMed]
Burger TJ, Goudriaan AE, de Haan L, de Koning MB, Duwen richting abstinentie: toepassing van drang en dwang bij schizofrenie met comorbide middelenafhankelijkheid. TIJDSCHR PSYCHIATR 2016;58 (6):481-484 [PubMed]
de Mooij LD, Kikkert M, Lommerse NM, Theunissen J, de Koning MB, de Haan L, Beekman ATF, Duurkoop PWRA, Dekker JJM, Homesick: residential and care patterns in patients with severe mental illness. BMC PSYCHIATRY 2016;16 (1):431 [PubMed]
de Nijs J, Pet MA [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer C, Myin-Germeys I, van Os J, Wiersma D]] , Metabolic syndrome in schizophrenia patients associated with poor premorbid school performance in early adolescence. ACTA PSYCHIAT SCAND 2016;133 (4):289-297 [PubMed]
Franke B, Stein JL, Ripke S, Anttila V, Hibar DP, van Hulzen KJE, Arias-Vasquez A, Smoller JW, Nichols TE, Neale MC, McIntosh AM, Lee P, McMahon FJ, Meyer-Lindenberg A, Mattheisen M, Andreassen OA, Gruber O, Sachdev PS, Roiz-Santiañez R, Saykin AJ, Ehrlich S, Mather KA, Turner JA, Schwarz E, Thalamuthu A, Yao Y, Ho YYW, Martin NG, Wright MJ, O'Donovan MC, Thompson PM, Neale BM, Medland SE, Sullivan PF [Contributors: Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, Lee P, Bulik-Sullivan B, Collier DA, Huang H, Pers TH, Agartz I, Agerbo E, Albus M, Alexander M, Amin F, Bacanu SA, Begemann M, Belliveau RA Jr, Bene J, Bergen SE, Bevilacqua E, Bigdeli TB, Black DW, Bruggeman R, Buccola NG, Buckner RL, Byerley WF, Cahn W, Cai G, Cairns MJ, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Chan RCK, Chen EYH, Chen RYL, Cheng W, Cheung EFC, Chong SA, Cloninger CR, Cohen D, Cohen N, Cormican P, Craddock N, Crespo-Facorro B, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, del Favero J, DeLisi LE, Demontis D, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedman JI, Fromer M, Genovese G, Georgieva L, Gershon ES, Giegling I, Giusti-Rodríguez P, Godard S, Goldstein JI, Gopal S, Gratten J, de Haan L, Hammer C, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms SL, Hirschhorn JN, Hoffmann P, Hofman A, Hollegaard MV, Hougaard DM, Ikeda M, Joa I, Julià A, Kähler AK, Kahn RS, Kalaydjieva L, Karachanak-Yankova S, Karjalainen J, Kavanagh D, Keller MC, Kelly BJ, Kennedy JL, Khrunin A, Kim Y, Klovins J, Knowles JA, Konte B, Kucinskas V, Kucinskiene ZA, Kuzelova-Ptackova H, Laurent C, Lee SH, Keong JLC, Legge SE, Lerer B, Li M, Li T, Liang KY, Lieberman J, Limborska S, Lönnqvist J, Loughland CM, Lubinski J, Macek M Jr, Magnusson PKE, Maher BS, Maier W, Mallet J, Marsal S, Mattheisen M, Mattingsdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Mors O, Müller-Myhsok B, Murphy KC, Murray RM, Myin-Germeys I, Nelis M, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nikitina-Zake L, Nisenbaum L, Nordin A, O'Callaghan E, O'Dushlaine C, O'Neill FA, Oh SY, Olincy A, Olsen L, van Os J, Pantelis C, Papadimitriou GN, Papiol S, Parkhomenko E, Pato MT, Paunio T, Perkins DO, Pietiläinen O, Pimm J, Pocklington AJ, Powell J, Price A, Pulver AE, Purcell SM, Quested D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Schall U, Schubert CR, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Silverman JM, Sim K, Slominsky P, Smoller JW, So HC, Söderman E, Spencer CCA, Stahl EA, Stogmann E, Straub RE, Strengman E, Strohmaier J, Stroup TS, Subramaniam M, Suvisaari J, Svrakic DM, Szatkiewicz JP, Thirumalai S, Toncheva D, Tooney PA, Veijola J, Waddington J, Walsh D, Wang D, Wang Q, Webb BT, Weiser M, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wong EHM, Wormley BK, Wu JQ, Xi HS, Zai CC, Zheng X, Zimprich F, Wray NR, Visscher PM, Adolfsson R, Andreassen OA, Blackwood DHR, Børglum AD, Bramon E, Buxbaum JD, Cichon S, Darvasi A, Domenici E, Ehrenreich H, Esko T, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jönsson EG, Kendler KS, Kirov G, Knight J, Lencz T, Levinson DF, Li QS, Liu J, Malhotra AK, McCarroll SA, McQuillin A, Moran JL, Mortensen PB, Mowry BJ, Nöthen MM, Ophoff RA, Owen MJ, Palotie A, Pato CN, Petryshen TL, Posthuma D, Rietschel M, Riley BP, Rujescu D, Sham PC, Sklar P, Clair DS, Weinberger DR, Wendland JR, Werge T, Daly MJ, Sullivan PF, O'Donovan MC, Hibar DP, Stein JL, Renteria ME, Arias-Vasquez A, Desrivières S, Jahanshad N, Toro R, Wittfeld K, Abramovic L, Andersson M, Aribisala BS, Armstrong NJ, Bernard M, Bohlken MM, Boks MP, Bralten J, Brown AA, Chakravarty MM, Chen Q, Ching CRK, Cuellar-Partida G, den Braber A, Giddaluru S, Goldman AL, Grimm O, Guadalupe T, Hass J, Woldehawariat G, Holmes AJ, Hoogman M, Janowitz D, Jia T, Kim S, Klein M, Kraemer B, Loohuis LMO, Luciano M, Macare C, Mather KA, Milaneschi Y, Nho K, Papmeyer M, Ramasamy A, Risacher SL, Roiz-Santiañez R, Rose EJ, Salami A, Sämann PG, Schmaal L, Schork AJ, Shin J, Strike LT, Teumer A, van Donkelaar MMJ, van Eijk KR, Walters RK, Westlye LT, Whelan CD, Winkler AM, Zwiers MP, Alhusaini S, Athanasiu L, Ehrlich S, Hakobjan MMH, Hartberg CB, Haukvik U, Heister AJGAM, Höhn D, Kasperaviciute D, Liewald DCM, Lopez LM, Makkinje RRR, Matarin M, Naber MAM, McKay DR, Needham M, Nugent AC, Pütz B, Royle NA, Shen L, Sprooten E, Trabzuni D, van der Marel SSL, van Hulzen KJE, Walton E, Wolf C, Almasy L, Ames D, Arepalli S, Assareh AA, Bastin ME, Brodaty H, Bulayeva KB, Carless MA, Curran JE, Czisch M, de Zubicaray GI, Dillman A, Duggirala R, Dyer TD, Erk S, Fedko IO, Ferrucci L, Foroud TM, Fox PT, Fukunaga M, Gibbs R, Göring HHH, Green RC, Guelfi S, Hansell NK, Hartman CA, Hegenscheid K, Heinz A, Hernandez DG, Heslenfeld DJ, Hoekstra PJ, Holsboer F, Homuth G, Hottenga JJ, Jack CR Jr, Jenkinson M, Johnson R, Kanai R, Keil M, Kent JW Jr, Kochunov P, Kwok JB, Lawrie SM, Liu X, Longo DL, McMahon KL, Meisenzahl E, Mohnke S, Montgomery GW, Mostert JC, Mühleisen TW, Nalls MA, Nichols TE, Nilsson LG, Ohi K, Olvera RL, Perez-Iglesias R, Pike GB, Potkin SG, Reinvang I, Reppermund S, Romanczuk-Seiferth N, Rosen GD, Schnell K, Schofield PR, Smith C, Steen VM, Sussmann JE, Thalamuthu A, Toga AW, Traynor B, Troncoso J, Turner JA, Hernández MCV, van 't Ent D, van der Brug M, van der Wee NJA, van Tol MJ, Veltman DJ, Wassink TH, Westman E, Zielke RH, Zonderman A, Ashbrook DG, Hager R, Lu L, McMahon FJ, Williams RW, Brunner HG, Buitelaar JK, Calhoun VD, Cavalleri GL, Dale AM, Davies GE, Delanty N, Depondt C, Drevets WC, Espeseth T, Gollub RL, Ho BC, Hoffmann W, Hosten N, LeHellard S, Meyer-Lindenberg A, Nauck M, Nyberg L, Pandolfo M, Penninx BWJH, Sisodiya SM, van Bokhoven H, van Haren NEM, Völzke H, Walter H, Weiner MW, Wen W, White T, Blangero J, Boomsma DI, Brouwer RM, Cannon DM, Cookson MR, de Geus EJC, Deary IJ, Fernández G, Fisher SE, Francks C, Glahn DC, Grabe HJ, Gruber O, Hardy J, Hashimoto R, Hulshoff Pol HE, Kloszewska I, Lovestone S, Mattay VS, Mecocci P, Paus T, Pausova Z, Ryten M, Sachdev PS, Saykin AJ, Simmons A, Singleton A, Soininen H, Wardlaw JM, Weale ME, Adams HHH, Launer LJ, Seiler S, Schmidt R, Chauhan G, Satizabal CL, Becker JT, Yanek L, van der Lee SJ, Ebling M, Fischl B, Longstreth WT, Greve D, Schmidt H, Nyquist P, Vinke LN, van Duijn CM, Luting X, Mazoyer B, Bis JC, Gudnason V, Seshadri S, Ikram MA, Martin NG, Wright MJ, Schumann G, Franke B, Thompson PM, Medland SE]] , Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. NAT NEUROSCI 2016;19 (3):420-+ [PubMed]
Heering HD, Goedhart S, Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D, Disturbed Experience of Self: Psychometric Analysis of the Self-Experience Lifetime Frequency Scale (SELF). PSYCHOPATHOLOGY 2016;49 (2):69-76 [PubMed]
Heering HD, van Haren NEM [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , Social functioning in patients with a psychotic disorder and first rank symptoms. PSYCHIAT RES 2016;237:147-152 [PubMed]
Janssens M, Boyette LL, Heering HD, Bartels-Velthuis AA, Lataster T [Contributors: Kahn RS, de Haan L, van Os J, Wiersma D, Bruggeman R, Cahn W, Meijer C, Myin-Germeys I]] , Developmental course of subclinical positive and negative psychotic symptoms and their associations with genetic risk status and impairment. SCHIZOPHR RES 2016;174 (1-3):177-182 [PubMed]
Koenders L. Structural brain alterations and cannabis in the healthy population and patients with schizophrenia. S.l.: s.n.; 2016. 220p. ISBN 9789082604900 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L, Veltman DJ; copromotor(s): Meijer CJ, Machielsen MWJ)
Koenders L, Cousijn J, Vingerhoets WAM, van den Brink W, Wiers RW, Meijer CJ, Machielsen MWJ, Veltman DJ, Goudriaan AE, de Haan L, Grey Matter Changes Associated with Heavy Cannabis Use: A Longitudinal sMRI Study. PLOS ONE 2016;11 (5):e0152482 [PubMed]
Kraan TC, Velthorst E, de Haan L, van der Gaag M, Disentangling cause and effect in the relationship between cannabis and psychosis: are we there yet? Reply. PSYCHOL MED 2016;46 (14):3063-3064
Kraan T, Velthorst E, Koenders L, Zwaart K, Ising HK, van den Berg D, de Haan L, van der Gaag M, Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. PSYCHOL MED 2016;46 (4):673-681 [PubMed]
Liemburg EJ, Bruins J, van Beveren N, Islam MA, Alizadeh BZ [Contributors: Bruggeman R, Wiersma D, Cahn W, Kahn RS, de Haan L, Meijer CJ, Myin-Germeys I, van Os J]] , Cannabis and a lower BMI in psychosis: What is the role of AKT1?. SCHIZOPHR RES 2016;176 (2-3):95-99 [PubMed]
Lim A, Hoek HW, Deen ML, Blom JD [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , Prevalence and classification of hallucinations in multiple sensory modalities in schizophrenia spectrum disorders. SCHIZOPHR RES 2016;176 (2-3):493-499 [PubMed]
Medema S, Mocking RJT, Koeter MWJ, Vaz FM, Meijer C, de Haan L, van Beveren NJM, Kahn R, van Os J, Wiersma D, Bruggeman R, Cahn W, Myin-Germeys I, Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls. SCHIZOPHRENIA BULL 2016;42 (2):358-368 [PubMed]
Meesters PD, Comijs HC, Smit JH, Eikelenboom P, de Haan L, Beekman ATF, Stek ML, Mortality and Its Determinants in Late-Life Schizophrenia: A 5-Year Prospective Study in a Dutch Catchment Area. AM J GERIAT PSYCHIAT 2016;24 (4):272-277 [PubMed]
Mehta D, Tropf FC, Gratten J, Bakshi A, Zhu Z, Bacanu SA, Hemani G, Magnusson PKE, Barban N, Esko T, Metspalu A, Snieder H, Mowry BJ, Kendler KS, Yang J, Visscher PM, McGrath JJ, Mills MC, Wray NR, Lee SH, Andreassen OA, Bramon E, Bruggeman R, Buxbaum JD, Cairns MJ, Cantor RM, Cloninger CR, Cohen D, Crespo-Facorro B, Darvasi A, DeLisi LE, Dinan T, Djurovic S, Donohoe G, Drapeau E, Escott-Price V, Freimer NB, Georgieva L, de Haan L, Henskens FA, Joa I, Julià A, Khrunin A, Lerer B, Limborska S, Loughland CM, Macek M Jr, Marsal S, McCarley RW, McIntosh AM, McQuillin A, Melegh B, Michie PT, Morris DW, Murphy KC, Myin-Germeys I, Olincy A, van Os J, Pantelis C, Posthuma D, Quested D, Schall U, Scott RJ, Seidman LJ, Toncheva D, Tooney PA, Waddington J, Weinberger DR, Weiser M, Wu JQ, Evidence for Genetic Overlap Between Schizophrenia and Age at First Birth in Women. JAMA PSYCHIAT 2016;73 (5):497-505 [PubMed]
Meijer JH, van Harten P, Meijer CJ, Koeter MW, Bruggeman R, Cahn W, Kahn RS, de Haan L, Association between olfactory identification and parkinsonism in patients with non-affective psychosis. EARLY INTERV PSYCHIA 2016;10 (5):404-410 [PubMed]
Modabbernia A, Velthorst E, Gennings C, de Haan L, Austin C, Sutterland A, Mollon J, Frangou S, Wright R, Arora M, Reichenberg A, Early-life metal exposure and schizophrenia: A proof-of-concept study using novel tooth-matrix biomarkers. EUR PSYCHIAT 2016;36:1-6 [PubMed]
Muller D, Schirmbeck F, de Haan L, Aanbevelingen voor diagnostiek en behandeling van dwangsymptomen bij schizofrenie. TIJDSCHR PSYCHIATR 2016;58 (7):529-534 [PubMed]
Nieman DH, Dragt S, van Duin EDA, Denneman N, Overbeek JM, de Haan L, Rietdijk J, Ising HK, Klaassen RMC, van Amelsvoort T, Wunderink L, van der Gaag M, Linszen DH, COMT Val(158)Met genotype and cannabis use in people with an At Risk Mental State for psychosis: Exploring Gene x Environment interactions. SCHIZOPHR RES 2016;174 (1-3):24-28 [PubMed]
Peeters SCT, Gronenschild EHBM, van Amelsvoort T, van Os J, Marcelis M, Kahn R, Wiersma D, Bruggeman R, Cahn W, de Haan L, Meijer C, Myin-Germeys I, Reduced specialized processing in psychotic disorder: a graph theoretical analysis of cerebral functional connectivity. BRAIN BEHAV 2016;6 (9):e00508 [PubMed]
Pos K, Boyette LL, Meijer CJ, Koeter M, Krabbendam L, de Haan L, The effect of childhood trauma and Five-Factor Model personality traits on exposure to adult life events in patients with psychotic disorders. COGN NEUROPSYCHIATRY 2016;21 (6):462-474 [PubMed]
Pouget JG, Gonçalves VF, Spain SL, Finucane HK, Raychaudhuri S, Kennedy JL, Knight J [Contributors: de Haan L, Meijer CJ, et al -]] , Genome-Wide Association Studies Suggest Limited Immune Gene Enrichment in Schizophrenia Compared to 5 Autoimmune Diseases. SCHIZOPHRENIA BULL 2016;42 (5):1176-1184 [PubMed]
Schirmbeck F, Swets M, Meijer CJ, Zink M, de Haan L [Contributors: Kahn RS, Cahn W, Meijer CJ, van Os J, Myin-Germeys I, Bruggeman R, Bartels A]] , Longitudinal association between cognitive performance and obsessive-compulsive symptoms in patients with psychosis and unaffected siblings. ACTA PSYCHIAT SCAND 2016;133 (5):399-409 [PubMed]
Schirmbeck F, Swets M, Meijer CJ, Zink M, de Haan L [Contributors: Kahn RS, van Os J, Bruggeman R, Cahn W, Bartels-Velthuis AA, Myin-Germeys I]] , Obsessive-compulsive symptoms and overall psychopathology in psychotic disorders: longitudinal assessment of patients and siblings. EUR ARCH PSY CLIN N 2016;ahead of print [PubMed]
Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, van Doren V, Genovese G, Rose SA, Handsaker RE, Daly MJ, Carroll MC, Stevens B, McCarroll SA [Contributors: Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, Lee P, Bulik-Sullivan B, Collier DA, Huang H, Pers TH, Agartz I, Agerbo E, Albus M, Alexander M, Amin F, Bacanu SA, Begemann M, Belliveau RA Jr, Bene J, Bergen SE, Bevilacqua E, Bigdeli TB, Black DW, Bruggeman R, Buccola NG, Buckner RL, Byerley W, Cahn W, Cai G, Cairns MJ, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Chan RCK, Chen RYL, Chen EYH, Cheng W, Cheung EFC, Chong SA, Cloninger CR, Cohen D, Cohen N, Cormican P, Craddock N, Crespo-Facorro B, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, del Favero J, DeLisi LE, Demontis D, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Durmishi N, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedl M, Friedman JI, Fromer M, Genovese G, Georgieva L, Gershon ES, Giegling I, Giusti-Rodríguez P, Godard S, Goldstein JI, Golimbet V, Gopal S, Gratten J, de Haan L, Hammer C, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms S, Hirschhorn JN, Hoffmann P, Hofman A, Hollegaard MV, Hougaard DM, Ikeda M, Joa I, Julià A, Kahn RS, Kalaydjieva L, Karachanak-Yankova S, Karjalainen J, Kavanagh D, Keller MC, Kelly BJ, Kennedy JL, Khrunin A, Kim Y, Klovins J, Knowles JA, Konte B, Kucinskas V, Kucinskiene ZA, Kuzelova-Ptackova H, Kähler AK, Laurent C, Keong JLC, Lee SH, Legge SE, Lerer B, Li M, Li T, Liang KY, Lieberman J, Limborska S, Loughland CM, Lubinski J, Lönnqvist J, Macek M Jr, Magnusson PKE, Maher BS, Maier W, Mallet J, Marsal S, Mattheisen M, Mattingsdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Mors O, Murphy KC, Murray RM, Myin-Germeys I, Müller-Myhsok B, Nelis M, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nikitina-Zake L, Nisenbaum L, Nordin A, O'Callaghan E, O'Dushlaine C, O'Neill FA, Oh SY, Olincy A, Olsen L, van Os J, Pantelis C, Papadimitriou GN, Papiol S, Parkhomenko E, Pato MT, Paunio T, Pejovic-Milovancevic M, Perkins DO, Pietiläinen O, Pimm J, Pocklington AJ, Powell J, Price A, Pulver AE, Purcell SM, Quested D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Schall U, Schubert CR, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Sigurdsson E, Silagadze T, Silverman JM, Sim K, Slominsky P, Smoller JW, So HC, Spencer CCA, Stahl EA, Stefansson H, Steinberg S, Stogmann E, Straub RE, Strengman E, Strohmaier J, Stroup TS, Subramaniam M, Suvisaari J, Svrakic DM, Szatkiewicz JP, Söderman E, Thirumalai S, Toncheva D, Tooney PA, Tosato S, Veijola J, Waddington J, Walsh D, Wang D, Wang Q, Webb BT, Weiser M, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wong EHM, Wormley BK, Wu JQ, Xi HS, Zai CC, Zheng X, Zimprich F, Wray NR, Stefansson K, Visscher PM, Adolfsson R, Andreassen OA, Blackwood DHR, Bramon E, Buxbaum JD, Børglum AD, Cichon S, Darvasi A, Domenici E, Ehrenreich H, Esko T, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jönsson EG, Kendler KS, Kirov G, Knight J, Lencz T, Levinson DF, Li QS, Liu J, Malhotra AK, McCarroll SA, McQuillin A, Moran JL, Mortensen PB, Mowry BJ, Nöthen MM, Ophoff RA, Owen MJ, Palotie A, Pato CN, Petryshen TL, Posthuma D, Rietschel M, Riley BP, Rujescu D, Sham PC, Sklar P, St Clair D, Weinberger DR, Wendland JR, Werge T, Daly MJ, Sullivan PF, O'Donovan MC]] , Schizophrenia risk from complex variation of complement component 4. NATURE 2016;530 (7589):177-+ [PubMed]
Sommer IE, Bearden CE, van Dellen E, Breetvelt EJ, Duijff SN, Maijer K, van Amelsvoort T, de Haan L, Gur RE, Arango C, Díaz-Caneja CM, Vinkers CH, Vorstman JAS, Early interventions in risk groups for schizophrenia: what are we waiting for?. NPJ SCHIZOPHR 2016;2:16003 [PubMed]
Sommer IEC, Hoencamp E, Spijker J, Kupka RW, Beekman ATF, de Haan L, De schijn tegen? Evidence-based in plaats van marketing-based psychiatrie. TIJDSCHR PSYCHIATR 2016;58 (2):154-156 [PubMed]
van der Doef TF, de Witte LD, Sutterland AL, Jobse E, Yaqub M, Boellaard R, de Haan L, Eriksson J, Lammertsma AA, Kahn RS, van Berckel BNM, In vivo (R)-[(11)C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis. NPJ SCHIZOPHR 2016;2:16031 [PubMed]
van der Lee A, de Haan L, Beekman A, Schizophrenia in the Netherlands: Continuity of Care with Better Quality of Care for Less Medical Costs. PLOS ONE 2016;11 (6):e0157150 [PubMed]
van Erp TGM, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA, Agartz I, Westlye LT, Haukvik UK, Dale AM, Melle I, Hartberg CB, Gruber O, Kraemer B, Zilles D, Donohoe G, Kelly S, McDonald C, Morris DW, Cannon DM, Corvin A, Machielsen MWJ, Koenders L, de Haan L, Veltman DJ, Satterthwaite TD, Wolf DH, Gur RC, Gur RE, Potkin SG, Mathalon DH, Mueller BA, Preda A, Macciardi F, Ehrlich S, Walton E, Hass J, Calhoun VD, Bockholt HJ, Sponheim SR, Shoemaker JM, van Haren NEM, Hulshoff Pol HE, Pol HEH, Ophoff RA, Kahn RS, Roiz-Santiañez R, Crespo-Facorro B, Wang L, Alpert KI, Jönsson EG, Dimitrova R, Bois C, Whalley HC, McIntosh AM, Lawrie SM, Hashimoto R, Thompson PM, Turner JA, Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. MOL PSYCHIATR 2016;21 (4):547-553 [PubMed]
van Nierop M, Bak M, de Graaf R, ten Have M, van Dorsselaer S, van Winkel R [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , The functional and clinical relevance of childhood trauma-related admixture of affective, anxious and psychosis symptoms. ACTA PSYCHIAT SCAND 2016;ahead of print [PubMed]
Veerman SRT, Schulte PFJ, Smith JD, de Haan L, Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. PSYCHOL MED 2016;46 (9):1909-1921 [PubMed]
Velthorst E, Reichenberg A, Kapara O, Goldberg S, Fromer M, Fruchter E, Ginat K, de Haan L, Davidson M, Weiser M, Developmental Trajectories of Impaired Community Functioning in Schizophrenia. JAMA PSYCHIAT 2016;73 (1):48-55 [PubMed]
Vingerhoets WAM, Koenders L, van den Brink W, Wiers RW, Goudriaan AE, van Amelsvoort T, de Haan L, Cousijn J, Cue-induced striatal activity in frequent cannabis users independently predicts cannabis problem severity three years later. J PSYCHOPHARMACOL 2016;30 (2):152-158 [PubMed]
Vreeker A, Boks MPM, Abramovic L, Verkooijen S, van Bergen AH, Hillegers MHJ, Spijker AT, Hoencamp E, Regeer EJ, Riemersma-van der Lek RF, Stevens AWMM, Schulte PFJ, Vonk R, Hoekstra R, van Beveren NJM, Kupka RW, Brouwer RM, Bearden CE, MacCabe JH, Ophoff RA [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , High educational performance is a distinctive feature of bipolar disorder: a study on cognition in bipolar disorder, schizophrenia patients, relatives and controls. PSYCHOL MED 2016;46 (4):807-818 [PubMed]
Barkhof E. Motivation for adherence to treatment in chronic psychotic disorders: Interventions strategies and social cognitive factors. S.l.: s.n.; 2015. 151p. ISBN 9789053359983 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L; copromotor(s): Meijer CJ, de Sonneville LMJ)
Barkhof E, de Sonneville LMJ, Meijer CJ, de Haan L, Processing of facial and nonsocial information is differentially associated with severity of symptoms in patients with multiepisode schizophrenia. J NERV MENT DIS 2015;203 (2):112-119 [PubMed]
Boyette LL, Nederlof J, Meijer C, de Boer F, de Haan L, Three year stability of Five-Factor Model personality traits in relation to changes in symptom levels in patients with schizophrenia or related disorders. PSYCHIAT RES 2015;229 (1-2):539-544 [PubMed]
Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, Neale BM [Contributors: Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, Lee P, Bulik-Sullivan B, Collier DA, Huang H, Pers TH, Agartz I, Agerbo E, Albus M, Alexander M, Amin F, Bacanu SA, Begemann M, Belliveau RA Jr, Bene J, Bergen SE, Bevilacqua E, Bigdeli TB, Black DW, Bruggeman R, Buccola NG, Buckner RL, Byerley W, Cahn W, Cai G, Cairns MJ, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Chan RCK, Chen RYL, Chen EYH, Cheng W, Cheung EFC, Chong SA, Cloninger CR, Cohen D, Cohen N, Cormican P, Craddock N, Crespo-Facorro B, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, del Favero J, DeLisi LE, Demontis D, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Durmishi N, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedl M, Friedman JI, Fromer M, Genovese G, Georgieva L, Gershon ES, Giegling I, Giusti-Rodríguez P, Godard S, Goldstein JI, Golimbet V, Gopal S, Gratten J, de Haan L, Hammer C, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms S, Hirschhorn JN, Hoffmann P, Hofman A, Hollegaard MV, Hougaard DM, Ikeda M, Joa I, Julià A, Kahn RS, Kalaydjieva L, Karachanak-Yankova S, Karjalainen J, Kavanagh D, Keller MC, Kelly BJ, Kennedy JL, Khrunin A, Kim Y, Klovins J, Knowles JA, Konte B, Kucinskas V, Kucinskiene ZA, Kuzelova-Ptackova H, Kähler AK, Laurent C, Keong JLC, Lee SH, Legge SE, Lerer B, Li M, Li T, Liang KY, Lieberman J, Limborska S, Loughland CM, Lubinski J, Lönnqvist J, Macek M Jr, Magnusson PKE, Maher BS, Maier W, Mallet J, Marsal S, Mattheisen M, Mattingsdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Mors O, Murphy KC, Murray RM, Myin-Germeys I, Müller-Myhsok B, Nelis M, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nikitina-Zake L, Nisenbaum L, Nordin A, O'Callaghan E, O'Dushlaine C, O'Neill FA, Oh SY, Olincy A, Olsen L, van Os J, Pantelis C, Papadimitriou GN, Papiol S, Parkhomenko E, Pato MT, Paunio T, Pejovic-Milovancevic M, Perkins DO, Pietiläinen O, Pimm J, Pocklington AJ, Powell J, Price A, Pulver AE, Purcell SM, Quested D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Schall U, Schubert CR, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Sigurdsson E, Silagadze T, Silverman JM, Sim K, Slominsky P, Smoller JW, So HC, Spencer CCA, Stahl EA, Stefansson H, Steinberg S, Stogmann E, Straub RE, Strengman E, Strohmaier J, Stroup TS, Subramaniam M, Suvisaari J, Svrakic DM, Szatkiewicz JP, Söderman E, Thirumalai S, Toncheva D, Tooney PA, Tosato S, Veijola J, Waddington J, Walsh D, Wang D, Wang Q, Webb BT, Weiser M, Wildenauer DD, Williams NM, Williams S, Witt SH, Wolen AR, Wong EHM, Wormley BK, Wu JQ, Xi HS, Zai CC, Zheng X, Zimprich F, Wray NR, Stefansson K, Visscher PM, Adolfsson R, Andreassen OA, Blackwood DHR, Bramon E, Buxbaum JD, Børglum AD, Cichon S, Darvasi A, Domenici E, Ehrenreich H, Esko T, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jönsson EG, Kendler KS, Kirov G, Knight J, Lencz T, Levinson DF, Li QS, Liu J, Malhotra AK, McCarroll SA, McQuillin A, Moran JL, Mortensen PB, Mowry BJ, Nöthen MM, Ophoff RA, Owen MJ, Palotie A, Pato CN, Petryshen TL, Posthuma D, Rietschel M, Riley BP, Rujescu D, Sham PC, Sklar P, St Clair D, Weinberger DR, Wendland JR, Werge T, Daly MJ, Sullivan PF, O'Donovan MC]] , LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. NAT GENET 2015;47 (3):291-+ [PubMed]
Canuti M, Buka S, Jazaeri Farsani SM, Oude Munnink BB, Jebbink MF, van Beveren NJM, de Haan L, Goldstein J, Seidman LJ, Tsuang MT, Storosum JG, van der Hoek L, Reduced maternal levels of common viruses during pregnancy predict offspring psychosis: potential role of enhanced maternal immune activity?. SCHIZOPHR RES 2015;166 (1-3):248-254 [PubMed]
Canuti M, van Beveren NJM, Jazaeri Farsani SM, de Vries M, Deijs M, Jebbink MF, Zaaijer HL, van Schaik BDC, van Kampen AHC, van der Kuyl AC, de Haan L, Storosum JG, van der Hoek L, Viral metagenomics in drug-naïve, first-onset schizophrenia patients with prominent negative symptoms. PSYCHIAT RES 2015;229 (3):678-684 [PubMed]
de Haan L, Hoge sterfte na een psychose: niet alleen door suicide. NED TIJDSCHR GENEESKD 2015;159:A9874 [PubMed]
de Haan L, Egberts ACG, Heerdink ER, The relation between risk-taking behavior and alcohol use in young adults is different for men and women. DRUG ALCOHOL DEPEN 2015;155:222-227 [PubMed]
de Haan L, Schirmbeck F, Zink M, editors, Obsessive-Compulsive Symptoms in Schizophrenia. New York: Springer; 2015. 221p. ISBN 978-3-319-12951-8 (Print), 978-3-319-12952-5 (Online)
de Haan L, Zink M. Clinical Presentation of Obsessive-Compulsive Symptoms in Patients with Psychotic Disorders Psychopathological Concepts, Differential Diagnosis, and Symptom Presentation in: de Haan L, Schirmbeck F, Zink M, editors. Obsessive-Compulsive Symptoms in Schizophrenia. New York: Springer; 2015., p. 33-45
Frissen A, Lieverse R, Drukker M, van Winkel R, Delespaul P [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn R, Meije C, Myin-Germeys I, van Os J, Wiersma D]] , Childhood trauma and childhood urbanicity in relation to psychotic disorder. SOC PSYCH PSYCH EPID 2015;50 (10):1481-1488 [PubMed]
Frissen A, Lieverse R, Marcelis M, Drukker M, Delespaul P [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn R, Meijer C, Myin-Germeys I, van Os J, Wiersma D]] , Psychotic disorder and educational achievement: a family-based analysis. SOC PSYCH PSYCH EPID 2015;50 (10):1511-1518 [PubMed]
Hanssen E, van der Velde J, Gromann PM, Shergill SS, de Haan L, Bruggeman R, Krabbendam L, Aleman A, van Atteveldt N, Neural correlates of reward processing in healthy siblings of patients with schizophrenia. FRONT HUM NEUROSCI 2015;9:504 [PubMed]
Heering HD. On heterogeneity and self-disturbance in psychotic disorders. S.l.: s.n.; 2015. 130p. ISBN 978-94-6182-582-7 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L; copromotor(s): Meijer CJ, van Haren NEM)
Heering HD, Janssens M, Boyette LL, van Haren NEM [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , Remission criteria and functional outcome in patients with schizophrenia, a longitudinal study. AUST NZ J PSYCHIAT 2015;49 (3):266-274 [PubMed]
Heering HD, Koevoets GJC, Koenders L, Machielsen MWJ, Meijer CJ, Kubota M, de Nijs J, Cahn W, Hulshoff Pol HE, de Haan L, Kahn RS, van Haren NEM, Structural MRI differences between patients with and without first rank symptoms: a delusion?. FRONT PSYCHIATRY 2015;6:107 [PubMed]
Koenders L, Machielsen MWJ, van der Meer FJ, van Gasselt ACM, Meijer CJ, van den Brink W, Koeter MWJ, Caan MWA, Cousijn J, den Braber A, van 't Ent D, Rive MM, Schene AH, van de Giessen E, Huyser C , de Kwaasteniet BP, Veltman DJ, de Haan L, Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J PSYCHIATR NEUROSCI 2015;40 (3):197-206 [PubMed]
Korver-Nieberg N, Berry K, Meijer C, de Haan L, Ponizovsky AM, Associations between attachment and psychopathology dimensions in a large sample of patients with psychosis. PSYCHIAT RES 2015;228 (1):83-88 [PubMed]
Kraan T, van Dam DS, Velthorst E, de Ruigh EL, Nieman DH, Durston S, Schothorst P, van der Gaag M, de Haan L, Childhood trauma and clinical outcome in patients at ultra-high risk of transition to psychosis. SCHIZOPHR RES 2015;169 (1-3):193-198 [PubMed]
Kraan T, Velthorst E, Smit F, de Haan L, van der Gaag M, Trauma and recent life events in individuals at ultra high risk for psychosis: review and meta-analysis. SCHIZOPHR RES 2015;161 (2-3):143-149 [PubMed]
Lee SH, Byrne EM, Hultman CM, Kähler A, Vinkhuyzen AAE, Ripke S, Andreassen OA, Frisell T, Gusev A, Hu X, Karlsson R, Mantzioris VX, McGrath JJ, Mehta D, Stahl EA, Zhao Q, Kendler KS, Sullivan PF, Price AL, O'Donovan M, Okada Y, Mowry BJ, Raychaudhuri S, Wray NR, Byerley W, Cahn W, Cantor RM, Cichon S, Cormican P, Curtis D, Djurovic S, Escott-Price V, Gejman PV, Georgieva L, Giegling I, Hansen TF, Ingason A, Kim Y, Konte B, Lee PH, McIntosh A, McQuillin A, Morris DW, Nöthen MM, O'Dushlaine C, Olincy A, Olsen L, Pato CN, Pato MT, Pickard BS, Posthuma D, Rasmussen HB, Rietschel M, Rujescu D, Schulze TG, Silverman JM, Thirumalai S, Werge T, Agartz I, Amin F, Azevedo MH, Bass N, Black DW, Blackwood DHR, Bruggeman R, Buccola NG, Choudhury K, Cloninger RC, Corvin A, Craddock N, Daly MJ, Datta S, Donohoe GJ, Duan J, Dudbridge F, Fanous A, Freedman R, Freimer NB, Friedl M, Gill M, Gurling H, de Haan L, Hamshere ML, Hartmann AM, Holmans PA, Kahn RS, Keller MC, Kenny E, Kirov GK, Krabbendam L, Krasucki R, Lawrence J, Lencz T, Levinson DF, Lieberman JA, Lin DY, Linszen DH, Magnusson PKE, Maier W, Malhotra AK, Mattheisen M, Mattingsdal M, McCarroll SA, Medeiros H, Melle I, Milanova V, Myin-Germeys I, Neale BM, Ophoff RA, Owen MJ, Pimm J, Purcell SM, Puri V, Quested DJ, Rossin L, Ruderfer D, Sanders AR, Shi J, Sklar P, St Clair D, Stroup TS, van Os J, Visscher PM, Wiersma D, Zammit S, Bridges SL Jr, Choi HK, Coenen MJH, de Vries N, Dieud P, Greenberg JD, Huizinga TWJ, Padyukov L, Siminovitch KA, Tak PP, Worthington J, de Jager PL, Denny JC, Gregersen PK, Klareskog L, Mariette X, Plenge RM, van Laar M, van Riel P, New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. INT J EPIDEMIOL 2015;44 (5):1706-1721 [PubMed]
Maat A, van Montfort SJT, de Nijs J, Derks EM, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, Emotion processing in schizophrenia is state and trait dependent. SCHIZOPHR RES 2015;161 (2-3):392-398 [PubMed]
Maier R, Moser G, Chen GB, Ripke S, Coryell W, Potash JB, Scheftner WA, Shi J, Weissman MM, Hultman CM, Landén M, Levinson DF, Kendler KS, Smoller JW, Wray NR, Lee SH [Contributors: Absher D, Agartz I, Akil H, Amin F, Andreassen OA, Anjorin A, Anney R, Arking DE, Asherson P, Azevedo MH, Backlund L, Badner JA, Bailey AJ, Banaschewski T, Barchas JD, Barnes MR, Barrett TB, Bass N, Battaglia A, Bauer M, Bayés M, Bellivier F, Bergen SE, Berrettini W, Betancur C, Bettecken T, Biederman J, Binder EB, Black DW, Blackwood DHR, Bloss CS, Boehnke M, Boomsma DI, Breen G, Breuer R, Bruggeman R, Buccola NG, Buitelaar JK, Bunney WE, Buxbaum JD, Byerley WF, Caesar S, Cahn W, Cantor RM, Casas M, Chakravarti A, Chambert K, Choudhury K, Cichon S, Cloninger CR, Collier DA, Cook EH, Coon H, Cormand B, Cormican P, Corvin A, Coryell WH, Craddock N, Craig DW, Craig IW, Crosbie J, Cuccaro ML, Curtis D, Czamara D, Daly MJ, Datta S, Dawson G, Day R, de Geus EJ, Degenhardt F, Devlin B, Djurovic S, Donohoe GJ, Doyle AE, Duan J, Dudbridge F, Duketis E, Ebstein RP, Edenberg HJ, Elia J, Ennis S, Etain B, Fanous A, Faraone SV, Farmer AE, Ferrier IN, Flickinger M, Fombonne E, Foroud T, Frank J, Franke B, Fraser C, Freedman R, Freimer NB, Freitag CM, Friedl M, Frisén L, Gallagher L, Gejman PV, Georgieva L, Gershon ES, Geschwind DH, Giegling I, Gill M, Gordon SD, Gordon-Smith K, Green EK, Greenwood TA, Grice DE, Gross M, Grozeva D, Guan W, Gurling H, de Haan L, Haines JL, Hakonarson H, Hallmayer J, Hamilton SP, Hamshere ML, Hansen TF, Hartmann AM, Hautzinger M, Heath AC, Henders AK, Herms S, Hickie IB, Hipolito M, Hoefels S, Holmans PA, Holsboer F, Hoogendijk WJ, Hottenga JJ, Hultman CM, Hus V, Ingason A, Ising M, Jamain S, Jones I, Jones L, Kähler AK, Kahn RS, Kandaswamy R, Keller MC, Kelsoe JR, Kendler KS, Kennedy JL, Kenny E, Kent L, Kim Y, Kirov GK, Klauck SM, Klei L, Knowles JA, Kohli MA, Koller DL, Konte B, Korszun A, Krabbendam L, Krasucki R, Kuntsi J, Kwan P, Landén M, Långström N, Lathrop M, Lawrence J, Lawson WB, Leboyer M, Ledbetter DH, Lee PH, Lencz T, Lesch KP, Levinson DF, Lewis CM, Li J, Lichtenstein P, Lieberman JA, Lin DY, Linszen DH, Liu C, Lohoff FW, Loo SK, Lord C, Lowe JK, Lucae S, MacIntyre DJ, Madden PAF, Maestrini E, Magnusson PKE, Mahon PB, Maier W, Malhotra AK, Mane SM, Martin CL, Martin NG, Mattheisen M, Matthews K, Mattingsdal M, McCarroll SA, McGhee KA, McGough JJ, McGrath PJ, McGuffin P, McInnis MG, McIntosh A, McKinney R, McLean AW, McMahon FJ, McMahon WM, McQuillin A, Medeiros H, Medland SE, Meier S, Melle I, Meng F, Meyer J, Middeldorp CM, Middleton L, Milanova V, Miranda A, Monaco AP, Montgomery GW, Moran JL, Moreno-de-Luca D, Morken G, Morris DW, Morrow EM, Moskvina V, Mowry BJ, Muglia P, Mühleisen TW, Müller-Myhsok B, Murtha M, Myers RM, Myin-Germeys I, Neale BM, Nelson SF, Nievergelt CM, Nikolov I, Nimgaonkar V, Nolen WA, Nöthen MM, Nurnberger JI, Nwulia EA, Nyholt DR, O'Donovan MC, O'Dushlaine C, Oades RD, Olincy A, Oliveira G, Olsen L, Ophoff RA, Osby U, Owen MJ, Palotie A, Parr JR, Paterson AD, Pato CN, Pato MT, Penninx BW, Pergadia ML, Pericak-Vance MA, Perlis RH, Pickard BS, Pimm J, Piven J, Posthuma D, Potash JB, Poustka F, Propping P, Purcell SM, Puri V, Quested DJ, Quinn EM, Ramos-Quiroga JA, Rasmussen HB, Raychaudhuri S, Rehnström K, Reif A, Ribasés M, Rice JP, Rietschel M, Ripke S, Roeder K, Roeyers H, Rossin L, Rothenberger A, Rouleau G, Ruderfer D, Rujescu D, Sanders AR, Sanders SJ, Santangelo SL, Schachar R, Schalling M, Schatzberg AF, Scheftner WA, Schellenberg GD, Scherer SW, Schork NJ, Schulze TG, Schumacher J, Schwarz M, Scolnick E, Scott LJ, Sergeant JA, Shi J, Shilling PD, Shyn SI, Silverman JM, Sklar P, Slager SL, Smalley SL, Smit JH, Smith EN, Smoller JW, Sonuga-Barke EJS, St Clair D, State M, Steffens M, Steinhausen HC, Strauss JS, Strohmaier J, Stroup TS, Sullivan PF, Sutcliffe J, Szatmari P, Szelinger S, Thapar A, Thirumalai S, Thompson RC, Todorov AA, Tozzi F, Treutlein J, Tzeng JY, Uhr M, van den Oord EJCG, van Grootheest G, van Os J, Vicente AM, Vieland VJ, Vincent JB, Visscher PM, Walsh CA, Wassink TH, Watson SJ, Weiss LA, Weissman MM, Werge T, Wienker TF, Wiersma D, Wijsman EM, Willemsen G, Williams N, Willsey AJ, Witt SH, Wray NR, Xu W, Young AH, Yu TW, Zammit S, Zandi PP, Zhang P, Zitman FG, Zöllner S]] , Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. AM J HUM GENET 2015;96 (2):283-294 [PubMed]
Mattila T, Koeter M, Wohlfarth T, Storosum J, van den Brink W, de Haan L, Derks E, Leufkens H, Denys D, Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia. SCHIZOPHRENIA BULL 2015;41 (3):637-643 [PubMed]
Peeters SCT, Gronenschild EHBM, van de Ven V, Habets P, Goebel R, van Os J, Marcelis M [Contributors: Kahn R, Linszen D, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Altered mesocorticolimbic functional connectivity in psychotic disorder: an analysis of proxy genetic and environmental effects. PSYCHOL MED 2015;45 (10):2157-2169 [PubMed]
Peeters SCT, van Bronswijk S, van de Ven V, Gronenschild EHBM, Goebel R, van Os J, Marcelis M [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn R, Meijer C, Myin-Germeys I, van Os J, Wiersma D]] , Cognitive correlates of frontoparietal network connectivity 'at rest' in individuals with differential risk for psychotic disorder. EUR NEUROPSYCHOPHARM 2015;25 (11):1922-1932 [PubMed]
Peeters SCT, van de Ven V, Gronenschild EHBM, Patel AX, Habets P, Goebel R, van Os J, Marcelis M [Contributors: Kahn R, Linszen D, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Default Mode Network Connectivity as a Function of Familial and Environmental Risk for Psychotic Disorder. PLOS ONE 2015;10 (3):e0120030 [PubMed]
Pos K, Bartels-Velthuis AA, Simons CJP, Korver-Nieberg N, Meijer CJ, de Haan L [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , Theory of Mind and attachment styles in people with psychotic disorders, their siblings, and controls. AUST NZ J PSYCHIAT 2015;49 (2):171-180 [PubMed]
Schirmbeck F, Boyette LL, van der Valk R, Meijer C, Dingemans P, van R, de Haan L, Kahn RS, van Os J, Wiersma D, Bruggeman R, Cahn W, Myin-Germeys I, Relevance of Five-Factor Model personality traits for obsessive-compulsive symptoms in patients with psychotic disorders and their un-affected siblings. PSYCHIAT RES 2015;225 (3):464-470 [PubMed]
Schirmbeck F, Swets M, de Haan L. Epidemiology: Prevalence and Clinical Characteristics of Obsessive-Compulsive Disorder and Obsessive-Compulsive Symptoms in Patients with Psychotic Disorders in: de Haan L, Schirmbeck F, Zink M, editors. Obsessive-Compulsive Symptoms in Schizophrenia. New York: Springer; 2015., p. 47-61
Smeerdijk AM. Family motivational intervention for reducing cannabis use in recent-onset schizophrenia. S.l.: s.n.; 2015. 153p. ISBN 978-94-6259-846-1 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schippers GM, de Haan L; copromotor(s): Keet IPM)
Smeerdijk M, Keet R, van Raaij B, Koeter M, Linszen D, de Haan L, Schippers G, Motivational interviewing and interaction skills training for parents of young adults with recent-onset schizophrenia and co-occurring cannabis use: 15-month follow-up. PSYCHOL MED 2015;45 (13):2839-2848 [PubMed]
Sutterland AL, Fond G, Kuin A, Koeter MWJ, Lutter R, van Gool T, Yolken R, Szoke A, Leboyer M, de Haan L, Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. ACTA PSYCHIAT SCAND 2015;132 (3):161-179 [PubMed]
Swets M, van Dael F, Roza S, Schoevers R, Myin-Germeys I, de Haan L [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , Evidence for a Shared Etiological Mechanism of Psychotic Symptoms and Obsessive-Compulsive Symptoms in Patients with Psychotic Disorders and Their Siblings. PLOS ONE 2015;10 (6):e0125103 [PubMed]
van Dam DS, van Nierop M, Viechtbauer W, Velthorst E, van Winkel R, Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D, Childhood abuse and neglect in relation to the presence and persistence of psychotic and depressive symptomatology. PSYCHOL MED 2015;45 (7):1363-1377 [PubMed]
van der Meer FJ, Velthorst E [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer C, Myin-Germeys I, van Os J, Wiersma D]] , Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. PSYCHOL MED 2015;45 (9):1977-1988 [PubMed]
van der Velde J, Gromann PM, Swart M, de Haan L, Wiersma D, Bruggeman R, Krabbendam L, Aleman A, Grey matter, an endophenotype for schizophrenia? A voxel-based morphometry study in siblings of patients with schizophrenia. J PSYCHIATR NEUROSCI 2015;40 (3):207-213 [PubMed]
van der Velde J, Gromann PM, Swart M, Wiersma D, de Haan L, Bruggeman R, Krabbendam L, Aleman A, Alexithymia influences brain activation during emotion perception but not regulation. SOC COGN AFFECT NEUR 2015;10 (2):285-293 [PubMed]
van Nierop M, Viechtbauer W, Gunther N, van Zelst C, de Graaf R, ten Have M, van Dorsselaer S, Bak M, van Winkel R [Contributors: Bruggeman R, Wiersma D, Cahn W, Kahn RS, de Haan L, Meijer CJ, Myin-Germeys I, van Os J]] , Childhood trauma is associated with a specific admixture of affective, anxiety, and psychosis symptoms cutting across traditional diagnostic boundaries. PSYCHOL MED 2015;45 (6):1277-1288 [PubMed]
van Tricht MJ, Bour LJ, Koelman JHTM, Derks EM, Braff DL, de Wilde OM, Boerée T, Linszen DH, de Haan L, Nieman DH, Qualitative and quantitative aspects of information processing in first psychosis: latent class analyses in patients, at-risk subjects, and controls. PSYCHOPHYSIOLOGY 2015;52 (4):585-593 [PubMed]
van Tricht MJ, Nieman DH, Koelman JTM, Mensink AJM, Bour LJ, van der Meer JN, van Amelsvoort TA, Linszen DH, de Haan L, Sensory gating in subjects at ultra high risk for developing a psychosis before and after a first psychotic episode. WORLD J BIOL PSYCHIA 2015;16 (1):12-21 [PubMed]
van Winkel R [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , Further Evidence That Cannabis Moderates Familial Correlation of Psychosis-Related Experiences. PLOS ONE 2015;10 (9):e0137625 [PubMed]
van Zelst C, van Nierop M, van Dam DS, Bartels-Velthuis AA, Delespaul P [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , Associations between Stereotype Awareness, Childhood Trauma and Psychopathology: A Study in People with Psychosis, Their Siblings and Controls. PLOS ONE 2015;10 (2):UNSP e0117386 [PubMed]
Velthorst E, Koeter M, van der Gaag M, Nieman DH, Fett AKJ, Smit F, Staring ABP, Meijer C, de Haan L, Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. PSYCHOL MED 2015;45 (3):453-465 [PubMed]
Vilhjálmsson BJ, Yang J, Finucane HK, Gusev A, Lindström S, Ripke S, Genovese G, Loh PR, Bhatia G, Do R, Hayeck T, Won HH, Kathiresan S, Pato M, Pato C, Tamimi R, Stahl E, Zaitlen N, Pasaniuc B, Belbin G, Kenny EE, Schierup MH, de Jager P, Patsopoulos NA, McCarroll S, Daly M, Purcell S, Chasman D, Neale B, Goddard M, Visscher PM, Kraft P, Patterson N, Price AL [Contributors: Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, Lee P, Bulik-Sullivan B, Collier DA, Huang H, Pers TH, Agartz I, Agerbo E, Albus M, Alexander M, Amin F, Bacanu SA, Begemann M, Belliveau RA Jr, Bene J, Bergen SE, Bevilacqua E, Bigdeli TB, Black DW, Bruggeman R, Buccola NG, Buckner RL, Byerley W, Cahn W, Cai G, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Chan RCK, Chen RYL, Chen EYH, Cheng W, Cheung EFC, Chong SA, Cloninger CR, Cohen D, Cohen N, Cormican P, Craddock N, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, del Favero J, DeLisi LE, Demontis D, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Durmishi N, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedl M, Friedman JI, Fromer M, Genovese G, Georgieva L, Gershon ES, Giegling I, Giusti-Rodrguez P, Godard S, Goldstein JI, Golimbet V, Gopal S, Gratten J, Grove J, de Haan L, Hammer C, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms S, Hirschhorn JN, Hoffmann P, Hofman A, Hollegaard MV, Hougaard DM, Ikeda M, Joa I, Julia A, Kahn RS, Kalaydjieva L, Karachanak-Yankova S, Karjalainen J, Kavanagh D, Keller MC, Kelly BJ, Kennedy JL, Khrunin A, Kim Y, Klovins J, Knowles JA, Konte B, Kucinskas V, Kucinskiene ZA, Kuzelova-Ptackova H, Kahler AK, Laurent C, Keong JLC, Lee SH, Legge SE, Lerer B, Li M, Li T, Liang KY, Lieberman J, Limborska S, Loughland CM, Lubinski J, Lnnqvist J, Macek M Jr, Magnusson PKE, Maher BS, Maier W, Mallet J, Marsal S, Mattheisen M, Mattingsdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Mors O, Mortensen PB, Murphy KC, Murray RM, Myin-Germeys I, Mller-Myhsok B, Nelis M, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nikitina-Zake L, Nisenbaum L, Nordin A, O'Callaghan E, O'Dushlaine C, O'Neill FA, Oh SY, Olincy A, Olsen L, van Os J, Pantelis C, Papadimitriou GN, Papiol S, Parkhomenko E, Pato MT, Paunio T, Pejovic-Milovancevic M, Perkins DO, Pietilinen O, Pimm J, Pocklington AJ, Powell J, Price A, Pulver AE, Purcell SM, Quested D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Schall U, Schubert CR, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Sigurdsson E, Silagadze T, Silverman JM, Sim K, Slominsky P, Smoller JW, So HC, Spencer CCA, Stahl EA, Stefansson H, Steinberg S, Stogmann E, Straub RE, Strengman E, Strohmaier J, Stroup TS, Subramaniam M, Suvisaari J, Svrakic DM, Szatkiewicz JP, Sderman E, Thirumalai S, Toncheva D, Tooney PA, Tosato S, Veijola J, Waddington J, Walsh D, Wang D, Wang Q, Webb BT, Weiser M, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wong EHM, Wormley BK, Wu JQ, Xi HS, Zai CC, Zheng X, Zimprich F, Wray NR, Stefansson K, Visscher PM, Adolfsson R, Andreassen OA, Blackwood DHR, Bramon E, Buxbaum JD, Børglum AD, Cichon S, Darvasi A, Domenici E, Ehrenreich H, Esko T, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jonsson EG, Kendler KS, Kirov G, Knight J, Lencz T, Levinson DF, Li QS, Liu J, Malhotra AK, McCarroll SA, McQuillin A, Moran JL, Mowry BJ, Nthen MM, Ophoff RA, Owen MJ, Palotie A, Pato CN, Petryshen TL, Posthuma D, Rietschel M, Riley BP, Rujescu D, Sham PC, Sklar P, St Clair D, Weinberger DR, Wendland JR, Werge T, Daly MJ, Sullivan PF, O'Donovan MC, Kraft P, Hunter DJ, Adank M, Ahsan H, Aittomäki K, Baglietto L, Berndt S, Blomquist C, Canzian F, Chang-Claude J, Chanock SJ, Crisponi L, Czene K, Dahmen N, Silva IDS, Easton D, Eliassen AH, Figueroa J, Fletcher O, Garcia-Closas M, Gaudet MM, Gibson L, Haiman CA, Hall P, Hazra A, Hein R, Henderson BE, Hofman A, Hopper JL, Irwanto A, Johansson M, Kaaks R, Kibriya MG, Lichtner P, Lindström S, Lund E, Makalic E, Meindl A, Meijers-Heijboer H, Müller-Myhsok B, Muranen TA, Nevanlinna H, Peeters PH, Peto J, Prentice RL, Rahman N, Sánchez MJ, Schmidt DF, Schmutzler RK, Southey MC, Tamimi R, Travis R, Turnbull C, Uitterlinden AG, van der Luijt RB, Waisfisz Q, Wang Z, Whittemore AS, Yang R, Zheng W]] , Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. AM J HUM GENET 2015;97 (4):576-592 [PubMed]
Wiersma D, Visser E, Bähler M, Bruggeman R, Delespaul PA, van der Gaag M, de Haan L, Keet IPM, Nijssen Y, van Os J, Pijnenborg GHM, Slooff C, Swildens W, de Vos AE, van Weeghel J, Wunderink L, Mulder CL, Functionele remissie bij mensen met een ernstige psychiatrische aandoening; psychometrische eigenschappen van een nieuw ROM-instrument. TIJDSCHR PSYCHIATR 2015;57 (6):395-404 [PubMed]
[Contributors: O'Dushlaine C, Rossin L, Lee PH, Duncan L, Parikshak NN, Newhouse S, Ripke S, Neale BM, Purcell SM, Posthuma D, Nurnberger JI, Lee SH, Faraone SV, Perlis RH, Mowry BJ, Thapar A, Goddard ME, Witte JS, Absher D, Agartz I, Akil H, Amin F, Andreassen OA, Anjorin A, Anney R, Anttila V, Arking DE, Asherson P, Azevedo MH, Backlund L, Badner JA, Bailey AJ, Banaschewski T, Barchas JD, Barnes MR, Barrett TB, Bass N, Battaglia A, Bauer M, Bayés M, Bellivier F, Bergen SE, Berrettini W, Betancur C, Bettecken T, Biederman J, Binder EB, Black DW, Blackwood DHR, Bloss CS, Boehnke M, Boomsma DI, Breuer R, Bruggeman R, Cormican P, Buccola NG, Buitelaar JK, Bunney WE, Buxbaum JD, Byerley WF, Byrne EM, Caesar S, Cahn W, Cantor RM, Casas M, Chakravarti A, Chambert K, Choudhury K, Cichon S, Mattheisen M, Cloninger CR, Collier DA, Cook EH, Coon H, Cormand B, Corvin A, Coryell WH, Craig DW, Craig IW, Crosbie J, Cuccaro ML, Curtis D, Czamara D, Datta S, Dawson G, Day R, de Geus EJ, Degenhardt F, Djurovic S, Donohoe GJ, Doyle AE, Duan J, Dudbridge F, Duketis E, Ebstein RP, Edenberg HJ, Elia J, Ennis S, Etain B, Fanous A, Farmer AE, Ferrier IN, Flickinger M, Fombonne E, Foroud T, Frank J, Franke B, Fraser C, Freedman R, Freimer NB, Freitag CM, Friedl M, Frisén L, Gallagher L, Gejman PV, Georgieva L, Gershon ES, Giegling I, Gill M, Gordon SD, Gordon-Smith K, Green EK, Greenwood TA, Grice DE, Gross M, Grozeva D, Guan W, Gurling H, de Haan L, Haines JL, Hakonarson H, Hallmayer J, Hamilton SP, Hamshere ML, Hansen TF, Hartmann AM, Hautzinger M, Heath AC, Henders AK, Herms S, Hickie IB, Hipolito M, Hoefels S, Holsboer F, Hoogendijk WJ, Hottenga JJ, Hultman CM, Hus V, Ingason A, Ising M, Jamain S, Jones EG, Jones I, Jones L, Tzeng JY, Kähler AK, Kahn RS, Kandaswamy R, Keller MC, Kennedy JL, Kenny E, Kent L, Kim Y, Kirov GK, Klauck SM, Klei L, Knowles JA, Kohli MA, Koller DL, Konte B, Korszun A, Krabbendam L, Krasucki R, Kuntsi J, Kwan P, Landén M, Längström N, Lathrop M, Lawrence J, Lawson WB, Leboyer M, Ledbetter DH, Lencz T, Lesch KP, Levinson DF, Lewis CM, Li J, Lichtenstein P, Lieberman JA, Lin DY, Linszen DH, Liu C, Lohoff FW, Loo SK, Lord C, Lowe JK, Lucae S, MacIntyre DJ, Madden PAF, Maestrini E, Magnusson PKE, Mahon PB, Maier W, Malhotra AK, Mane SM, Martin CL, Martin NG, Matthews K, Mattingsdal M, McCarroll SA, McGhee KA, McGough JJ, McGrath PJ, McGuffin P, McInnis MG, McIntosh A, McKinney R, McLean AW, McMahon FJ, McMahon WM, McQuillin A, Medeiros H, Medland SE, Meier S, Melle I, Meyer J, Middeldorp CM, Middleton L, Milanova V, Miranda A, Monaco AP, Montgomery GW, Moran JL, Moreno-de-Luca D, Morken G, Morris DW, Morrow EM, Moskvina V, Muglia P, Mühleisen TW, Muir WJ, Müller-Myhsok B, Murtha M, Myers RM, Myin-Germeys I, Neale MC, Nelson SF, Nievergelt CM, Nikolov I, Nimgaonkar V, Nolen WA, Nöthen MM, Nwulia EA, Nyholt DR, Oades RD, Olincy A, Oliveira G, Olsen L, Ophoff RA, Osby U, Owen MJ, Palotie A, Parr JR, Paterson AD, Pato CN, Pato MT, Penninx BW, Pergadia ML, Pericak-Vance MA, Pickard BS, Pimm J, Piven J, Potash JB, Poustka F, Propping P, Puri V, Quested DJ, Quinn EM, Ramos-Quiroga JA, Rasmussen HB, Raychaudhuri S, Rehnström K, Reif A, Ribasés M, Rice JP, Rietschel M, Roeder K, Roeyers H, Rothenberger A, Rouleau G, Ruderfer D, Rujescu D, Sanders AR, Sanders SJ, Santangelo SL, Sergeant JA, Schachar R, Schalling M, Schatzberg AF, Scheftner WA, Schellenberg GD, Scherer SW, Schork NJ, Schulze TG, Schumacher J, Schwarz M, Scolnick E, Scott LJ, Shi J, Shilling PD, Shyn SI, Silverman JM, Slager SL, Smalley SL, Smit JH, Smith EN, Sonuga-Barke EJS, St Clair D, State M, Steffens M, Steinhausen HC, Strauss JS, Strohmaier J, Stroup TS, Sutcliffe JS, Szatmari P, Szelinger S, Thirumalai S, Thompson RC, Todorov AA, Tozzi F, Treutlein J, Uhr M, van den Oord JCG, van Grootheest G, van Os J, Vicente AM, Vieland VJ, Vincent JB, Visscher PM, Walsh CA, Wassink TH, Watson SJ, Weissman MM, Werge T, Wienker TF, Wijsman EM, Willemsen G, Williams N, Willsey AJ, Witt SH, Xu W, Young AH, Yu TW, Zammit S, Zandi PP, Zhang P, Zitman FG, Zöllner S, Devlin B, Kelsoe JR, Sklar P, Daly MJ, O'Donovan MC, Craddock N, Kendler KS, Weiss LA, Wray NR, Zhao Z, Geschwind DH, Sullivan PF, Smoller JW, Holmans PA, Breen G]] , Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. NAT NEUROSCI 2015;18 (2):199-209 [PubMed]
Apeldoorn SY, Sterk B, van den Heuvel ER, Schoevers RA, Islam MA, Bruggeman R, Cahn W, deHaan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , Factors contributing to the duration of untreated psychosis. SCHIZOPHR RES 2014;158 (1-3):76-81 [PubMed]
Børglum AD, Demontis D, Grove J, Pallesen J, Hollegaard MV, Pedersen CB, Hedemand A, Mattheisen M, Uitterlinden A, Nyegaard M, Ørntoft T, Wiuf C, Didriksen M, Nordentoft M, Nöthen MM, Rietschel M, Ophoff RA, Cichon S, Yolken RH, Hougaard DM, Mortensen PB, Mors O [Contributors: Kahn RS, Linszen DH, van Os J, Durk-Wiersma NN, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci. MOL PSYCHIATR 2014;19 (3):325-333 [PubMed]
Boyette LL, Korver-Nieberg N, Meijer C, de Haan L [Contributors: Kahn RS, de Haan L, van Os J, Wiersma D, Bruggeman R, Cahn W, Meijer C, Myin-Germeys I]] , Quality of Life in Patients With Psychotic Disorders Impact of Symptoms, Personality, and Attachment. J NERV MENT DIS 2014;202 (1):64-69 [PubMed]
Boyette LLNJ. Personality and psychotic disorders. S.l.: s.n.; 2014. 172p. ISBN 9789461825032 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L; copromotor(s): Meijer CJ, Dingemans PMAJ)
Boyette LL, van Dam D, Meijer C, Velthorst E, Cahn W, de Haan L, Kahn R, van Os J, Wiersma D, Bruggeman R, Myin-Germeys I, Personality compensates for impaired quality of life and social functioning in patients with psychotic disorders who experienced traumatic events. SCHIZOPHRENIA BULL 2014;40 (6):1356-1365 [PubMed]
Bramon E, Pirinen M, Strange A, Lin K, Freeman C, Bellenguez C, Su Z, Band G, Pearson R, Vukcevic D, Langford C, Deloukas P, Hunt S, Gray E, Dronov S, Potter SC, Tashakkori-Ghanbaria A, Edkins S, Bumpstead SJ, Arranz MJ, Bakker S, Bender S, Bruggeman R, Cahn W, Chandler D, Collier DA, Crespo-Facorro B, Dazzan P, de Haan L, Di Forti M, Dragović M, Giegling I, Hall J, Iyegbe C, Jablensky A, Kahn RS, Kalaydjieva L, Kravariti E, Lawrie S, Linszen DH, Mata I, McDonald C, McIntosh A, Myin-Germeys I, Ophoff RA, Pariante CM, Paunio T, Picchioni M, Ripke S, Rujescu D, Sauer H, Shaikh M, Sussmann J, Suvisaari J, Tosato S, Toulopoulou T, van Os J, Walshe M, Weisbrod M, Whalley H, Wiersma D, Blackwell JM, Brown MA, Casas JP, Corvin A, Duncanson A, Jankowski JAZ, Markus HS, Mathew CG, Palmer CNA, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Wood NW, Barroso I, Peltonen L, Lewis CM, Murray RM, Donnelly P, Powell J, Spencer CCA [Contributors: Arranz MJ, Bakker S, Bender S, Bramon E, Collier D, Crespo-Facorro B, Hall J, Iyegbe C, Jablensky A, Kahn RS, Kalaydjieva L, Lawrie S, Lewis CM, Lin K, Linszen DH, Mata I, McIntosh A, Murray RM, Ophoff RA, Powell J, Rujescu D, van J, Walshe M, Weisbrod M, Wiersma D, Donnelly P, Barroso I, Blackwell JM, Brown MA, Casas JP, Corvin A, Deloukas P, Duncanson A, Jankowski J, Markus HS, Mathew CG, Palmer CNA, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Viswanathan AC, Wood NW, Spencer CCA, Band G, Bellenguez C, Freeman C, Hellenthal G, Giannoulatou E, Pirinen M, Pearson R, Strange A, Su Z, Vukcevic D, Langford C, Hunt SE, Edkins S, Gwilliam R, Blackburn H, Bumpstead SJ, Dronov S, Gillman M, Gray E, Hammond N, Jayakumar A, McCann OT, Liddle J, Potter SC, Ravindrarajah R, Ricketts M, Tashakkori-Ghanbaria A, Waller M, Weston P, Widaa S, Whittaker P, McCarthy MI]] , A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. BIOL PSYCHIAT 2014;75 (5):386-397 [PubMed]
Cousijn J, Vingerhoets WAM, Koenders L, de Haan L, van den Brink W, Wiers RW, Goudriaan AE, Relationship between working-memory network function and substance use: a 3-year longitudinal fMRI study in heavy cannabis users and controls. ADDICT BIOL 2014;19 (2):282-293 [PubMed]
de Koning MB, Bloemen OJN, van Duin EDA, Booij J, Abel KM, de Haan L, Linszen DH, van Amelsvoort TAMJ, Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis. J PSYCHOPHARMACOL 2014;28 (6):553-560 [PubMed]
Gromann PM, Shergill SS, de Haan L, Meewis DGJ, Fett AKJ, Korver-Nieberg N, Krabbendam L, Reduced brain reward response during cooperation in first-degree relatives of patients with psychosis: an fMRI study. PSYCHOL MED 2014;44 (16):3445-3454 [PubMed]
Gusev A, Lee SH, Trynka G, Finucane H, Vilhjálmsson BJ, Xu H, Zang C, Ripke S, Bulik-Sullivan B, Stahl E, Kähler AK, Hultman CM, Purcell SM, McCarroll SA, Daly M, Pasaniuc B, Sullivan PF, Neale BM, Wray NR, Raychaudhuri S, Price AL [Contributors: Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, Lee P, Bulik-Sullivan B, Collier DA, Huang H, Pers TH, Agartz I, Agerbo E, Albus M, Alexander M, Amin F, Bacanu SA, Begemann M, Belliveau RA Jr, Bene J, Bergen SE, Bevilacqua E, Bigdeli TB, Black DW, Børglum AD, Bruggeman R, Buccola NG, Buckner RL, Byerley W, Cahn W, Cai G, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Chan RCK, Chen RYL, Chen EYH, Cheng W, Cheung EFC, Chong SA, Cloninger CR, Cohen D, Cohen N, Cormican P, Craddock N, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, del Favero J, DeLisi LE, Demontis D, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Durmishi N, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedl M, Friedman JI, Fromer M, Genovese G, Georgieva L, Gershon ES, Giegling I, Giusti-Rodrguez P, Godard S, Goldstein JI, Golimbet V, Gopal S, Gratten J, Grove J, de Haan L, Hammer C, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms S, Hirschhorn JN, Hoffmann P, Hofman A, Hollegaard MV, Hougaard DM, Ikeda M, Joa I, Julià A, Kahn RS, Kalaydjieva L, Karachanak-Yankova S, Karjalainen J, Kavanagh D, Keller MC, Kelly BJ, Kennedy JL, Khrunin A, Kim Y, Klovins J, Knowles JA, Konte B, Kucinskas V, Kucinskiene ZA, Kuzelova-Ptackova H, Kähler AK, Laurent C, Keong JLC, Lee SH, Legge SE, Lerer B, Li M, Li T, Liang KY, Lieberman J, Limborska S, Loughland CM, Lubinski J, Lnnqvist J, Macek M Jr, Magnusson PKE, Maher BS, Maier W, Mallet J, Marsal S, Mattheisen M, Mattingsdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Mors O, Mortensen PB, Murphy KC, Murray RM, Myin-Germeys I, Mller-Myhsok B, Nelis M, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nikitina-Zake L, Nisenbaum L, Nordin A, O'Callaghan E, O'Dushlaine C, O'Neill FA, Oh SY, Olincy A, Olsen L, van Os J, Pantelis C, Papadimitriou GN, Papiol S, Parkhomenko E, Pato MT, Paunio T, Pejovic-Milovancevic M, Perkins DO, Pietilinen O, Pimm J, Pocklington AJ, Powell J, Price A, Pulver AE, Purcell SM, Quested D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Schall U, Schubert CR, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Sigurdsson E, Silagadze T, Silverman JM, Sim K, Slominsky P, Smoller JW, So HC, Spencer CCA, Stahl EA, Stefansson H, Steinberg S, Stogmann E, Straub RE, Strengman E, Strohmaier J, Stroup TS, Subramaniam M, Suvisaari J, Svrakic DM, Szatkiewicz JP, Sderman E, Thirumalai S, Toncheva D, Tooney PA, Tosato S, Veijola J, Waddington J, Walsh D, Wang D, Wang Q, Webb BT, Weiser M, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wong EHM, Wormley BK, Wu JQ, Xi HS, Zai CC, Zheng X, Zimprich F, Wray NR, Stefansson K, Visscher PM, Adolfsson R, Andreassen OA, Blackwood DHR, Bramon E, Buxbaum JD, Brglum AD, Cichon S, Darvasi A, Domenici E, Ehrenreich H, Esko T, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jönsson EG, Kendler KS, Kirov G, Knight J, Lencz T, Levinson DF, Li QS, Liu J, Malhotra AK, McCarroll SA, McQuillin A, Moran JL, Mowry BJ, Nthen MM, Ophoff RA, Owen MJ, Palotie A, Pato CN, Petryshen TL, Posthuma D, Rietschel M, Riley BP, Rujescu D, Sham PC, Sklar P, St Clair D, Weinberger DR, Wendland JR, Werge T, Daly MJ, Sullivan PF, O'Donovan MC, Chambert K, Akterin S, Bergen S, Ruderfer D, Scolnick E, Purcell S, McCarroll S]] , Partitioning Heritability of Regulatory and Cell-Type-Specific Variants across 11 Common Diseases. AM J HUM GENET 2014;95 (5):535-552 [PubMed]
Jagt YQ, Sutterland AL, Meijer JH, Oudijn MS, Kemperman PM, Vulink NCC, de Haan L, Parasieten- of infestatiewaan: een therapeutische uitdaging. NED TIJDSCHR GENEESKD 2014;158:A7548 [PubMed]
Juraeva D, Haenisch B, Zapatka M, Frank J, Witt SH, Mühleisen TW, Treutlein J, Strohmaier J, Meier S, Degenhardt F, Giegling I, Ripke S, Leber M, Lange C, Schulze TG, Mössner R, Nenadic I, Sauer H, Rujescu D, Maier W, Børglum A, Ophoff R, Cichon S, Nöthen MM, Rietschel M, Mattheisen M, Brors B [Contributors: Kahn RS, Cahn W, Linszen DH, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R, Mors O, Børglum AD, Mortensen PB, Pedersen CB, Demontis D, Grove J, Mattheisen M, Hougaard DM]] , Integrated Pathway-Based Approach Identifies Association between Genomic Regions at CTCF and CACNB2 and Schizophrenia. PLOS GENET 2014;10 (6):e1004345 [PubMed]
Korver N. Attachment and psychosis. S.l.: s.n.; 2014. 212p. ISBN 9789461824479 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L; copromotor(s): Meijer CJ, Koeter MWJ)
Korver-Nieberg N, Berry K, Meijer CJ, de Haan L, Adult attachment and psychotic phenomenology in clinical and non-clinical samples: a systematic review. PSYCHOL PSYCHOTHER-T 2014;87 (2):127-154 [PubMed]
Lako IM, Wigman JTW, Klaassen RMC, Slooff CJ, Taxis K, Bartels-Velthuis AA [Contributors: Bruggeman R, Wiersma D, Cahn W, Kahn RS, de Haan L, Meijer CJ, Myin-Germeys I, van Os J]] , Psychometric properties of the self-report version of the Quick Inventory of Depressive Symptoms (QIDS-SR16) questionnaire in patients with schizophrenia. BMC PSYCHIATRY 2014;14:247 [PubMed]
Lataster T, Verweij K, Viechtbauer W [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Effect of illness expression and liability on familial associations of clinical and subclinical psychosis phenotypes. ACTA PSYCHIAT SCAND 2014;129 (1):44-53 [PubMed]
Luijten M, Machielsen MWJ, Veltman DJ, Hester R, de Haan L, Franken IHA, Systematic review of ERP and fMRI studies investigating inhibitory control and error processing in people with substance dependence and behavioural addictions. J PSYCHIATR NEUROSCI 2014;39 (3):149-169 [PubMed]
Machielsen MWJ. Schizophrenia and comorbid cannabis use disorders. Brain structure, function and the effect of antipsychotic medications. s.l.: s.n.; 2014. 245p. ISBN 9789088918131 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L, Veltman DJ; copromotor(s): van den Brink W)
Machielsen MWJ, Veltman DJ, van den Brink W, de Haan L, The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. J PSYCHOPHARMACOL 2014;28 (7):633-642 [PubMed]
Mattila T, Wohlfarth T, Koeter M, Storosum J, van den Brink W, de Haan L, Leufkens H, Denys D, Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia - an individual patient data meta-analysis. EUR NEUROPSYCHOPHARM 2014;24 (7):1067-1077 [PubMed]
Meesters PD, Comijs HC, Sonnenberg CM, Hoogendoorn AW, de Haan L, Eikelenboom P, Beekman ATF, Stek ML, Prevalence and correlates of depressive symptoms in a catchment-area based cohort of older community-living schizophrenia patients. SCHIZOPHR RES 2014;157 (1-3):285-291 [PubMed]
Nicodemus KK, Hargreaves A, Morris D, Anney R, Gill M, Corvin A, Donohoe G [Contributors: Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DHR, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, de Hert M, Jönsson EG, Bitter I, Pietiläinen OPH, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, de Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jürgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lönnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nöthen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Ørntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Réthelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CCA, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman P, Barroso I, Blackwell JM, Bramon E, Casas JP, Deloukas P, Duncanson A, Jankowski J, Markus HS, Mathew CG, Palmer CNA, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Viswanathan AC, Wood NW, Band G, Bellenguez C, Freeman C, Hellenthal G, Giannoulatou E, Pirinen M, Pearson R, Su Z, Vukcevic D, Langford C, Hunt SE, Edkins S, Gwilliam R, Blackburn H, Bumpstead SJ, Dronov S, Gillman M, Gray E, Hammond N, Jayakumar A, McCann OT, Liddle J, Potter SC, Ravindrarajah R, Ricketts M, Waller M, Weston P, Widaa S, Whittaker P]] , Variability in working memory performance explained by epistasis vs polygenic scores in the ZNF804A pathway. JAMA PSYCHIAT 2014;71 (7):778-785 [PubMed]
Nieman DH, Ruhrmann S, Dragt S, Soen F, van Tricht MJ, Koelman JHTM, Bour LJ, Velthorst E, Becker HE, Weiser M, Linszen DH, de Haan L, Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables. SCHIZOPHRENIA BULL 2014;40 (6):1482-1490 [PubMed]
Postmes L, Sno HN, Goedhart S, van der Stel J, Heering HD, de Haan L, Schizophrenia as a self-disorder due to perceptual incoherence. SCHIZOPHR RES 2014;152 (1):41-50 [PubMed]
Quee PJ, Alizadeh BZ, Aleman A, van den Heuvel ER [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, Bruggeman R]] , Cognitive subtypes in non-affected siblings of schizophrenia patients: characteristics and profile congruency with affected family members. PSYCHOL MED 2014;44 (2):395-405 [PubMed]
Quee PJ, Van der Meer L, Krabbendam L, de Haan L, Cahn W, Wiersma D, van Beveren N, Pijnenborg GHM, Mulder CL, Bruggeman R, Aleman A, Insight change in psychosis: relationship with neurocognition, social cognition, clinical symptoms and phase of illness. ACTA PSYCHIAT SCAND 2014;129 (2):126-133 [PubMed]
Smeerdijk M, Keet R, de Haan L, Barrowclough C, Linszen D, Schippers G, Feasibility of teaching motivational interviewing to parents of young adults with recent-onset schizophrenia and co-occurring cannabis use. J SUBST ABUSE TREAT 2014;46 (3):340-345 [PubMed]
Swets M, Dekker J, van Emmerik-van Oortmerssen K, Smid GE, Smit F, de Haan L, Schoevers RA, The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. SCHIZOPHR RES 2014;152 (2-3):458-468 [PubMed]
Thompson PM, Stein JL, Medland SE, Hibar DP, Vasquez AA, Renteria ME, Toro R, Jahanshad N, Schumann G, Franke B, Wright MJ, Martin NG, Agartz I, Alda M, Alhusaini S, Almasy L, Almeida J, Alpert K, Andreasen NC, Andreassen OA, Apostolova LG, Appel K, Armstrong NJ, Aribisala B, Bastin ME, Bauer M, Bearden CE, Bergmann O, Binder EB, Blangero J, Bockholt HJ, Bøen E, Bois C, Boomsma DI, Booth T, Bowman IJ, Bralten J, Brouwer RM, Brunner HG, Brohawn DG, Buckner RL, Buitelaar J, Bulayeva K, Bustillo JR, Calhoun VD, Cannon DM, Cantor RM, Carless MA, Caseras X, Cavalleri GL, Chakravarty MM, Chang KD, Ching CRK, Christoforou A, Cichon S, Clark VP, Conrod P, Coppola G, Crespo-Facorro B, Curran JE, Czisch M, Deary IJ, de Geus EJC, den Braber A, Delvecchio G, Depondt C, de Haan L, de Zubicaray GI, Dima D, Dimitrova R, Djurovic S, Dong H, Donohoe G, Duggirala R, Dyer TD, Ehrlich S, Ekman CJ, Elvsåshagen T, Emsell L, Erk S, Espeseth T, Fagerness J, Fears S, Fedko I, Fernández G, Fisher SE, Foroud T, Fox PT, Francks C, Frangou S, Frey EM, Frodl T, Frouin V, Garavan H, Giddaluru S, Glahn DC, Godlewska B, Goldstein RZ, Gollub RL, Grabe HJ, Grimm O, Gruber O, Guadalupe T, Gur RE, Gur RC, Göring HHH, Hagenaars S, Hajek T, Hall GB, Hall J, Hardy J, Hartman CA, Hass J, Hatton SN, Haukvik UK, Hegenscheid K, Heinz A, Hickie IB, Ho BC, Hoehn D, Hoekstra PJ, Hollinshead M, Holmes AJ, Homuth G, Hoogman M, Hong LE, Hosten N, Hottenga JJ, Hulshoff Pol HE, Hwang KS, Jack CR Jr, Jenkinson M, Johnston C, Jönsson EG, Kahn RS, Kasperaviciute D, Kelly S, Kim S, Kochunov P, Koenders L, Krämer B, Kwok JBJ, Lagopoulos J, Laje G, Landen M, Landman BA, Lauriello J, Lawrie SM, Lee PH, Le Hellard S, Lemaître H, Leonardo CD, Li CS, Liberg B, Liewald DC, Liu X, Lopez LM, Loth E, Lourdusamy A, Luciano M, Macciardi F, Machielsen MWJ, Macqueen GM, Malt UF, Mandl R, Manoach DS, Martinot JL, Matarin M, Mather KA, Mattheisen M, Mattingsdal M, Meyer-Lindenberg A, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Meisenzahl E, Melle I, Milaneschi Y, Mohnke S, Montgomery GW, Morris DW, Moses EK, Mueller BA, Muñoz Maniega S, Mühleisen TW, Müller-Myhsok B, Mwangi B, Nauck M, Nho K, Nichols TE, Nilsson LG, Nugent AC, Nyberg L, Olvera RL, Oosterlaan J, Ophoff RA, Pandolfo M, Papalampropoulou-Tsiridou M, Papmeyer M, Paus T, Pausova Z, Pearlson GD, Penninx BW, Peterson CP, Pfennig A, Phillips M, Pike GB, Poline JB, Potkin SG, Pütz B, Ramasamy A, Rasmussen J, Rietschel M, Rijpkema M, Risacher SL, Roffman JL, Roiz-Santiañez R, Romanczuk-Seiferth N, Rose EJ, Royle NA, Rujescu D, Ryten M, Sachdev PS, Salami A, Satterthwaite TD, Savitz J, Saykin AJ, Scanlon C, Schmaal L, Schnack HG, Schork AJ, Schulz SC, Schür R, Seidman L, Shen L, Shoemaker JM, Simmons A, Sisodiya SM, Smith C, Smoller JW, Soares JC, Sponheim SR, Sprooten E, Starr JM, Steen VM, Strakowski S, Strike L, Sussmann J, Sämann PG, Teumer A, Toga AW, Tordesillas-Gutierrez D, Trabzuni D, Trost S, Turner J, van den Heuvel M, van der Wee NJ, van Eijk K, van Erp TGM, van Haren NEM, van 't Ent D, van Tol MJ, Valdés Hernández MC, Veltman DJ, Versace A, Völzke H, Walker R, Walter H, Wang L, Wardlaw JM, Weale ME, Weiner MW, Wen W, Westlye LT, Whalley HC, Whelan CD, White T, Winkler AM, Wittfeld K, Woldehawariat G, Wolf C, Zilles D, Zwiers MP, Thalamuthu A, Schofield PR, Freimer NB, Lawrence NS, Drevets W, The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. BRAIN IMAGING BEHAV 2014;8 (2):153-182 [PubMed]
van Beveren NJM, Schwarz E, Noll R, Guest PC, Meijer C, de Haan L, Bahn S, Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. TRANSL PSYCHIAT 2014;4:e430 [PubMed]
van Dam DS, Korver-Nieberg N, Velthorst E, Meijer CJ, de Haan L [Contributors: Kahn RS, de Haan L, van Os J, Wiersma D, Bruggeman R, Cahn W, Meijer CJ, Myin-Germeys I]] , Childhood maltreatment, adult attachment and psychotic symptomatology: a study in patients, siblings and controls. SOC PSYCH PSYCH EPID 2014;49 (11):1759-1767 [PubMed]
van der Meer FJ, Meijer JH, Meijer CJ, van den Brink W, Velthorst E [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls. PSYCHOL MED 2014;44 (9):1901-1911 [PubMed]
van der Velde J, van Tol MJ, Goerlich-Dobre KS, Gromann PM, Swart M, de Haan L, Wiersma D, Bruggeman R, Krabbendam L, Aleman A, Dissociable morphometric profiles of the affective and cognitive dimensions of alexithymia. CORTEX 2014;54:190-199 [PubMed]
van Os J, Rutten BP, Myin-Germeys I, Delespaul P, Viechtbauer W, van Zelst C, Bruggeman R, Reininghaus U, Morgan C, Murray RM, Di Forti M, McGuire P, Valmaggia LR, Kempton MJ, Gayer-Anderson C, Hubbard K, Beards S, Stilo SA, Onyejiaka A, Bourque F, Modinos G, Tognin S, Calem M, O'Donovan MC, Owen MJ, Holmans P, Williams N, Craddock N, Richards A, Humphreys I, Meyer-Lindenberg A, Leweke FM, Tost H, Akdeniz C, Rohleder C, Bumb JM, Schwarz E, Alptekin K, Üçok A, Saka MC, Atbaşoğlu EC, Gülöksüz S, Gumus-Akay G, Cihan B, Karadağ H, Soygür H, Cankurtaran EŞ, Ulusoy S, Akdede B, Binbay T, Ayer A, Noyan H, Karadayı G, Akturan E, Ulaş H, Arango C, Parellada M, Bernardo M, Sanjuán J, Bobes J, Arrojo M, Santos JL, Cuadrado P, Rodríguez Solano JJ, Carracedo A, García Bernardo E, Roldán L, López G, Cabrera B, Cruz S, Díaz Mesa EM, Pouso M, Jiménez E, Sánchez T, Rapado M, González E, Martínez C, Sánchez E, Olmeda MS, de Haan L, Velthorst E, van der Gaag M, Selten JP, van Dam D, van der Ven E, van der Meer F, Messchaert E, Kraan T, Burger N, Leboyer M, Szoke A, Schürhoff F, Llorca PM, Jamain S, Tortelli A, Frijda F, Vilain J, Galliot AM, Baudin G, Ferchiou A, Richard JR, Bulzacka E, Charpeaud T, Tronche AM, de Hert M, van Winkel R, Decoster J, Derom C, Thiery E, Stefanis NC, Sachs G, Aschauer H, Lasser I, Winklbaur B, Schlögelhofer M, Riecher-Rössler A, Borgwardt S, Walter A, Harrisberger F, Smieskova R, Rapp C, Ittig S, Soguel-Dit-Piquard F, Studerus E, Klosterkötter J, Ruhrmann S, Paruch J, Julkowski D, Hilboll D, Sham PC, Cherny SS, Chen EYH, Campbell DD, Li M, Romeo-Casabona CM, Emaldi Cirión A, Urruela Mora A, Jones P, Kirkbride J, Cannon M, Rujescu D, Tarricone I, Berardi D, Bonora E, Seri M, Marcacci T, Chiri L, Chierzi F, Storbini V, Braca M, Minenna MG, Donegani I, Fioritti A, La Barbera D, La Cascia CE, Mulè A, Sideli L, Sartorio R, Ferraro L, Tripoli G, Seminerio F, Marinaro AM, McGorry P, Nelson B, Amminger GP, Pantelis C, Menezes PR, del-Ben CM, Gallo Tenan SH, Shuhama R, Ruggeri M, Tosato S, Lasalvia A, Bonetto C, Ira E, Nordentoft M, Krebs MO, Barrantes-Vidal N, Cristóbal P, Kwapil TR, Brietzke E, Bressan RA, Gadelha A, Maric NP, Andric S, Mihaljevic M, Mirjanic T, Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. SCHIZOPHRENIA BULL 2014;40 (4):729-736 [PubMed]
van Tricht MJ, Ruhrmann S, Arns M, Müller R, Bodatsch M, Velthorst E, Koelman JHTM, Bour LJ, Zurek K, Schultze-Lutter F, Klosterkötter J, Linszen DH, de Haan L, Brockhaus-Dumke A, Nieman DH, Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. SCHIZOPHR RES 2014;153 (1-3):42-47 [PubMed]
van Zelst C, van Nierop M, Oorschot M, Myin-Germeys I, van Os J, Delespaul P [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , Stereotype awareness, self-esteem and psychopathology in people with psychosis. PLOS ONE 2014;9 (2):e88586 [PubMed]
Veerman SRT, Schulte PFJ, Begemann MJH, de Haan L, Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. PHARMACOPSYCHIATRY 2014;47 (7):231-238 [PubMed]
Veerman SRT, Schulte PFJ, Begemann MJH, Engelsbel F, de Haan L, Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. PHARMACOPSYCHIATRY 2014;47 (6):185-194 [PubMed]
Veerman SRT, Schulte PFJ, de Haan L, The Glutamate Hypothesis: A Pathogenic Pathway from which Pharmacological interventions have Emerged. PHARMACOPSYCHIATRY 2014;47 (4-5):121-130 [PubMed]
Velthorst E, de Haan L, Sociaal disfunctioneren van jongeren met een ultrahoog risico op het ontwikkelen van een eerste psychose. TIJDSCHR PSYCHIATR 2014;56 (1):40-49 [PubMed]
Won S, Kwon MS, Mattheisen M, Park S, Park C, Kihara D, Cichon S, Ophoff R, Nöthen MM, Rietschel M, Baur M, Uitterlinden AG, Hofmann A, Lange C [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Efficient strategy for detecting gene × gene joint action and its application in schizophrenia. GENET EPIDEMIOL 2014;38 (1):60-71 [PubMed]
[Contributors: Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, Lee P, Bulik-Sullivan B, Collier DA, Huang H, Pers TH, Agartz I, Agerbo E, Albus M, Alexander M, Amin F, Bacanu SA, Begemann M, Belliveau RA Jr, Bene J, Bergen SE, Bevilacqua E, Bigdeli TB, Black DW, Bruggeman R, Buccola NG, Buckner RL, Byerley W, Cahn W, Cai G, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Chan RCK, Chen RYL, Chen EYH, Cheng W, Cheung EFC, Chong SA, Cloninger CR, Cohen D, Cohen N, Cormican P, Craddock N, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, del Favero J, Demontis D, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Durmishi N, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedl M, Friedman JI, Fromer M, Genovese G, Georgieva L, Giegling I, Giusti-Rodríguez P, Godard S, Goldstein JI, Golimbet V, Gopal S, Gratten J, de Haan L, Hammer C, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms S, Hirschhorn JN, Hoffmann P, Hofman A, Hollegaard MV, Hougaard DM, Ikeda M, Joa I, Julià A, Kahn RS, Kalaydjieva L, Karachanak-Yankova S, Karjalainen J, Kavanagh D, Keller MC, Kennedy JL, Khrunin A, Kim Y, Klovins J, Knowles JA, Konte B, Kucinskas V, Ausrele Kucinskiene Z, Kuzelova-Ptackova H, Kähler AK, Laurent C, Keong JLC, Lee SH, Legge SE, Lerer B, Li M, Li T, Liang KY, Lieberman J, Limborska S, Loughland CM, Lubinski J, Lönnqvist J, Macek M Jr, Magnusson PKE, Maher BS, Maier W, Mallet J, Marsal S, Mattheisen M, Mattingsdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Mors O, Murphy KC, Murray RM, Myin-Germeys I, Müller-Myhsok B, Nelis M, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nikitina-Zake L, Nisenbaum L, Nordin A, O'Callaghan E, O'Dushlaine C, O'Neill FA, Oh SY, Olincy A, Olsen L, van Os J, Pantelis C, Papadimitriou GN, Papiol S, Parkhomenko E, Pato MT, Paunio T, Pejovic-Milovancevic M, Perkins DO, Pietiläinen O, Pimm J, Pocklington AJ, Powell J, Price A, Pulver AE, Purcell SM, Quested D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Schall U, Schubert CR, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Sigurdsson E, Silagadze T, Silverman JM, Sim K, Slominsky P, Smoller JW, So HC, Spencer CA, Stahl EA, Stefansson H, Steinberg S, Stogmann E, Straub RE, Strengman E, Strohmaier J, Stroup TS, Subramaniam M, Suvisaari J, Svrakic DM, Szatkiewicz JP, Söderman E, Thirumalai S, Toncheva D, Tosato S, Veijola J, Waddington J, Walsh D, Wang D, Wang Q, Webb BT, Weiser M, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wong EHM, Wormley BK, Xi HS, Zai CC, Zheng X, Zimprich F, Wray NR, Stefansson K, Visscher PM, Adolfsson R, Andreassen OA, Blackwood DHR, Bramon E, Buxbaum JD, Børglum AD, Cichon S, Darvasi A, Domenici E, Ehrenreich H, Esko T, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jönsson EG, Kendler KS, Kirov G, Knight J, Lencz T, Levinson DF, Li QS, Liu J, Malhotra AK, McCarroll SA, McQuillin A, Moran JL, Mortensen PB, Mowry BJ, Nöthen MM, Ophoff RA, Owen MJ, Palotie A, Pato CN, Petryshen TL, Posthuma D, Rietschel M, Riley BP, Rujescu D, Sham PC, Sklar P, St Clair D, Weinberger DR, Wendland JR, Werge T, Daly MJ, Sullivan PF, O'Donovan MC]] , Biological insights from 108 schizophrenia-associated genetic loci. NATURE 2014;511 (7510):421-427 [PubMed]
Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC, Rujescu D, Werge T, van de Bunt M, Morris AP, McCarthy MI, Roddey JC, McEvoy LK, Desikan RS, Dale AM [Contributors: O'Donovan MC, Craddock N, Holmans PA, Hamshere ML, Moskvina V, Zammit S, Owen MJ, Sullivan PF, Kim Y, Stroup TS, Lieberman JA, Clair DS, Kirov GK, Georgieva L, Morris DW, O'Dushlaine CT, Kenny E, Gill M, Corvin A, Blackwood DHR, McIntosh AM, Pickard BS, Bass N, Choudhury K, Curtis D, Datta S, Gurling H, Krasucki R, Lawrence J, McQuillin A, Pimm J, Puri V, Quested D, Thirumalai S, Pato CN, Pato MT, Fanous AH, Medeiros H, Azevedo MH, Hultman CM, Kahler A, McCarroll S, Purcell S, Sklar P, Shi J, Levinson DF, Duan J, Sanders AR, Keller MC, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley W, Black DW, Kendler KS, Freedman R, Gejman PV, Cichon S, Rietschel M, Nöthen MM, Maier W, Schulze TG, Mattheisen M, Werge T, Hansen T, Olsen L, Ingason A, Rasmussen HB, Rujescu D, Giegling I, Hartmann AM, Konte B, Friedl M, Andreassen OA, Djurovic S, Melle I, Agartz I, Mattingsdal M, Opohff RA, Cantor RM, Freimer NB, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn WC, de Haan L, Krabbendam L, Myin-Germeys I, Malhotra AK, Lencz T, Lee PH, Neale B, Ripke S, Daly M, Lin DY, Dudbridge F, Rossin L, Visscher P, Posthuma D, Ruderfer D]] , Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. AM J HUM GENET 2013;92 (2):197-209 [PubMed]
Barkhof E, Meijer CJ, de Sonneville LMJ, Linszen DH, de Haan L, The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. SCHIZOPHRENIA BULL 2013;39 (6):1242-1251 [PubMed]
Bloemen OJN, de Koning MB, Gleich T, Meijer J, de Haan L, Linszen DH, Booij J, van Amelsvoort TAMJ, Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis. EUR NEUROPSYCHOPHARM 2013;23 (2):126-132 [PubMed]
Boyette LL, Korver-Nieberg N, Verweij K, Meijer C, Dingemans P, Cahn W, de Haan L [Contributors: Kahn RS, de Haan L, van Os J, Wiersma D, Bruggeman R, Cahn W, Ca Meijer C, Myin-Germeys I]] , Associations between the Five-Factor Model personality traits and psychotic experiences in patients with psychotic disorders, their siblings and controls. PSYCHIAT RES 2013;210 (2):491-497 [PubMed]
da Silva Alves F, Bakker G, Schmitz N, Abeling N, Hasler G, van der Meer J, Nederveen A, de Haan L, Linszen D, van Amelsvoort T, Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study. EUR NEUROPSYCHOPHARM 2013;23 (11):1577-1586 [PubMed]
Degenhardt F, Priebe L, Meier S, Lennertz L, Streit F, Witt SH, Hofmann A, Becker T, Mössner R, Maier W, Nenadic I, Sauer H, Mattheisen M, Buizer-Voskamp J, Ophoff RA, Rujescu D, Giegling I, Ingason A, Wagner M, Delobel B, Andrieux J, Meyer-Lindenberg A, Heinz A, Walter H, Moebus S, Corvin A, Rietschel M, Nöthen MM, Cichon S [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Duplications in RB1CC1 are associated with schizophrenia; identification in large European sample sets. TRANSL PSYCHIAT 2013;3:e326 [PubMed]
de Haan L, Sterk B, van der Valk R, Presence of obsessive compulsive symptoms in first-episode schizophrenia or related disorders is associated with subjective well-being and quality of life. EARLY INTERV PSYCHIA 2013;7 (3):285-290 [PubMed]
de Haan L, Sterk B, Wouters L, Linszen DH, The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. SCHIZOPHRENIA BULL 2013;39 (1):151-160 [PubMed]
de Haan L, Velthorst E, Nieman DH, Becker HE, de Lange MA, van der Gaag M, Preventie van een psychotische aandoening: rijp voor klinische toepassing?. NED TIJDSCHR GENEESKD 2013;157 (9):A5641 [PubMed]
Dekker N, Swets M [Contributors: Kahn RS, Cahn W, Linszen DH, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R]] , Substance use in a large sample of patients with schizophrenia or related disorders and co-morbid obsessive-compulsive symptoms. AUST NZ J PSYCHIAT 2013;47 (9):868-874 [PubMed]
Delespaul P [Contributors: de Haan L, van Hoof F, van der Gaag M, Keet R, Kroon H, Mulder N, van Os J, Slooff C, Sytema S, van Weeghel J, Wiersma D]] , Consensus over de definitie van mensen met een ernstige psychische aandoening (epa) en hun aantal in Nederland. TIJDSCHR PSYCHIATR 2013;55 (6):427-437
Derks EM, Ophoff RA [Contributors: Kahn RS, Linszen D, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Replication and refinement of the role of rs548181 in schizophrenia: results from a family based study. AM J MED GENET B 2013;162 (1):75-77 [PubMed]
de Vries R , Heering HD, Postmes L, Goedhart S, Sno HN, de Haan L, Self-disturbance in schizophrenia: a phenomenological approach to better understand our patients. PRIM CARE COMPANION CNS DISORD 2013;15 (1):12m01382 [PubMed]
Fernandes CPD, Christoforou A, Giddaluru S, Ersland KM, Djurovic S, Mattheisen M, Lundervold AJ, Reinvang I, Nöthen MM, Rietschel M, Ophoff RA, Hofman A, Uitterlinden AG, Werge T, Cichon S, Espeseth T, Andreassen OA, Steen VM, Le Hellard S [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , A Genetic Deconstruction of Neurocognitive Traits in Schizophrenia and Bipolar Disorder. PLOS ONE 2013;8 (12):e81052 [PubMed]
Fett AKJ, Maat A [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Social cognitive impairments and psychotic symptoms: what is the nature of their association?. SCHIZOPHRENIA BULL 2013;39 (1):77-85 [PubMed]
Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, Schultze-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, Cannon T, Velthorst E, de Haan L, Cornblatt B, Bonoldi I, Birchwood M, McGlashan T, Carpenter W, McGorry P, Klosterkötter J, McGuire P, Yung A, The Psychosis High-Risk State A Comprehensive State-of-the-Art Review. JAMA PSYCHIAT 2013;70 (1):107-120 [PubMed]
Heering HD, van Haren NEM, Derks EM [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer C, Myin-Germeys I, van Os J, Wiersma D]] , A two-factor structure of first rank symptoms in patients with a psychotic disorder. SCHIZOPHR RES 2013;147 (2-3):269-274 [PubMed]
Hoen WP, Lijmer JG, Duran M, Wanders RJA, van Beveren NJM, de Haan L, Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. PSYCHIAT RES 2013;207 (1-2):1-12 [PubMed]
Klaassen RMC. Emerging symptoms on the pathway to psychosis. s.l.: s.n.; 2013. 179p. ISBN 9789088917110 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L, van der Gaag M; copromotor(s): Nieman DH, van Beveren N)
Klaassen RMC, Heins M, Luteijn LB, van der Gaag M, van Beveren NJM [Contributors: Kahn R, Linszen D, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Depressive symptoms are associated with (sub)clinical psychotic symptoms in patients with non-affective psychotic disorder, siblings and healthy controls. PSYCHOL MED 2013;43 (4):747-756 [PubMed]
Korver-Nieberg N, Fett AKJ, Meijer CJ, Koeter MWJ, Shergill SS, de Haan L, Krabbendam L, Theory of mind, insecure attachment and paranoia in adolescents with early psychosis and healthy controls. AUST NZ J PSYCHIAT 2013;47 (8):737-745 [PubMed]
Kroon JS, Wohlfarth TD, Dieleman J, Sutterland AL, Storosum JG, Denys D, de Haan L, Sturkenboom MCJM, Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. BIPOLAR DISORD 2013;15 (3):306-313 [PubMed]
Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, Mowry BJ, Thapar A, Goddard ME, Witte JS, Absher D, Agartz I, Akil H, Amin F, Andreassen OA, Anjorin A, Anney R, Anttila V, Arking DE, Asherson P, Azevedo MH, Backlund L, Badner JA, Bailey AJ, Banaschewski T, Barchas JD, Barnes MR, Barrett TB, Bass N, Battaglia A, Bauer M, Bayés M, Bellivier F, Bergen SE, Berrettini W, Betancur C, Bettecken T, Biederman J, Binder EB, Black DW, Blackwood DHR, Bloss CS, Boehnke M, Boomsma DI, Breen G, Breuer R, Bruggeman R, Cormican P, Buccola NG, Buitelaar JK, Bunney WE, Buxbaum JD, Byerley WF, Byrne EM, Caesar S, Cahn W, Cantor RM, Casas M, Chakravarti A, Chambert K, Choudhury K, Cichon S, Cloninger CR, Collier DA, Cook EH, Coon H, Cormand B, Corvin A, Coryell WH, Craig DW, Craig IW, Crosbie J, Cuccaro ML, Curtis D, Czamara D, Datta S, Dawson G, Day R, de Geus EJ, Degenhardt F, Djurovic S, Donohoe GJ, Doyle AE, Duan J, Dudbridge F, Duketis E, Ebstein RP, Edenberg HJ, Elia J, Ennis S, Etain B, Fanous A, Farmer AE, Ferrier IN, Flickinger M, Fombonne E, Foroud T, Frank J, Franke B, Fraser C, Freedman R, Freimer NB, Freitag CM, Friedl M, Frisén L, Gallagher L, Gejman PV, Georgieva L, Gershon ES, Geschwind DH, Giegling I, Gill M, Gordon SD, Gordon-Smith K, Green EK, Greenwood TA, Grice DE, Gross M, Grozeva D, Guan W, Gurling H, de Haan L, Haines JL, Hakonarson H, Hallmayer J, Hamilton SP, Hamshere ML, Hansen TF, Hartmann AM, Hautzinger M, Heath AC, Henders AK, Herms S, Hickie IB, Hipolito M, Hoefels S, Holmans PA, Holsboer F, Hoogendijk WJ, Hottenga JJ, Hultman CM, Hus V, Ingason A, Ising M, Jamain S, Jones EG, Jones I, Jones L, Tzeng JY, Kähler AK, Kahn RS, Kandaswamy R, Keller MC, Kennedy JL, Kenny E, Kent L, Kim Y, Kirov GK, Klauck SM, Klei L, Knowles JA, Kohli MA, Koller DL, Konte B, Korszun A, Krabbendam L, Krasucki R, Kuntsi J, Kwan P, Landén M, Långström N, Lathrop M, Lawrence J, Lawson WB, Leboyer M, Ledbetter DH, Lee PH, Lencz T, Lesch KP, Levinson DF, Lewis CM, Li J, Lichtenstein P, Lieberman JA, Lin DY, Linszen DH, Liu C, Lohoff FW, Loo SK, Lord C, Lowe JK, Lucae S, MacIntyre DJ, Madden PAF, Maestrini E, Magnusson PKE, Mahon PB, Maier W, Malhotra AK, Mane SM, Martin CL, Martin NG, Mattheisen M, Matthews K, Mattingsdal M, McCarroll SA, McGhee KA, McGough JJ, McGrath PJ, McGuffin P, McInnis MG, McIntosh A, McKinney R, McLean AW, McMahon FJ, McMahon WM, McQuillin A, Medeiros H, Medland SE, Meier S, Melle I, Meng F, Meyer J, Middeldorp CM, Middleton L, Milanova V, Miranda A, Monaco AP, Montgomery GW, Moran JL, Moreno-de-Luca D, Morken G, Morris DW, Morrow EM, Moskvina V, Muglia P, Mühleisen TW, Muir WJ, Müller-Myhsok B, Murtha M, Myers RM, Myin-Germeys I, Neale MC, Nelson SF, Nievergelt CM, Nikolov I, Nimgaonkar V, Nolen WA, Nöthen MM, Nurnberger JI, Nwulia EA, Nyholt DR, O'Dushlaine C, Oades RD, Olincy A, Oliveira G, Olsen L, Ophoff RA, Osby U, Owen MJ, Palotie A, Parr JR, Paterson AD, Pato CN, Pato MT, Penninx BW, Pergadia ML, Pericak-Vance MA, Pickard BS, Pimm J, Piven J, Posthuma D, Potash JB, Poustka F, Propping P, Puri V, Quested DJ, Quinn EM, Ramos-Quiroga JA, Rasmussen HB, Raychaudhuri S, Rehnström K, Reif A, Ribasés M, Rice JP, Rietschel M, Roeder K, Roeyers H, Rossin L, Rothenberger A, Rouleau G, Ruderfer D, Rujescu D, Sanders AR, Sanders SJ, Santangelo SL, Sergeant JA, Schachar R, Schalling M, Schatzberg AF, Scheftner WA, Schellenberg GD, Scherer SW, Schork NJ, Schulze TG, Schumacher J, Schwarz M, Scolnick E, Scott LJ, Shi J, Shilling PD, Shyn SI, Silverman JM, Slager SL, Smalley SL, Smit JH, Smith EN, Sonuga-Barke EJS, St Clair D, State M, Steffens M, Steinhausen HC, Strauss JS, Strohmaier J, Stroup TS, Sutcliffe JS, Szatmari P, Szelinger S, Thirumalai S, Thompson RC, Todorov AA, Tozzi F, Treutlein J, Uhr M, van den Oord EJCG, van Grootheest G, van Os J, Vicente AM, Vieland VJ, Vincent JB, Visscher PM, Walsh CA, Wassink TH, Watson SJ, Weissman MM, Werge T, Wienker TF, Wijsman EM, Willemsen G, Williams N, Willsey AJ, Witt SH, Xu W, Young AH, Yu TW, Zammit S, Zandi PP, Zhang P, Zitman FG, Zöllner S, Devlin B, Kelsoe JR, Sklar P, Daly MJ, O'Donovan MC, Craddock N, Sullivan PF, Smoller JW, Kendler KS, Wray NR, Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. NAT GENET 2013;45 (9):984-994 [PubMed]
Liemburg E, Castelein S, Stewart R, van der Gaag M, Aleman A, Knegtering H [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J PSYCHIATR RES 2013;47 (6):718-725 [PubMed]
Meesters PD, Comijs HC, de Haan L, Smit JH, Eikelenboom P, Beekman ATF, Stek ML, Subjective quality of life and its determinants in a catchment area based population of elderly schizophrenia patients. SCHIZOPHR RES 2013;147 (2-3):275-280 [PubMed]
Meesters PD, Comijs HC, Dröes RM, de Haan L, Smit JH, Eikelenboom P, Beekman ATF, Stek ML, The care needs of elderly patients with schizophrenia spectrum disorders. AM J GERIAT PSYCHIAT 2013;21 (2):129-137 [PubMed]
Meesters PD, Comijs H, Dröes RM, de Haan L, Smit J, Eikelenboom P, Beekman A, Stek M, Ouderen met schizofrenie: zorgbehoeften en zorgvernieuwing. MGV: MAANDBL GEEST VOLKSGEZOND 2013;68 (4):174-183
Meesters PD, Schouws S, Stek M, de Haan L, Smit J, Eikelenboom P, Beekman A, Comijs H, Cognitive impairment in late life schizophrenia and bipolar I disorder. INT J GERIATR PSYCH 2013;28 (1):82-90 [PubMed]
Meijer JH, Swets M, Keeman S, Nieman DH, Meijer CJ [Contributors: Kahn R, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Is a schizo-obsessive subtype associated with cognitive impairment? Results from a large cross-sectional study in patients with psychosis and their unaffected relatives. J NERV MENT DIS 2013;201 (1):30-35 [PubMed]
Nieman DH, Velthorst E, Becker HE, de Haan L, Dingemans PM, Linszen DH, Birchwood M, Patterson P, Salokangas RKR, Heinimaa M, Heinz A, Juckel G, von Reventlow HG, Morrison A, Schultze-Lutter F, Klosterkötter J, Ruhrmann S [Contributors: McGorry PD, McGlashan TH, Knapp M, van de Fliert R, Klaassen R, Picker H, Neumann M, Brockhaus-Dumke A, Pukrop R, Svirskis T, Huttunen J, Laine T, Ilonen T, Ristkari T, Hietala J, Skeate A, Gudlowski Y, Ozgürdal S, French P, Stevens H]] , The Strauss and Carpenter Prognostic Scale in subjects clinically at high risk of psychosis. ACTA PSYCHIAT SCAND 2013;127 (1):53-61 [PubMed]
Peters BD, Machielsen MWJ, Hoen WP, Caan MWA, Malhotra AK, Szeszko PR, Duran M, Olabarriaga SD, de Haan L, Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis. SCHIZOPHRENIA BULL 2013;39 (4):830-838 [PubMed]
Schork AJ, Thompson WK, Pham P, Torkamani A, Roddey JC, Sullivan PF, Kelsoe JR, O'Donovan MC, Furberg H, Schork NJ, Andreassen OA, Dale AM [Contributors: Absher D, Agudo A, Almgren P, Ardissino D, Assimes TL, Bandinelli S, Barzan L, Bencko V, Benhamou S, Benjamin EJ, Bernardinelli L, Bis J, Boehnke M, Boerwinkle E, Boomsma DI, Brennan P, Canova C, Castellsagué X, Chanock S, Chasman D, Conway DI, Dackor J, de Geus EJC, Duan J, Elosua R, Everett B, Fabianova E, Ferrucci L, Foretova L, Fortmann SP, Franceschini N, Frayling T, Furberg C, Gejman PV, Groop L, Gu F, Guralnik J, Hankinson SE, Haritunians T, Healy C, Hofman A, Holcátová I, Hunter DJ, Hwang SJ, Ioannidis JPA, Iribarren C, Jackson AU, Janout V, Kaprio J, Kim Y, Kjaerheim K, Knowles JW, Kraft P, Ladenvall C, Lagiou P, Lanthrop M, Lerman C, Levinson DF, Levy D, Li MD, Lin DY, Lips EH, Lissowska J, Lowry R, Lucas G, Macfarlane TV, Maes H, Mannucci PM, Mates D, Mauri F, McGovern JA, McKay JD, McKnight B, Melander O, Merlini PA, Milaneschi Y, Mohlke KL, O'Donnell CJ, Pare G, Penninx BW, Perry J, Posthuma D, Preis SR, Psaty B, Quertermous T, Ramachandran VS, Richiardi L, Ridker P, Rose J, Rudnai P, Salomaa V, Sanders AR, Schwartz SM, Shi J, Smit JH, Stringham HM, Szeszenia-Dabrowska N, Tanaka T, Taylor K, Thacker E, Thornton L, Tiemeier H, Tuomilehto J, Uitterlinden AG, van Duijn CM, Vink JM, Vogelzangs N, Voight BF, Walter S, Willemsen G, Zaridze D, Znaor A, Akil H, Anjorin A, Backlund L, Badner JA, Barchas JD, Barrett TB, Bass N, Bauer M, Bellivier F, Bergen SE, Berrettini W, Blackwood D, Bloss CS, Breen G, Breuer R, Bunner WE, Burmeister M, Byerley W, Caesar S, Chambert K, Cichon S, St Clair D, Collier DA, Corvin A, Coryell WH, Craddock N, Craig DW, Daly M, Day R, Degenhardt F, Djurovic S, Dudbridge F, Edenberg HJ, Elkin A, Etain B, Farmer AE, Ferreira MA, Ferrier IN, Flickinger M, Foroud T, Frank J, Fraser C, Frisén L, Gershon ES, Gill M, Gordon-Smith K, Green EK, Greenwood TA, Grozeva D, Guan W, Gurling H, Gustafsson Ó, Hamshere ML, Hautzinger M, Herms S, Hipolito M, Holmans PA, Hultman CM, Jamain S, Jones EG, Jones I, Jones L, Kandaswamy R, Kennedy JL, Kirov GK, Koller DL, Kwan P, Landén M, Langstrom N, Lathrop M, Lawrence J, Lawson WB, Leboyer M, Lee PH, Li J, Lichtenstein P, Lin D, Liu C, Lohoff FW, Lucae S, Mahon PB, Maier W, Martin NG, Mattheisen M, Matthews K, Mattingsdal M, McGhee KA, McGuffin P, McInnis MG, McIntosh A, McKinney R, McLean AW, McMahon FJ, McQuillin A, Meier S, Melle I, Meng F, Mitchell PB, Montgomery GW, Moran J, Morken G, Morris DW, Moskvina V, Muglia P, Mühleisen TW, Muir WJ, Müller-Myhsok B, Myers RM, Nievergelt CM, Nikolov I, Nimgaonkar V, Nöthen MM, Nurnberger JI, Nwulia EA, O'Dushlaine C, Osby U, Óskarsson H, Owen MJ, Petursson H, Pickard BS, Porgeirsson P, Potash JB, Propping P, Purcell SM, Quinn E, Raychaudhuri S, Rice J, Rietschel M, Ruderfer D, Schalling M, Schatzberg AF, Scheftner WA, Schofield PR, Schulze TG, Schumacher J, Schwarz MM, Scolnick E, Scott LJ, Shilling PD, Sigurdsson E, Sklar P, Smith EN, Stefansson H, Stefansson K, Steffens M, Steinberg S, Strauss J, Strohmaier J, Szelinger S, Thompson RC, Tozzi F, Treutlein J, Vincent JB, Watson SJ, Wienker TF, Williamson R, Witt SH, Wright A, Xu W, Young AH, Zandi PP, Zhang P, Zöllner S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bitter I, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Danoy PA, Datta S, DeHert M, Demontis D, Dikeos D, Donnelly P, Donohoe G, Duong L, Dwyer S, Fanous A, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Glenthøj B, Godard S, Golimbet V, de Haan L, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jönsson EG, Jürgens G, Kahn RS, Keller MC, Kendler KS, Kenis G, Kenny E, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lencz T, Lerer FB, Liang KY, Lieberman JA, Linszen DH, Lönnqvist J, Loughland CM, Maclean AW, Maher BS, Malhotra AK, Mallet J, Malloy P, McGrath JJ, McLean DE, Michie PT, Milanova V, Mors O, Mortensen PB, Mowry BJ, Myin-Germeys I, Neale B, Nertney DA, Nestadt G, Nielsen J, Nordentoft M, Norton N, O'Neill FA, Olincy A, Olsen L, Ophoff RA, Ørntoft TF, van Os J, Pantelis C, Papadimitriou G, Pato CN, Pato MT, Peltonen L, Pickard B, Pietiläinen OPH, Pimm J, Pulver AE, Puri V, Quested D, Rasmussen HB, Réthelyi JM, Ribble R, Riley BP, Rossin L, Ruggeri M, Rujescu D, Schall U, Schwab SG, Scolnick E, Scott RJ, Silverman JM, Spencer CCA, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Timm S, Toncheva D, Tosato S, van den Oord EJCG, Veldink J, Visscher PM, Walsh D, Wang AG, Werge T, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, van Winkel R, Wormley B, Zammit S]] , All SNPs Are Not Created Equal: Genome-Wide Association Studies Reveal a Consistent Pattern of Enrichment among Functionally Annotated SNPs. PLOS GENET 2013;9 (4):e1003449 [PubMed]
Simon AE, Borgwardt S, Riecher-Rössler A, Velthorst E, de Haan L, Fusar-Poli P, Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. PSYCHIAT RES 2013;209 (3):266-272 [PubMed]
Simons CJP, van Winkel R [Contributors: Kahn RS, Cahn W, Linszen DH, de Haan L, van Os J, Wiersma D, Bruggeman R, Krabbendam L, Myin-Germeys I]] , Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition. SCHIZOPHRENIA BULL 2013;39 (4):848-856 [PubMed]
Smeets-Janssen MMJ, Meesters PD, Comijs HC, Eikelenboom P, Smit JH, de Haan L, Beekman ATF, Stek ML, Theory of Mind differences in older patients with early-onset and late-onset paranoid schizophrenia. INT J GERIATR PSYCH 2013;28 (11):1141-1146 [PubMed]
Sterk B, Winter van Rossum I, Muis M, de Haan L, Priorities, satisfaction and treatment goals in psychosis patients: an online consumer's survey. PHARMACOPSYCHIATRY 2013;46 (3):88-93 [PubMed]
Sutterland AL, Dieleman J, Storosum JG, Voordouw BAC, Kroon J, Veldhuis J, Denys DAJP, de Haan L, Sturkenboom MCJM, Annual incidence rate of schizophrenia and schizophrenia spectrum disorders in a longitudinal population-based cohort study. SOC PSYCH PSYCH EPID 2013;48 (9):1357-1365 [PubMed]
Terwisscha van Scheltinga AF, Bakker SC, van Haren NEM, Derks EM, Buizer-Voskamp JE, Boos HBM, Cahn W, Hulshoff Pol HE, Ripke S, Ophoff RA, Kahn RS [Contributors: Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DHR, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, de Hert M, Jonsson EG, Bitter I, Pietiläinen OPH, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, de Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegline I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jürgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lönnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nöthen MM, O'Dushlaine C, Olincy A, Olsen L, O'Neill FA, Ørntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Réthelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CCA, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV]] , Genetic schizophrenia risk variants jointly modulate total brain and white matter volume. BIOL PSYCHIAT 2013;73 (6):525-531 [PubMed]
van den Berg SM, Paap MCS, Derks EM [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Using multidimensional modeling to combine self-report symptoms with clinical judgment of schizotypy. PSYCHIAT RES 2013;206 (1):75-80 [PubMed]
van der Leeuw C, Marcelis M, Peeters SCT, Verbeek MM, Menheere PPCA, de Haan L, van Os J, van Beveren NJM, Replicated evidence of absence of association between serum S100B and (risk of) psychotic disorder. PLOS ONE 2013;8 (12):e82535 [PubMed]
van der Valk R, van de Waerdt S, Meijer CJ, van den Hout I, de Haan L, Feasibility of mindfulness-based therapy in patients recovering from a first psychotic episode: a pilot study. EARLY INTERV PSYCHIA 2013;7 (1):64-70 [PubMed]
van Nierop M, Janssens M, Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D, Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLOS ONE 2013;8 (11):e76690 [PubMed]
van Scheltinga AFT, Bakker SC, van Haren NEM, Derks EM, Buizer-Voskamp JE, Cahn W, Ripke S, Ophoff RA, Kahn RS [Contributors: Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DHR, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, de Hert M, Jonsson EG, Bitter I, Pietilainen OPH, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, de Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jurgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lonnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nothen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Ørntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Rethelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CCA, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV]] , Schizophrenia genetic variants are not associated with intelligence. PSYCHOL MED 2013;43 (12):2563-2570 [PubMed]
van Tricht MJ. Neurophysiological correlates of the pathway to the early stages of psychosis. s.l.: s.n.; 2013. 218p. ISBN 9789461822710 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, de Haan L; copromotor(s): Nieman DH, Koelman JHTM)
van Tricht MJ, Harmsen EC, Koelman JHTM, Bour LJ, van Amelsvoort TA, Linszen DH, de Haan L, Nieman DH, Effects of cannabis use on event related potentials in subjects at ultra high risk for psychosis and healthy controls. INT J PSYCHOPHYSIOL 2013;88 (2):149-156 [PubMed]
Velthorst E, Derks EM, Schothorst P, Becker H, Durston S, Ziermans T, Nieman DH, de Haan L, Quantitative and qualitative symptomatic differences in individuals at Ultra-High Risk for psychosis and healthy controls. PSYCHIAT RES 2013;210 (2):432-437 [PubMed]
Velthorst E, Levine SZ, Henquet C, de Haan L, van Os J, Myin-Germeys I, Reichenberg A, To cut a short test even shorter: reliability and validity of a brief assessment of intellectual ability in schizophrenia--a control-case family study. COGN NEUROPSYCHIATRY 2013;18 (6):574-593 [PubMed]
Velthorst E, Nelson B, O'Connor K, Mossaheb N, de Haan L, Bruxner A, Simmons MB, Yung AR, Thompson A, History of trauma and the association with baseline symptoms in an Ultra-High Risk for psychosis cohort. PSYCHIAT RES 2013;210 (1):75-81 [PubMed]
Velthorst E, Nelson B, Wiltink S, de Haan L, Wood SJ, Lin A, Yung AR, Transition to first episode psychosis in ultra high risk populations: does baseline functioning hold the key?. SCHIZOPHR RES 2013;143 (1):132-137 [PubMed]
Verweij KHW, Derks EM [Contributors: Kahn RS, Linszen D, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , The association between intelligence scores and family history of psychiatric disorder in schizophrenia patients, their siblings and healthy controls. PLOS ONE 2013;8 (10):e77215 [PubMed]
Vinkers CH, van Gastel WA, Schubart CD, van Eijk KR, Luykx JJ, van Winkel R, Joëls M, Ophoff RA, Boks MPM, Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D [Contributors: Bruggeman R, Cahn W, de Haan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D]] , The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val¹⁵⁸Met polymorphism. SCHIZOPHR RES 2013;150 (1):303-311 [PubMed]
Vothknecht S, Meijer C, Zwinderman A, Kikkert M, Dekker J, van Beveren N, Schoevers R, de Haan L, Psychometric evaluation of the Subjective Well-being Under Neuroleptic Treatment Scale (SWN) in patients with schizophrenia, their relatives and controls. PSYCHIAT RES 2013;206 (1):62-67 [PubMed]
Barkhof E, Meijer CJ, de Sonneville LMJ, Linszen DH, de Haan L, Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-A review of the past decade. EUR PSYCHIAT 2012;27 (1):9-18 [PubMed]
Boonstra N, Klaassen R, Sytema S, Marshall M, de Haan L, Wunderink L, Wiersma D, Duration of untreated psychosis and negative symptoms - A systematic review and meta-analysis of individual patient data. SCHIZOPHR RES 2012;142 (1-3):12-19 [PubMed]
Boonstra N, Sterk B, Wunderink L, Sytema S, de Haan L, Wiersma D, Association of treatment delay, migration and urbanicity in psychosis. EUR PSYCHIAT 2012;27 (7):500-505 [PubMed]
de Haan L, Klaassen R, van Beveren N, Wunderink L, Rutten BPF, van Os J, Stagering van psychotische stoornissen. TIJDSCHR PSYCHIATR 2012;54 (11):927-933 [PubMed]
Dekker N, Koeter M, van den Brink W [Contributors: Kahn RS, Linszen DH, Vanos J, Wiersma D, Bruggeman R, Cahn W, Haan Ld, Krabbendam L, Myin-Germeys I]] , Craving for cannabis in patients with psychotic disorder, their non-affected siblings and healthy controls: psychometric analysis of the obsessive compulsive drug use scale. INT J METH PSYCH RES 2012;21 (4):286-300 [PubMed]
Dekker N, Meijer J, Koeter M, van den Brink W, van Beveren N, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. PSYCHOL MED 2012;42 (9):1903-1911 [PubMed]
de Koning MB, Boot E, Bloemen OJN, van Duin EDA, Abel KM, de Haan L, Linszen DH, van Amelsvoort TAMJ, Startle reactivity and prepulse inhibition of the acoustic startle response are modulated by catechol-O-methyl-transferase Val(158) Met polymorphism in adults with 22q11 deletion syndrome. J PSYCHOPHARMACOL 2012;26 (12):1548-1560 [PubMed]
Derks EM, Allardyce J, Boks MP, Vermunt JK, Hijman R, Ophoff RA [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Kraepelin was right: a latent class analysis of symptom dimensions in patients and controls. SCHIZOPHRENIA BULL 2012;38 (3):495-505 [PubMed]
Derks EM, Boks MPM, Vermunt JK [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , The identification of family subtype based on the assessment of subclinical levels of psychosis in relatives. BMC PSYCHIATRY 2012;12:71 [PubMed]
Derks EM, Vorstman JAS, Ripke S, Kahn RS, Ophoff RA [Contributors: O'Donovan MC, Craddock N, Holmans PA, Hamshere M, Williams HJ, Moskvina V, Dwyer S, Georgieva L, Zammit S, Owen MJ, Sullivan PF, Lin DY, van den Oord E, Kim Y, Stroup TS, Lieberman JA, St Clair D, Kirov GK, Nikolov I, Toncheva D, Milanova V, Morris DW, O'Dushlaine CT, Kenny E, Quinn EM, Gill M, Corvin A, Blackwood DHR, McGhee KA, Pickard B, Malloy P, Maclean AW, McIntosh A, McQuillin A, Choudhury K, Datta S, Pimm J, Thirumalai S, Puri V, Krasucki R, Lawrence J, Quested D, Bass N, Gurling H, Pato MT, Pato CN, Fanous A, Hultman CM, Lichtenstein P, Bergen SE, Purcell S, Scolnick E, Sklar P, Gejman PV, Sanders AR, Duan J, Levinson DF, Shi J, Buccola NG, Mowry BJ, Freedman R, Amin F, Black DW, Black DW, Silverman JM, Byerley WF, Cloninger CR, Cichon S, Rietschel M, Nöthen MM, Maier W, Schulze TG, Mattheisen M, Hansen T, Olsen L, Jakobsen KD, Schmock H, Skjødt C, Rosengren A, Høffding LKE, Thygersen JH, Vangkilde A, Werge T, Giegling I, Hartmann AM, Konnerth H, Friedl M, Konte B, Muglia P, Rujescu D, Djurovic S, Mattingsdal M, Agartz I, Melle I, Andreassen OA, Ophoff RA, Cantor RM, Freimer NB, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, Strengman E, Malhotra AK, Lencz T, Ripke S, Daly MJ, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Kendler KS]] , Investigation of the Genetic Association between Quantitative Measures of Psychosis and Schizophrenia: A Polygenic Risk Score Analysis. PLOS ONE 2012;7 (6):e37852 [PubMed]
Dragt S, Nieman DH, Schultze-Lutter F, van der Meer F, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RKR, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Ruhrmann S, Klosterkötter J, Linszen DH [Contributors: McGorry PD, McGlashan TH, Knapp M, van de Fliert R, Klaassen R, Picker H, Neumann M, Brockhaus-Dumke A, Pukrop R, Svirskis T, Huttunen J, Laine T, Ilonen T, Ristkari T, Hietala J, Skeate A, Gudlowski Y, Ozgürdal S, Witthaus H, Lewis S, Morrisson A]] , Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. ACTA PSYCHIAT SCAND 2012;125 (1):45-53 [PubMed]
Gladwin TE, Derks EM, Rietschel M, Mattheisen M, Breuer R, Schulze TG, Nöthen MM, Levinson D, Shi J, Gejman PV, Cichon S, Ophoff RA [Contributors: Kahn RS, Linszen D, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Segment-Wise Genome-Wide Association Analysis Identifies a Candidate Region Associated with Schizophrenia in Three Independent Samples. PLOS ONE 2012;7 (6):e38828 [PubMed]
Janssens M, Lataster T, Simons CJP, Oorschot M, Lardinois M, van Os J, Myin-Germeys I [Contributors: de Haan L, et al -]] , Emotion recognition in psychosis: No evidence for an association with real world social functioning. SCHIZOPHR RES 2012;142 (1-3):116-121 [PubMed]
Keller MC, Simonson MA, Ripke S, Neale BM, Gejman PV, Howrigan DP, Lee SH, Lencz T, Levinson DF, Sullivan PF [Contributors: St Clair D, Cichon S, Rietschel M, Nöthen MM, Maier W, Schulze TG, Mattheisen M, Kirov GK, O'Donovan MC, Holmans PA, Georgieva L, Nikolov I, Williams HJ, Toncheva D, Milanova V, Owen MJ, Craddock N, Hamshere M, Moskvina V, Dwyer S, Zammit S, Sullivan PF, Lin DY, van den Oord E, Kim Y, Stroup TS, Lieberman JA, Hansen T, Ingason A, Olsen L, Schmock H, Skjødt C, Thygesen JH, Rosengren A, Werge T, Morris DW, O'Dushlaine CT, Kenny E, Quinn EM, Gill M, Corvin A, Blackwood DHR, McGhee KA, Pickard B, Malloy P, Maclean AW, McIntosh A, Gejman PV, Sanders AR, Duan J, Levinson DF, Shi J, Buccola NG, Mowry BJ, Freedman R, Amin F, Black DW, Silverman JM, Byerley WF, Cloninger CR, Giegling I, Hartmann AM, Konnerth H, Friedl M, Konte B, Muglia P, Rujescu D, Pato MT, Pato CN, Fanous A, Hultman CM, Lichtenstein P, Bergen SE, Purcell S, Scolnick E, Sklar P, Djurovic S, Mattingsdal M, Agartz I, Melle I, Andreassen OA, Ophoff RA, Cantor RM, Freimer NB, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, Strengman E, McQuillin A, Choudhury K, Datta S, Pimm J, Thirumalai S, Puri V, Krasucki R, Lawrence J, Quested D, Bass N, Gurling H, Malhotra AK, Lencz T]] , Runs of homozygosity implicate autozygosity as a schizophrenia risk factor. PLOS GENET 2012;8 (4):e1002656 [PubMed]
Koning JP, Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh B, van Harten PN, Snieder H [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. PSYCHOPHARMACOLOGY 2012;219 (3):727-736 [PubMed]
Korver N, Quee PJ, Boos HBM, Simons CJP, de Haan L [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, van den Berg SE, Schroeder CLA, van der Valk R, Dekker N, Meijer CJ, Korver N, Boyette LN, Meijer J, van Dam D, de Rijke I, Huinink S, de Vries RJ, Jansen M, Bos D, Hoen WP, te West EM, Groeneveld SHJ, Vergunst EM, Swets M, Vothknecht S, Poleacov I, van Dijk D, de Metz S, Hasty MT, Geertsa G, de Baaij PM, Metzger A, van Beveren NJM, Baldini M, Grimbergen FD, Boerma MAM, Agsteribbe C, Wisman HP, Monden MAH, Bosman MM, van Dijk M, Klaassen R, van der Tang T, Luteijn B, Winkel H, Weisz H, Strater ACP, Landman A, Vorstenbosch M, Op't Eijnde D, Lenders K, Loyen S, Roberts R, Sweers K, Gielen H, Soons N, Hintzen A, Habets V, Riské I, Vossen C, Martens E, Apers S, Wijnhoven L, Konings E, Lataster T, Lardinois M, Versmissen D, Simons C, van der Werf M, Habets P, Pfeiffer S, de Loore E, Heins M, Oorschot M, Meys M, Dietvorst M, van Zelst C, Crolla I, Mengelers R, van Goethem F, Beuken W, Byniam D, Driesen T, Marcelis M, Driessen G, Shazad A, van Winkel R, Henquet C, Kenis G, Delespaul P, Anema P, van Baaren EMJ, Bakker SC, Boos HBM, Caspers E, Derks EM, van Hemert S, Hemkes A, Hijman R, van Leeuwen M, Machielsen JEH, Ophoff RA, Rais M, Salden M, van Someren H, Strengman E, Vleesschouwer M, van Beek M, van Harten PN, Koning JPF, Schep W, Vollema MG, Prins P, Viester T, Akdeniz A, Verweij K, Kaymaz N, v d Heuvel F, v d Goot B, Hovens JE, Loonen AJM, Bous J, Veenstra M, van't Hag E, Quee PJ, Nienhuis FJ, Veermans E, Bartels AA, Duijndam F, Lugtenberg T, Knegtering H, Blaauw W, Wunderink A, Touw KP, Arends J, Slooff CJ, Brilman J, Schomaker M, van Wijk M, Wessels A, Vroom E, Meijerink K, Bogert I, Janssen W, de Berk H, Noorthoorn EO, Ising H, Blom JD, van der Gaag M, Mensen G, van der Snoek R, Smit R, Faber G]] , Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. INT J METH PSYCH RES 2012;21 (3):205-221 [PubMed]
Lataster T, Shazad A, Henquet C, Quee P [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , No evidence for familial covariation of neurocognition and negative symptoms in psychotic disorders. SCHIZOPHR RES 2012;139 (1-3):271-272 [PubMed]
Maat A, Fett AK, Derks E [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Social cognition and quality of life in schizophrenia. SCHIZOPHR RES 2012;137 (1-3):212-218 [PubMed]
Machielsen M, Scheltema Beduin A, Dekker N, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J PSYCHOPHARMACOL 2012;26 (1):189-195 [PubMed]
Meesters PD, Comijs HC, de Haan L, Smit JH, Eikelenboom P, Beekman ATF, Stek ML, Minderheid van oudere patiënten met schizofrenie in symptomatische remissie*. NED TIJDSCHR GENEESKD 2012;156 (32):A4701 [PubMed]
Meesters PD, de Haan L, Comijs HC, Stek ML, Smeets-Janssen MMJ, Weeda MR, Eikelenboom P, Smit JH, Beekman ATF, Schizophrenia Spectrum Disorders in Later Life: Prevalence and Distribution of Age at Onset and Sex in a Dutch Catchment Area. AM J GERIAT PSYCHIAT 2012;20 (1):18-28 [PubMed]
Meijer JH. Understanding cognitive heterogeneity in psychosis and high risk individuals. s.l.: s.n.; 2012. 168p. ISBN 9789461821461 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L, Linszen DH; copromotor(s): Meijer CJ)
Meijer JH, Dekker N, Koeter MW, Quee PJ, van Beveren NJM, Meijer CJ [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. PSYCHOL MED 2012;42 (4):705-716 [PubMed]
Meijer J, Simons CJP, Quee PJ, Verweij K [Contributors: Kahn RS, Cahn W, Linszen DH, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R]] , Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents. ACTA PSYCHIAT SCAND 2012;125 (1):66-76 [PubMed]
Mühleisen TW, Mattheisen M, Strohmaier J, Degenhardt F, Priebe L, Schultz CC, Breuer R, Meier S, Hoffmann P, Rivandeneira F, Hofman A, Uitterlinden AG, Moebus S, Gieger C, Emeny R, Ladwig KH, Wichmann HE, Schwarz M, Kammerer-Ciernioch J, Schlösser RGM, Nenadic I, Sauer H, Mössner R, Maier W, Rujescu D, Lange C, Ophoff RA, Schulze TG, Rietschel M, Nöthen MM, Cichon S [Contributors: Mühleisen TW, Mattheisen M, Rietschel M, Nöthen MM, Cichon S, Schulze TG, Strohmaier J, Rujescu D, Mössner R, Maier W, Schwarz M, Kammerer-Ciernioch J, Schultz CC, Nenadic I, Schlösser RGM, Sauer H, Ophoff RA, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, Moebus S, Gieger C, Emeny R, Ladwig KH, Wichmann HE, Rivandeneira F, Hofman A, Uitterlinden AG, Breuer R, Meier S, Degenhardt F, Priebe L, Hoffmann P, Lange C, Nöthen M]] , Association between schizophrenia and common variation in neurocan (NCAN), a genetic risk factor for bipolar disorder. SCHIZOPHR RES 2012;138 (1):69-73 [PubMed]
Rietschel M, Mattheisen M, Degenhardt F, Mühleisen TW, Kirsch P, Esslinger C, Herms S, Demontis D, Steffens M, Strohmaier J, Haenisch B, Breuer R, Czerski PM, Giegling I, Strengman E, Schmael C, Mors O, Mortensen PB, Hougaard DM, Ørntoft T, Kapelski P, Priebe L, Basmanav FF, Forstner AJ, Hoffman P, Meier S, Nikitopoulos J, Moebus S, Alexander M, Mössner R, Wichmann HE, Schreiber S, Rivandeneira F, Hofman A, Uitterlinden AG, Wienker TF, Schumacher J, Hauser J, Maier W, Cantor RM, Erk S, Schulze TG, Craddock N, Owen MJ, O'Donovan MC, Børglum AD, Rujescu D, Walter H, Meyer-Lindenberg A, Nöthen NM, Ophoff RA, Cichon S [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, Stefansson H, Steinberg S, Gustafsson O, Sigurdsson E, Petursson H, Kong A, Stefansson K, Pietiläinen OPH, Tuulio-Henriksson A, Paunio T, Lonnqvist J, Suvisaari J, Peltonen L, Ruggeri M, Tosato S, Walshe M, Murray R, Collier DA, St Clair D, Hansen T, Ingason A, Jakobsen KD, Duong L, Werge T, Melle I, Andreassen OA, Djurovic S, Bitter I, Réthelyi JM, Abramova L, Kaleda V, Golimbet V, Jönsson EG, Terenius L, Agartz I, van Winkel R, Kenis G, de Hert M, Veldink J, Wiuf C, Didriksen M]] , Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. MOL PSYCHIATR 2012;17 (9):906-917 [PubMed]
Scheltema Beduin AA, Swets M, Machielsen M, Korver N [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Obsessive-Compulsive Symptoms in Patients With Schizophrenia: A Naturalistic Cross-Sectional Study Comparing Treatment With Clozapine, Olanzapine, Risperidone, and No Antipsychotics in 543 Patients. J CLIN PSYCHIAT 2012;73 (11):1395-1402 [PubMed]
Smeerdijk M, Keet R, Dekker N, van Raaij B, Krikke M, Koeter M, de Haan L, Barrowclough C, Schippers G, Linszen D, Motivational interviewing and interaction skills training for parents to change cannabis use in young adults with recent-onset schizophrenia: a randomized controlled trial. PSYCHOL MED 2012;42 (8):1627-1636 [PubMed]
ter Meulen WG, de Haan L, Interventies om mensen met schizofrenie aan het bewegen te krijgen en te houden. TIJDSCHR PSYCHIATR 2012;54 (8):741-746 [PubMed]
van Beveren NJM, Buitendijk GHS, Swagemakers S, Krab LC, Röder C, de Haan L, van der Spek P, Elgersma Y, Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients. PLOS ONE 2012;7 (2):e32618 [PubMed]
van Dam DS, van der Ven E, Velthorst E, Selten JP, Morgan C, de Haan L, Childhood bullying and the association with psychosis in non-clinical and clinical samples: a review and meta-analysis. PSYCHOL MED 2012;42 (12):2463-2474 [PubMed]
van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MWJ, de Haan L, Cannabis Use in Patients at Clinical High Risk of Psychosis: Impact on Prodromal Symptoms and Transition to Psychosis. CURR PHARM DESIGN 2012;18 (32):5036-5044 [PubMed]
van der Werf M, Köhler S, Verkaaik M, Verhey F, van Os J [Contributors: de Haan L, et al -]] , Cognitive functioning and age at onset in non-affective psychotic disorder. ACTA PSYCHIAT SCAND 2012;126 (4):274-281 [PubMed]
van Leeuwen WA, Schellens JHM, Becker HE, de Haan L, van Westrhenen R, Het subklinische beloop van een paracetamolintoxicatie: valkuil voor patiënt en behandelaar. TIJDSCHR PSYCHIATR 2012;54 (6):555-559 [PubMed]
Vassos E, Steinberg S, Cichon S, Breen G, Sigurdsson E, Andreassen OA, Djurovic S, Morken G, Grigoroiu-Serbanescu M, Diaconu CC, Czerski PM, Hauser J, Babadjanova G, Abramova LI, Mühleisen TW, Nöthen MM, Rietschel M, McGuffin P, St Clair D, Gustafsson O, Melle I, Pietiläinen OPH, Ruggeri M, Tosato S, Werge T, Ophoff RA, Rujescu D, Børglum AD, Mors O, Mortensen PB, Demontis D, Hollegaard MV, van Winkel R, Kenis G, de Hert M, Réthelyi JM, Bitter I, Rubino IA, Golimbet V, Kiemeney LA, van den Berg LH, Franke B, Jönsson EG, Farmer A, Stefansson H, Stefansson K, Collier DA [Contributors: de Haan L, et al -]] , Replication study and meta-analysis in European samples supports association of the 3p21.1 locus with bipolar disorder. BIOL PSYCHIAT 2012;72 (8):645-650 [PubMed]
Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh BZ, Snieder H [Contributors: de Haan L, et al -]] , Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes. EUR NEUROPSYCHOPHARM 2012;22 (9):625-631 [PubMed]
Velthorst E, Meijer C [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , The association between social anhedonia, withdrawal and psychotic experiences in general and high-risk populations. SCHIZOPHR RES 2012;138 (2-3):290-294 [PubMed]
Velthorst E, Nieman DH, Veling W, Klaassen RM, Dragt S, Rietdijk J, Ising H, Wunderink L, Linszen DH, de Haan L, van der Gaag M, Ethnicity and baseline symptomatology in patients with an At Risk Mental State for psychosis. PSYCHOL MED 2012;42 (2):247-256 [PubMed]
Yung AR, Woods SW, Ruhrmann S, Addington J, Schultze-Lutter F, Cornblatt BA, Amminger GP, Bechdolf A, Birchwood M, Borgwardt S, Cannon TD, de Haan L, French P, Fusar-Poli P, Keshavan M, Klosterkötter J, Kwon JS, McGorry PD, McGuire P, Mizuno M, Morrison AP, Riecher-Rössler A, Salokangas RKR, Seidman LJ, Suzuki M, Valmaggia L, van der Gaag M, Wood SJ, McGlashan TH, Whither the Attenuated Psychosis Syndrome?. SCHIZOPHRENIA BULL 2012;38 (6):1130-1134 [PubMed]
Bloemen OJN, Gleich T, de Koning MB, da Silva Alvis F, de Haan L, Linszen DH, Booij J, van Amelsvoort TAMJ, Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. BIOL PSYCHIAT 2011;70 (1):e1-2; author reply e3 [PubMed]
Boyette L, Swets M, Meijer C, Wouters L [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Factor structure of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) in a large sample of patients with schizophrenia or related disorders and comorbid obsessive-compulsive symptoms. PSYCHIAT RES 2011;186 (2-3):409-413 [PubMed]
Buizer-Voskamp JE, Muntjewerff JW, Strengman E, Sabatti C, Stefansson H, Vorstman JAS, Ophoff RA [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Genome-wide analysis shows increased frequency of copy number variation deletions in Dutch schizophrenia patients. BIOL PSYCHIAT 2011;70 (7):655-662 [PubMed]
Cahn W, Krabbendam L, Myin-Germeys I, Bruggeman R, de Haan L, editors, Handboek schizofrenie. S.l.: Tijdstroom; 2011. 552p. ISBN 9789058981790
Chen X, Lee G, Maher BS, Fanous AH, Chen J, Zhao Z, Guo A, van den Oord E, Sullivan PF, Shi J, Levinson DF, Gejman PV, Sanders A, Duan J, Owen MJ, Craddock NJ, O'Donovan MC, Blackman J, Lewis D, Kirov GK, Qin W, Schwab S, Wildenauer D, Chowdari K, Nimgaonkar V, Straub RE, Weinberger DR, O'Neill FA, Walsh D, Bronstein M, Darvasi A, Lencz T, Malhotra AK, Rujescu D, Giegling I, Werge T, Hansen T, Ingason A, Nöethen MM, Rietschel M, Cichon S, Djurovic S, Andreassen OA, Cantor RM, Ophoff R, Corvin A, Morris DW, Gill M, Pato CN, Pato MT, Macedo A, Gurling HMD, McQuillin A, Pimm J, Hultman C, Lichtenstein P, Sklar P, Purcell SM, Scolnick E, St Clair D, Blackwood DHR, Kendler KS [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, O'Donovan MC, Kirov GK, Craddock NJ, Holmans PA, Williams NM, Georgieva L, Nikolov I, Norton N, Williams H, Toncheva D, Milanova V, Owen MJ, Hultman CM, Lichtenstein P, Thelander EF, Sullivan P, Morris DW, O'Dushlaine CT, Kenny E, Quinn EM, Gill M, Corvin A, McQuillin A, Choudhury K, Datta S, Pimm J, Thirumalai S, Puri V, Krasucki R, Lawrence J, Quested D, Bass N, Gurling H, Crombie C, Fraser G, Kuan SL, Walker N, St Clair D, Blackwood DHR, Muir WJ, McGhee KA, Pickard B, Malloy P, Maclean AW, van Beck M, Wray NR, Macgregor S, Visscher PM, Pato MT, Medeiros H, Middleton F, Carvalho C, Morley C, Fanous A, Conti D, Knowles JA, Ferreira CP, Macedo A, Azevedo MH, Pato CN, Stone JL, Ruderfer DM, Kirby AN, Ferreira MAR, Daly MJ, Purcell SM, Sklar P, Chambert K, Kuruvilla F, Gabriel SB, Ardlie K, Moran JL, Scolnick EM]] , GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. MOL PSYCHIATR 2011;16 (11):1117-1129 [PubMed]
Collip D, Nicolson NA, Lardinois M, Lataster T, van Os J, Myin-Germeys I [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis. PSYCHOL MED 2011;41 (11):2305-2315 [PubMed]
da Silva Alves F, Boot E, Schmitz N, Nederveen A, Vorstman J, Lavini C, Pouwels PJ, Pouwels P, de Haan L, Linszen D, van Amelsvoort T, Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. PLOS ONE 2011;6 (6):e21685 [PubMed]
da Silva Alves F, Schmitz N, Bloemen O, van der Meer J, Meijer J, Boot E, Nederveen A, de Haan L, Linszen D, van Amelsvoort T, White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. SCHIZOPHR RES 2011;132 (1):75-83 [PubMed]
da Silva Alves F, Schmitz N, Figee M, Abeling N, Hasler G, van der Meer J, Nederveen A, de Haan L, Linszen D, van Amelsvoort T, Dopaminergic modulation of the human reward system: a placebo-controlled dopamine depletion fMRI study. J PSYCHOPHARMACOL 2011;25 (4):538-549 [PubMed]
Dekker N. Cannabis use in patients with schizophrenia. Motivation for use and relation to clinical variables. s.l.: s.n.; 2011. 206p. ISBN 9789491211843 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): de Haan L, Linszen DH; copromotor(s): Koeter MWJ)
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, de Haan L, A call for more care when investigating the cannabis-psychosis link Reply. PSYCHIAT RES-NEUROIM 2011;191 (1):85
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, de Haan L, Reply to fan and hart. PSYCHIAT RES 2011;191 (1):85
Dragt S, Nieman DH, Veltman D, Becker HE, van de Fliert R, de Haan L, Linszen DH, Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. SCHIZOPHR RES 2011;125 (1):69-76 [PubMed]
Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggerman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. BIOL PSYCHIAT 2011;69 (5):487-494 [PubMed]
Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD, Kristinsson KT, le Roux L, Gustafsson O, Craddock N, Möller HJ, McQuillin A, Muglia P, Cichon S, Rietschel M, Ophoff RA, Djurovic S, Andreassen OA, Pietiläinen OPH, Peltonen L, Dempster E, Collier DA, St Clair D, Rasmussen HB, Glenthøj BY, Kiemeney LA, Franke B, Tosato S, Bonetto C, Saemundsen E, Hreidarsson SJ, Nöthen MM, Gurling H, O'Donovan MC, Owen MJ, Sigurdsson E, Petursson H, Stefansson H, Rujescu D, Stefansson K, Werge T, Linszen D [Contributors: Linszen D, de Haan L, et al -]] , Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. AM J PSYCHIAT 2011;168 (4):408-417 [PubMed]
Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietiläinen OPH, Buizer-Voskamp JE, Strengman E, Francks C, Muglia P, Gylfason A, Gustafsson O, Olason PI, Steinberg S, Hansen T, Jakobsen KD, Rasmussen HB, Giegling I, Möller HJ, Hartmann A, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Bramon E, Kiemeney LA, Franke B, Murray R, Vassos E, Toulopoulou T, Mühleisen TW, Tosato S, Ruggeri M, Djurovic S, Andreassen OA, Zhang Z, Werge T, Ophoff RA, Rietschel M, Nöthen MM, Petursson H, Stefansson H, Peltonen L, Collier D, Stefansson K, St Clair DM [Contributors: Kahn RS, Cahn W, Linszen D, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R]] , Copy number variations of chromosome 16p13.1 region associated with schizophrenia. MOL PSYCHIATR 2011;16 (1):17-25 [PubMed]
Klaassen RMC, Velthorst E, Nieman DH, de Haan L, Becker HE, Dingemans PM, van de Fliert JR, van der Gaag M, Linszen DH, Factor analysis of the scale of prodromal symptoms: differentiating between negative and depression symptoms. PSYCHOPATHOLOGY 2011;44 (6):379-385 [PubMed]
Korver-Nieberg N, Quee PJ, Boos HB, Simons CJ [Contributors: Kahn RS, Cahn W, Linszen DH, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R, van den Berg SE, Schroeder CLA, van der Valk R, Dekker N, Meijer CJ, Korver N, Boyette LN, Meijer J, van Dam D, de Rijke I, Huinink S, de Vries RJ, Jansen M, Bos D, Hoen WP, te West EM, Groeneveld SHJ, Vergunst EM, Swets M, Vothknecht S, Poleacov I, van Dijk D, de Metz S, Hasty MT, Geertsa G, de Baaij PM, Metzger A, van Beveren NJM, Baldini M, Grimbergen FD, Boerma MAM, Agsteribbe C, Wisman HP, Monden MAH, Bosman MM, van Dijk M, Klaassen R, van der Tang T, Luteijn B, Winkel H, Weisz H, Strater ACP, Landman A, Vorstenbosch M, Op 't Eijnde D, Lenders K, Loyen S, Roberts R, Sweers K, Gielen H, Soons N, Hintzen A, Habets V, Risk é I, Vossen C, Martens E, Apers S, Wijnhoven L, Konings E, Lataster T, Lardinois M, Versmissen D, Simons C, van der Werf M, Habets P, Pfeifer S, de Loore E, Heins M, Oorschot M, Meys M, Dietvorst M, van Zelst C, Crolla I, Mengelers R, van Goethem F, Beuken W, Byniam D, Driesen T, Marcelis M, Driessen G, Shazad A, van Winkel R, Henquet C, Kenis G, Delespaul P, Anema P, van Baaren EMJ, Bakker SC, Boos HBM, Caspers E, Derks EM, van Hemert S, Hemkes A, Hijman R, van Leeuwen M, Machielsen JEH, Ophoff RA, Rais M, Salden M, van Someren H, Strengman E, Vleesschouwer M, van Beek M, van Harten PN, Koning JPF, Schep W, Vollema MG, Prins P, Viester T, Akdeniz A, Verweij K, Kaymaz N, v d Heuvel F, v d Goot B, Hovens JE, Loonen AJM, Bous J, Veenstra M, van 't Hag E, Quee PJ, Nienhuis FJ, Smid HGOM, Veermans E, Bartels AA, Duijndam F, Lugtenberg T, Knegtering H, Blaauw W, Wunderink A, Touw KP, Arends J, Slooff CJ, Brilman J, Schomaker M, van Wijk M, Wessels A, Vroom E, Meijerink K, Bogert I, Janssen W, de Berk H, Noorthoorn EO, Ising H, Blom JD, van der Gaag M, Mensen G, van der Snoek R, Smit R, Faber G]] , The validity of the DSM-IV diagnostic classification system of non-affective psychoses. AUST NZ J PSYCHIAT 2011;45 (12):1061-1068 [PubMed]
Lataster J, van Os J, de Haan L, Thewissen V, Bak M, Lataster T, Lardinois M, Delespaul PAGE, Myin-Germeys I, Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. J CLIN PSYCHIAT 2011;72 (10):1397-1404 [PubMed]
Meesters PD. Schizophrenia in Later Life - studies on prevalence, phenomenology and care needs. s.l.: s.n.; 2011. -p. Proefschrift VU, VUmc. (Promotor(s): Stek ML, Beekman ATF, de Haan L; copromotor(s): )
Meesters PD, Comijs HC, de Haan L, Smit JH, Eikelenboom P, Beekman ATF, Stek ML, Symptomatic remission and associated factors in a catchment area based population of older patients with schizophrenia. SCHIZOPHR RES 2011;126 (1-3):237-244 [PubMed]
Meijer JH, Schmitz N, Nieman DH, Becker HE, van Amelsvoort TAMJ, Dingemans PM, Linszen DH, de Haan L, Semantic fluency deficits and reduced grey matter before transition to psychosis: a voxelwise correlational analysis. PSYCHIAT RES 2011;194 (1):1-6 [PubMed]
Muntjewerff JW, Ophoff RA, Buizer-Voskamp JE, Strengman E, den Heijer M [Contributors: Linszen DH, de Haan L, et al -]] , Effects of season of birth and a common MTHFR gene variant on the risk of schizophrenia. EUR NEUROPSYCHOPHARM 2011;21 (4):300-305 [PubMed]
Nieman DH, Sutterland AL, Otten J, Becker HE, Drent ML, van der Gaag M, Birchwood M, de Haan L, Treating prolactinoma and psychosis: medication and cognitive behavioural therapy. BMJ CASE REP 2011;2011:bcr0720103185 [PubMed]
Quee PJ, van der Meer L, Bruggeman R, de Haan L, Krabbendam L, Cahn W, Mulder NCL, Wiersma D, Aleman A, Insight in Psychosis: Relationship With Neurocognition, Social Cognition and Clinical Symptoms Depends on Phase of Illness. SCHIZOPHRENIA BULL 2011;37 (1):29-37 [PubMed]
Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DHR, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, de Hert M, Jönsson EG, Bitter I, Pietiläinen OPH, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, de Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jürgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lönnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nöthen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Orntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Réthelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CCA, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV, Genome-wide association study identifies five new schizophrenia loci. NAT GENET 2011;43 (10):969-976 [PubMed]
Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, de Haan L, Ultra high-risk state for psychosis and non-transition: a systematic review. SCHIZOPHR RES 2011;132 (1):8-17 [PubMed]
Steinberg S, de Jong S, Andreassen OA, Werge T, Børglum AD, Mors O, Mortensen PB, Gustafsson O, Costas J, Pietiläinen OPH, Demontis D, Papiol S, Huttenlocher J, Mattheisen M, Breuer R, Vassos E, Giegling I, Fraser G, Walker N, Tuulio-Henriksson A, Suvisaari J, Lönnqvist J, Paunio T, Agartz I, Melle I, Djurovic S, Strengman E, Jürgens G, Glenthøj B, Terenius L, Hougaard DM, Ørntoft T, Wiuf C, Didriksen M, Hollegaard MV, Nordentoft M, van Winkel R, Kenis G, Abramova L, Kaleda V, Arrojo M, Sanjuán J, Arango C, Sperling S, Rossner M, Ribolsi M, Magni V, Siracusano A, Christiansen C, Kiemeney LA, Veldink J, van den Berg L, Ingason A, Muglia P, Murray R, Nöthen MM, Sigurdsson E, Petursson H, Thorsteinsdottir U, Kong A, Rubino IA, de Hert M, Réthelyi JM, Bitter I, Jönsson EG, Golimbet V, Carracedo A, Ehrenreich H, Craddock N, Owen MJ, O'Donovan MC, Ruggeri M, Tosato S, Peltonen L, Ophoff RA, Collier DA, St Clair D, Rietschel M, Cichon S, Stefansson H, Rujescu D, Stefansson K [Contributors: Linszen DH, de Haan L, et al -]] , Common variants at VRK2 and TCF4 conferring risk of schizophrenia. HUM MOL GENET 2011;20 (20):4076-4081 [PubMed]
Steinberg S, Mors O, Børglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Böttcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietiläinen OPH, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Athanasiu L, Suvisaari J, Lonnqvist J, Paunio T, Hartmann A, Jürgens G, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Breuer R, Möller HJ, Giegling I, Glenthøj B, Rasmussen HB, Mattheisen M, Bitter I, Réthelyi JM, Sigmundsson T, Fossdal R, Thorsteinsdottir U, Ruggeri M, Tosato S, Strengman E, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Walshe M, Bramon E, Vassos E, Li T, Fraser G, Walker N, Toulopoulou T, Yoon J, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Peltonen L, Rujescu D, Collier DA, Stefansson H, St Clair D, Stefansson K [Contributors: Kahn RS, Cahn W, Linszen DH, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R]] , Expanding the range of ZNF804A variants conferring risk of psychosis. MOL PSYCHIATR 2011;16 (1):59-66 [PubMed]
Sterk B, Lankreijer K, Linszen DH, de Haan L, Obsessive-compulsive symptoms in first episode psychosis and in subjects at ultra high risk for developing psychosis; onset and relationship to psychotic symptoms. AUST NZ J PSYCHIAT 2011;45 (5):400-406 [PubMed]
van Tricht MJ, Nieman DH, Koelman JHTM, Bour LJ, van der Meer JN, van Amelsvoort TA, Linszen DH, de Haan L, Auditory ERP components before and after transition to a first psychotic episode. BIOL PSYCHOL 2011;87 (3):350-357 [PubMed]
van Winkel R [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Family-Based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis: Sibling Analysis and Proband Follow-up. ARCH GEN PSYCHIAT 2011;68 (2):148-157 [PubMed]
van Winkel R, van Beveren NJM, Simons C [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. NEUROPSYCHOPHARMACOL 2011;36 (12):2529-2537 [PubMed]
Velthorst E. The lonely soul wanders. On the role of impaired social functioning in the prediction of first psychosis. s.l.: s.n.; 2011. 191p. ISBN 9789090263083 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, de Haan L; copromotor(s): Nieman DH)
Velthorst E, Nieman DH, Klaassen RMC, Becker HE, Dingemans PM, Linszen DH, de Haan L, Three-year course of clinical symptomatology in young people at ultra high risk for transition to psychosis. ACTA PSYCHIAT SCAND 2011;123 (1):36-42 [PubMed]
Velthorst E, Nieman DH, Meijer C, Linszen D, de Haan L, Social Disability at Admission for a First Psychosis Does Not Predict Clinical Outcome at 5-Year Follow-Up. J NERV MENT DIS 2011;199 (7):510-512 [PubMed]
Vothknecht S, Schoevers RA, de Haan L, Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review. AUST NZ J PSYCHIAT 2011;45 (3):182-192 [PubMed]
Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, Georgieva L, Williams NM, Morris DW, Quinn EM, Giegling I, Ikeda M, Wood J, Lencz T, Hultman C, Lichtenstein P, Thiselton D, Maher BS, Malhotra AK, Riley B, Kendler KS, Gill M, Sullivan P, Sklar P, Purcell S, Nimgaonkar VL, Kirov G, Holmans P, Corvin A, Rujescu D, Craddock N, Owen MJ, O'Donovan MC [Contributors: de Haan L, et al -]] , Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. MOL PSYCHIATR 2011;16 (4):429-441 [PubMed]
[Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Evidence That Familial Liability for Psychosis Is Expressed as Differential Sensitivity to Cannabis An Analysis of Patient-Sibling and Sibling-Control Pairs. ARCH GEN PSYCHIAT 2011;68 (2):138-147 [PubMed]
Becker HE, Nieman DH, Dingemans PM, van de Fliert JR, de Haan L, Linszen DH, Verbal fluency as a possible predictor for psychosis. EUR PSYCHIAT 2010;25 (2):105-110 [PubMed]
Becker HE, Nieman DH, Wiltink S, Dingemans PM, van de Fliert JR, Velthorst E, de Haan L, van Amelsvoort TA, Linszen DH, Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration?. PSYCHOL MED 2010;40 (10):1599-1606 [PubMed]
Bloemen OJN, de Koning MB, Schmitz N, Nieman DH, Becker HE, de Haan L, Dingemans P, Linszen DH, van Amelsvoort TAMJ, White-matter markers for psychosis in a prospective ultra-high-risk cohort. PSYCHOL MED 2010;40 (8):1297-1304 [PubMed]
Boerma MAM, van der Stel JC, van Amelsvoort T, Linszen DH, de Haan L, Vrouwen, schizofrenie en oestrogeen; neurobiologische hypothesen en interventiestudies. TIJDSCHR PSYCHIATR 2010;52 (4):235-244 [PubMed]
Boot E, Booij J, Zinkstok JR, de Haan L, Linszen DH, Baas F, van Amelsvoort TA, Striatal D₂ receptor binding in 22q11 deletion syndrome: an [¹²³I]IBZM SPECT study. J PSYCHOPHARMACOL 2010;24 (10):1525-1531 [PubMed]
de Haan L, Onderzoek de toekomst. TIJDSCHR PSYCHIATR 2010;52 (9):611-613 [PubMed]
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, de Haan L, Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. PSYCHIAT RES-NEUROIM 2010;181 (1):51-56 [PubMed]
Dekker N, Smeerdijk AM, Wiers RW, Duits JH, van Gelder G, Houben K, Schippers G, Linszen DH, de Haan L, Implicit and explicit affective associations towards cannabis use in patients with recent-onset schizophrenia and healthy controls. PSYCHOL MED 2010;40 (8):1325-1336 [PubMed]
Dragt S, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, de Haan L, van Amelsvoort TA, Linszen DH, Age of Onset of Cannabis Use Is Associated With Age of Onset of High-Risk Symptoms for Psychosis. CAN J PSYCHIAT 2010;55 (3):165-171 [PubMed]
Ingason A, Giegling I, Cichon S, Hansen T, Rasmussen HB, Nielsen J, Jürgens G, Muglia P, Hartmann AM, Strengman E, Vasilescu C, Mühleisen TW, Djurovic S, Melle I, Lerer B, Möller HJ, Francks C, Pietiläinen OPH, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Walshe M, Vassos E, Di Forti M, Murray R, Bonetto C, Tosato S, Cantor RM, Rietschel M, Craddock N, Owen MJ, Peltonen L, Andreassen OA, Nöthen MM, St Clair D, Ophoff RA, O'Donovan MC, Collier DA, Werge T, Rujescu D [Contributors: Kahn RS, Cahn W, Linszen D, de Haan L, van Os J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R]] , A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia. HUM MOL GENET 2010;19 (7):1379-1386 [PubMed]
Karagianis J, Landry J, Hoffmann VP, Grossman L, de Haan L, Maguire G, Milev R, Holt S, An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study. INT J CLIN PRACT 2010;64 (11):1520-1529 [PubMed]
Korver N, Nieman DH, Becker HE, van de Fliert JR, Dingemans PH, de Haan L, Spiering M, Schmitz N, Linszen DH, Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. AUST NZ J PSYCHIAT 2010;44 (3):230-236 [PubMed]
Machielsen M, van der Sluis S, de Haan L, Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic and pre-psychotic symptoms. AUST NZ J PSYCHIAT 2010;44 (8):721-728 [PubMed]
Meesters PD, Stek ML, Comijs HC, de Haan L, Patterson TL, Eikelenboom P, Beekman ATF, Social Functioning Among Older Community-Dwelling Patients With Schizophrenia: A Review. AM J GERIAT PSYCHIAT 2010;18 (10):862-878 [PubMed]
Mulder CL, van der Gaag M, Bruggeman R, Cahn W, Delespaul PAE, Dries P, Faber G, de Haan L, van der Heijden FMMA, Kempen RW, Mogendorff ESG, Slooff CJ, Sytema S, Wiersma D, Wunderink L, van Os J, Routine outcome monitoring voor patiënten met ernstige psychiatrische aandoeningen; een consensusdocument. TIJDSCHR PSYCHIATR 2010;52 (3):169-179 [PubMed]
Peters BD. White matters. Diffusion tensor imaging in the early ohase of schizophrenia. s.l.: s.n.; 2010. 185p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, den Heeten GJ; copromotor(s): de Haan L, Majoie CB)
Peters BD, Blaas J, de Haan L, Diffusion tensor imaging in the early phase of schizophrenia What have we learned?. J PSYCHIATR RES 2010;44 (15):993-1004 [PubMed]
Peters BD, Dingemans PM, Dekker N, Blaas J, Akkerman E, van Amelsvoort TA, Majoie CB, den Heeten GJ, Linszen DH, de Haan L, White matter connectivity and psychosis in ultra-high-risk subjects: A diffusion tensor fiber tracking study. PSYCHIAT RES-NEUROIM 2010;181 (1):44-50 [PubMed]
Scheltema Beduin A, de Haan L, Off-label second generation antipsychotics for impulse regulation disorders: a review. PSYCHOPHARMACOL BULL 2010;43 (3):45-81 [PubMed]
Sterk B, Slief EM, Blankers M, Linszen DH, de Haan L, Duration of untreated psychosis and ethnicity. SCHIZOPHR RES 2010;124 (1-3):238-239 [PubMed]
Talamini LM, de Haan L, Nieman DH, Linszen DH, Meeter M, Reduced Context Effects on Retrieval in First-Episode Schizophrenia. PLOS ONE 2010;5 (4):e10356 [PubMed]
Tricht MJv, Nieman DH, Koelman JHTM, van der Meer JN, Bour LJ, de Haan L, Linszen DH, Reduced Parietal P300 Amplitude is Associated with an Increased Risk for a First Psychotic Episode. BIOL PSYCHIAT 2010;68 (7):642-648 [PubMed]
van der Post LFM, Dekker JJM, Jonkers JFJ, Beekman ATF, Mulder CL, de Haan L, Mulder WG, Schoevers RA, Crisis intervention and acute psychiatry in Amsterdam, 20 years of change: a historical comparison of consultations in 1983 and 2004-2005. INT J SOC PSYCHIATR 2010;56 (4):348-358 [PubMed]
van Nimwegen-Campailla L, van Beveren N, Laan W, van den Brink W, Linszen D, de Haan L, Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis. PHARMACOPSYCHIATRY 2010;43 (7):281-282 [PubMed]
Van Tricht MJ, Nieman DH, Bour LJ, Boerée T, Koelman JHTM, de Haan L, Linszen DH, Increased saccadic rate during smooth pursuit eye movements in patients at Ultra High Risk for developing a psychosis. BRAIN COGNITION 2010;73 (3):215-221 [PubMed]
Velthorst E, Nieman DH, Linszen D, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RKR, Heinimaa M, Heinz A, Juckel G, von Reventlow HG, French P, Stevens H, Schultze-Lutter F, Klosterkötter J, Ruhrmann S, Disability in people clinically at high risk of psychosis. BRIT J PSYCHIAT 2010;197 (4):278-284 [PubMed]
de Haan L, Bewegen. TIJDSCHR PSYCHIATR 2009;51 (5):275-277 [PubMed]
de Haan L, Dudek-Hodge C, Verhoeven Y, Denys D, Prevalence of psychotic disorders in patients with obsessive-compulsive disorder. CNS SPECTRUMS 2009;14 (8):415-417 [PubMed]
Dekker N, Linszen DH, de Haan L, Reasons for Cannabis Use and Effects of Cannabis Use as Reported by Patients with Psychotic Disorders. PSYCHOPATHOLOGY 2009;42 (6):350-360 [PubMed]
Karagianis J, Grossman L, Landry J, Reed VA, de Haan L, Maguire GA, Hoffmann VP, Milev R, A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. SCHIZOPHR RES 2009;113 (1):41-48 [PubMed]
Machielsen MWJ, de Haan L, Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. PSYCHOPHARMACOL BULL 2009;42 (4):40-52 [PubMed]
Nieman DH, Rike WH, Becker HE, Dingemans PM, van Amelsvoort TA, de Haan L, van der Gaag M, Denys DAJP, Linszen DH, Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. INT CLIN PSYCHOPHARM 2009;24 (4):223-228 [PubMed]
Peters BD, de Haan L, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH, Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity?. PSYCHOPHARMACOL BULL 2009;42 (2):75-88 [PubMed]
Peters BD, de Koning P, Dingemans P, Becker H, Linszen DH, de Haan L, Subjective effects of cannabis before the first psychotic episode. AUST NZ J PSYCHIAT 2009;43 (12):1155-1162 [PubMed]
Peters BD, Duran M, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH, de Haan L, Polyunsaturated fatty acids and brain white matter anisotropy in recent-onset schizophrenia: a preliminary study. PROSTAG LEUKOTR ESS 2009;81 (1):61-63 [PubMed]
Peters B, de Haan L, Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. PROG NEURO-PSYCHOPH 2009;33 (8):1576-1577 [PubMed]
Peters BD, Schmitz N, Dingemans PM, van Amelsvoort TA, Linszen DH, de Haan L, Majoie CB, den Heeten GJ, Preliminary evidence for reduced frontal white matter integrity in subjects at ultra-high-risk for psychosis. SCHIZOPHR RES 2009;111 (1-3):192-193 [PubMed]
Rujescu D, Ingason A, Cichon S, Pietiläinen OPH, Barnes MR, Toulopoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Möller HJ, Hartmann AM, Hoffmann P, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Djurovic S, Melle I, Andreassen OA, Hansen T, Werge T, Kiemeney LA, Franke B, Veltman J, Buizer-Voskamp JE, Sabatti C, Ophoff RA, Rietschel M, Nöthen MM, Stefansson K, Peltonen L, St Clair D, Stefansson H, Collier DA [Contributors: Kahn RS, Linszen D, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Disruption of the neurexin 1 gene is associated with schizophrenia. HUM MOL GENET 2009;18 (5):988-996 [PubMed]
Staring ABP, Mulder CL, Duivenvoorden HJ, de Haan L, van der Gaag M, Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life. SCHIZOPHR RES 2009;113 (1):27-33 [PubMed]
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OPH, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Common variants conferring risk of schizophrenia. NATURE 2009;460 (7256):744-747 [PubMed]
van Bruggen M, van Amelsvoort T, Wouters L, Dingemans P, de Haan L, Linszen D, Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. PSYCHONEUROENDOCRINO 2009;34 (7):989-995 [PubMed]
van der Post LFM, Dekker JJM, Jonkers JFJ, Beekman ATF, Mulder CL, de Haan L, Mulder WG, Schoevers RA, Veranderingen in crisisinterventie en acute psychiatrie; Amsterdamse consulten in 1983 en 2005. TIJDSCHR PSYCHIATR 2009;51 (3):139-150 [PubMed]
Velthorst E, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, Klaassen R, de Haan L, van Amelsvoort T, Linszen DH, Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. SCHIZOPHR RES 2009;109 (1-3):60-65 [PubMed]
Boot E, Booij J, Hasler G, Zinkstok JR, de Haan L, Linszen DH, van Amelsvoort TA, AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. EUR J NUCL MED MOL I 2008;35 (7):1350-1356 [PubMed]
Boot E, Booij J, Zinkstok J, Abeling N, de Haan L, Baas F, Linszen D, van Amelsvoort T, Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. NEUROPSYCHOPHARMACOL 2008;33 (6):1252-1258 [PubMed]
Cahn W, Ramlal D, Bruggeman R, de Haan L, Scheepers FE, van Soest MM, Assies J , Slooff CJ, Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. TIJDSCHR PSYCHIATR 2008;50 (9):579-591 [PubMed]
da Silva Alves F, Figee M, van Amelsvoort T, Veltman D, de Haan L, The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. PSYCHOPHARMACOL BULL 2008;41 (1):121-132 [PubMed]
de Haan L, van Nimwegen L, van Amelsvoort T, Dingemans P, Linszen D, Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. PHARMACOPSYCHIATRY 2008;41 (4):125-128 [PubMed]
Dekker N, de Haan L, van den Berg S, de Gier M, Becker H, Linzen DH, Cessation of cannabis use by patients with recent-onset schizophrenia and related disorders. PSYCHOPHARMACOL BULL 2008;41 (1):142-153 [PubMed]
Denys D, de Haan L, 25 jaar antipsychotica: back to the future?. TIJDSCHR PSYCHIATR 2008;50 (13):105-109 [PubMed]
Karagianis J, Hoffmann VP, Arranz B, Treuer T, Maguire GA, de Haan L, Chawla B, Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. HUM PSYCHOPHARM CLIN 2008;23 (4):275-281 [PubMed]
Maat A, Fouwels A , de Haan L, Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. PSYCHOPHARMACOL BULL 2008;41 (3):5-10 [PubMed]
Peters BD, de Haan L, Dekker N, Blaas J, Becker HE, Dingemans PM, Akkerman EM, Majoie CB, van Amelsvoort T, den Heeten GJ, Linszen DH, White matter fibertracking in first-episode schizophrenia, schizoaffective patients and subjects at ultra-high risk of psychosis. NEUROPSYCHOBIOLOGY 2008;58 (1):19-28 [PubMed]
Stefansson H, Rujescu D, Cichon S, Pietiläinen OPH, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Möller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon E, Di Forti M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Mühleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney LA, Franke B, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nöthen MM, Peltonen L, Collier DA, St Clair D, Stefansson K [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Large recurrent microdeletions associated with schizophrenia. NATURE 2008;455 (7210):232-236 [PubMed]
van Amelsvoort T, Zinkstok J, Figee M, Daly E, Morris R, Owen MJ, Murphy KC, de Haan L, Linszen DH, Glaser B, Murphy DGM, Effects of a functional COMT polymorphism on brain anatomy and cognitive function in adults with velo-cardio-facial syndrome. PSYCHOL MED 2008;38 (1):89-100 [PubMed]
van Beveren NJM, de Haan L, A visual metaphor describing neural dynamics in schizophrenia. PLOS ONE 2008;3 (7):e2577 [PubMed]
van der Post L, Schoevers R, Koppelmans V, Visch I, Bernardt C, Mulder N, Beekman A, de Haan L, Dekker J, The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area. BMC PSYCHIATRY 2008;8 (1):35 [PubMed]
van Nimwegen L, de Haan L, van Beveren N, Laan W, van den Brink W, Linszen D, Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. J CLIN PSYCHOPHARM 2008;28 (2):214-218 [PubMed]
van Nimwegen LJ, de Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D, Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. CAN J PSYCHIAT 2008;53 (6):400-405 [PubMed]
van Nimwegen LJM. Well-being and co-morbidity in recent onset schizophrenia. s.l.: s.n.; 2008. 167p. ISBN 9789085594178 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, Hengeveld MW; copromotor(s): de Haan L, van den Brink W)
van Nimwegen LJM, Storosum JG, Blumer RME, Allick G, Venema HW, de Haan L, Becker H, van Amelsvoort T, Ackermans MT, Fliers E, Serlie MJM, Sauerwein HP, Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J CLIN ENDOCR METAB 2008;93 (2):572-577 [PubMed]
Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E, Sabatti C, Geurts van Kessel A, Brunner HG, Ophoff RA, Veltman JA [Contributors: Kahn RS, Linszen DH, Os Jv, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Recurrent CNVs disrupt three candidate genes in schizophrenia patients. AM J HUM GENET 2008;83 (4):504-510 [PubMed]
Zinkstok J, van Nimwegen L, van Amelsvoort T, de Haan L, Yusuf MA, Baas F, Linszen D, Catechol-O-methyltransferase gene and obsessive-compulsive symptoms in patients with recent-onset schizophrenia: Preliminary results. PSYCHIAT RES 2008;157 (1-3):1-8 [PubMed]
[Contributors: Leboyer M, Meyer-Lindenberg A, Stefanis N, Rutten BPF, Arango C, Jones P, Kapur S, Lewis S, Murray R, Owen MJ, Linszen D, Kahn R, van Os J, Wiersma D, Bruggeman R, Cahn W, Germeys I, de Haan L, Krabbendam L]] , Schizophrenia aetiology: do gene-environment interactions hold the key?. SCHIZOPHR RES 2008;102 (1-3):21-26 [PubMed]
de Haan L, Alledaagse vragen en wetenschap. TIJDSCHR PSYCHIATR 2007;49 (11):785-788 [PubMed]
de Haan L, van Amelsvoort T, Dingemans P, Linszen D, Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up. PHARMACOPSYCHIATRY 2007;40 (6):264-268 [PubMed]
Thijs WJ, Karrenbeld A, van der Zouwen L, de Haan L, Metastatic endometrial cancer; a rare intestinal localization. ENDOSCOPY 2007;39 Suppl 1 (S 1):E131 [PubMed]
van Nimwegen L, de Haan L, van Beveren N, van den Brink W, Linszen D, Adolescentie, schizofrenie en drugs: interacterende kwetsbaarheid. Een hypothese. TIJDSCHR PSYCHIATR 2007;49 (3):169-178 [PubMed]
Barkhof E, de Haan L, Meijer CJ, Fouwels AJ , Keet IPM, Hulstijn KP, Schippers GM, Linszen DH, Motivational interviewing in psychotic disorders. CURR PSYCHIAT REV 2006;2:207-213
de Haan L, Ontwikkeling van psychopathologie. TIJDSCHR PSYCHIATR 2006;48 (5):359-360 [PubMed]
de Haan L, Booij J, Lavalaye J, van Amelsvoort T, Linszen D, Occupancy of dopamine D-2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. PSYCHOPHARMACOLOGY 2006;183 (4):500-505 [PubMed]
de Haan L, Hoogeboom B, Beuk N, Wouters L, Dingemans PMAJ, Linszen DH, Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. PSYCHOPHARMACOL BULL 2006;39 (1):25-30 [PubMed]
van Beveren NJM, van der Spelt JJ, de Haan L, Fekkes D, Schizophrenia-associated neural growth factors in peripheral blood. A review. EUR NEUROPSYCHOPHARM 2006;16 (7):469-480 [PubMed]
van der Gaag M, Cuijpers A, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, de Hert M, Wiersma D, The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions. SCHIZOPHR RES 2006;85 (1-3):273-279 [PubMed]
van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, de Hert M, Cuijpers A, Wiersma D, The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. SCHIZOPHR RES 2006;85 (1-3):280-287 [PubMed]
van Nimwegen L, de Haan L, Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis. PSYCHOPATHOLOGY 2006;39 (3):158 [PubMed]
Weeda MR, Peters BD, de Haan L, Linszen DH, Blijvende neuropsychologische stoornissen en structurele en functionele hersenafwijkingen na langdurig cannabisgebruik. TIJDSCHR PSYCHIATR 2006;48 (3):185-193 [PubMed]
de Haan L, Het optimale niveau van dopaminerge neurotransmissie. NED TIJDSCHR GENEESKD 2005;149 (31):1721-1722 [PubMed]
de Haan L, Booij J, Lavalye J, van Amelsvoort T, Linszen D, Subjective experiences during dopamine depletion. AM J PSYCHIAT 2005;162 (9):1755 [PubMed]
de Haan L, Hoogenboom B, Beuk N, van Amelsvoort T, Linszen D, Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders. CAN J PSYCHIAT 2005;50 (9):519-524 [PubMed]
de Haan L, Lavalaye J, Booij J, Linszen D, Comfort, self-confidence, safety, and dopamine D2 receptor occupancy by antipsychotics. AM J PSYCHIAT 2005;162 (8):1544-1545 [PubMed]
de Haan L, van Beveren N, Olanzapine and haloperidol for residual symptoms. AM J PSYCHIAT 2005;162 (7):1392-1393 [PubMed]
Heeg B, Buskens E, Knapp M, van Aalst G, Dries PJT, de Haan L, van Hout BA, Modelling the treated course of schizophrenia: Development of a discrete event simulation model. PHARMACOECONOMICS 2005;23 (Suppl. 1):17-33 [PubMed]
van Nimwegen L, de Haan L, van Beveren N, van den Brink W, Linszen D, Adolescence, schizophrenia and drug abuse: a window of vulnerability. ACTA PSYCHIAT SCAND 2005;111 (Suppl. 427):35-42 [PubMed]
Zinkstok J, van Amelsvoort T, de Haan L, Baas F, Linszen DH. The catechol-O-methyltransferase gene and schizofphrenia in: Lang MV, editors. Trends in schizophrenia research. S.l.: Nova Science Publishers, Inc; 2005., p. 45-78
Boot E, de Haan L, Guzelcan Y, Scholte WF, Assies H, Pericardial and bilateral pleural effusion associated with clozapine treatment. EUR PSYCHIAT 2004;19 (1):65 [PubMed]
de Haan L, Bakker JM, Overview of neuropathological theories of schizophrenia: From degeneration to progressive developmental disorder. PSYCHOPATHOLOGY 2004;37 (1):1-7 [PubMed]
de Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booij J, van Amelsvoort T, Linszen D, Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. CAN J PSYCHIAT 2004;49 (5):290-296 [PubMed]
de Haan L, Oekeneva A, van Amelsvoort T, Linszen D, Obsessive-compulsive disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders. EUR PSYCHIAT 2004;19 (8):524 [PubMed]
de Haan L, van Amelsvoort T, Linszen DH, Elevated homocysteine levels in schizophrenia. AM J PSYCHIAT 2004;161 (6):1131-1132 [PubMed]
de Haan L, van Amelsvoort T, Rosien K, Linszen D, Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. PSYCHOPHARMACOLOGY 2004;175 (3):389-390 [PubMed]
de Haan L, van Beveren N, Olanzapine vs haloperidol for treatment of schizophrenia. JAMA-J AM MED ASSOC 2004;291 (9):1065-1065; author reply 1066 [PubMed]
de Haan L, Welborn K, Krikke M, Linszen DH, Opinions of mothers on the first psychotic episode and the start of treatment of their child. EUR PSYCHIAT 2004;19 (4):226-229 [PubMed]
Sluys M, Güzelcan Y, Casteelen G, de Haan L, Risperidone-induced leucopenia and neutropenia: a case report. EUR PSYCHIAT 2004;19 (2):117 [PubMed]
de Haan L, Linszen DH, Lenior ME, de Win ED, Gorsira R, Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. SCHIZOPHRENIA BULL 2003;29 (2):341-348 [PubMed]
de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PMAJ, Linszen D, Subjective experience and D-2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: A randomized, double-blind study. AM J PSYCHIAT 2003;160 (2):303-309 [PubMed]
Storosum JG, van Zwieten BJ, Wohlfarth T, de Haan L, Khan A, van den Brink W, Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. ARCH GEN PSYCHIAT 2003;60 (4):365-368 [PubMed]
van der Gaag M, Wolthaus J, de Haan L, Wykes T, School performance in secundary education shows no decline before the onset of a first episode of psychosis in schizophrenia. J MENT HEALTH 2003;12 (6):585-593
de Haan L. Patients' perspectives. Subjective experiences and attitudes of patients with recent onset schizophrenia. S.l.: s.n.; 2002. 227p. ISBN 90-9015265-2 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Linszen DH, Gersons BPR; copromotor(s): Dingemans PMAJ)
de Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D, Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: A prospective study of 113 patients with recent-onset schizophrenia or related disorders. J CLIN PSYCHIAT 2002;63 (2):104-107 [PubMed]
de Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L, Priorities and satisfaction on the help needed and provided in a first episode of psychosis. A survey in five European Family Associations. EUR PSYCHIAT 2002;17 (8):425-433 [PubMed]
de Haan L, Peters B, Dingemans P, Wouters L, Linszen D, Attitudes of patients toward the first psychotic episode and the start of treatment. SCHIZOPHRENIA BULL 2002;28 (3):431-442 [PubMed]
de Haan L, van Amelsvoort T, Comparable dopamine 2 receptor occupancy. AM J PSYCHIAT 2002;159 (12):2118-2118; author reply 2119 [PubMed]
de Haan L, Weisfelt M, Dingemans PMAJ, Linszen DH, Wouters L, Psychometric properties of the Subjective Well-Being Under Neuroleptics Scale and the Subjective Deficit Syndrome Scale. PSYCHOPHARMACOLOGY 2002;162 (1):24-28 [PubMed]
Denys D, de Haan L, Reply to Neurotic Excoriations and OCD. TIJDSCHR PSYCHIATR 2002;44:409-411
Güzelcan Y, de Haan L, Scholte WF, Risperidone may induce mania. PSYCHOPHARMACOLOGY 2002;162 (1):85-86 [PubMed]
Güzelcan Y, van Amelsvoort T, de Haan L, van Schaik P, Linszen DH, Schizofrenie en het 22q11-deletiesyndroom. NED TIJDSCHR GENEESKD 2002;146 (43):2019-2021 [PubMed]
Jonkers F, de Haan L, Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder. PSYCHOPHARMACOLOGY 2002;162 (1):87-88 [PubMed]
Storosum J, van Zwieten B, de Haan L, Informed consent from behaviourally disturbed patients. LANCET 2002;359 (9300):83 [PubMed]
de Haan L, van Raaij B, van den Berg R, Jager M, Houweling P, Stockmann M, Delsing P, Linszen D, Peters B, Wouters L, Preferences for treatment during a first psychotic episode. EUR PSYCHIAT 2001;16 (2):83-89 [PubMed]
de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L, Interaction of olanzapine with fluvoxamine. PSYCHOPHARMACOLOGY 2001;155 (2):219-220 [PubMed]
Lenior ME, Dingemans PM, Linszen DH, de Haan L, Schene AH, Social functioning and the course of early-onset schizophrenia: five-year follow-up of a psychosocial intervention. BRIT J PSYCHIAT 2001;179:53-58 [PubMed]
Boot E, de Haan L, Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. PSYCHOPHARMACOLOGY 2000;150 (3):347-348 [PubMed]
de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J, Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. AM J PSYCHIAT 2000;157 (6):1019-1020 [PubMed]
de Haan L, van der Gaag M, Wolthaus J, Duration of untreated psychosis and the long-term course of schizophrenia. EUR PSYCHIAT 2000;15 (4):264-267 [PubMed]
de Haan L, Linszen DH, Gorsira R, Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J CLIN PSYCHIAT 1999;60 (6):364-365 [PubMed]
Linszen DH, Dingemans PM, Lenior ME, Scholte WF , de Haan L, Goldstein MJ, Early detection and intervention in schizophrenia. INT CLIN PSYCHOPHARM 1998;13 (Suppl. 3):S31-S34 [PubMed]
Linszen D, Lenior M, de Haan L, Dingemans P, Gersons B, Early intervention, untreated psychosis and the course of early schizophrenia. BR J PSYCHIATRY SUPPL 1998;172 (33):84-89 [PubMed]
Key publications

de Haan L, Sterk B, Wouters L, Linszen DH, The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. SCHIZOPHRENIA BULL 2013;39 (1):151-160 [PubMed]
[Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Evidence That Familial Liability for Psychosis Is Expressed as Differential Sensitivity to Cannabis An Analysis of Patient-Sibling and Sibling-Control Pairs. ARCH GEN PSYCHIAT 2011;68 (2):138-147 [PubMed]
van Winkel R [Contributors: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I]] , Family-Based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis: Sibling Analysis and Proband Follow-up. ARCH GEN PSYCHIAT 2011;68 (2):148-157 [PubMed]
Nieman DH, Ruhrmann S, Dragt S, Soen F, van Tricht MJ, Koelman JHTM, Bour LJ, Velthorst E, Becker HE, Weiser M, Linszen DH, de Haan L, Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables. SCHIZOPHRENIA BULL 2014;40 (6):1482-1490 [PubMed]
Peters BD, Blaas J, de Haan L, Diffusion tensor imaging in the early phase of schizophrenia What have we learned?. J PSYCHIATR RES 2010;44 (15):993-1004 [PubMed]


All Publications

Curriculum Vitae

Curriculum Vitae Lieuwe de Haan, Version 30-6-2010

MD PhD, Lieuwe de Haan
Male, Married, 3 children
26 April 1960, Assen

Master’s

Vrije Universiteit Amsterdam
August 1986 M.D. (Cum Laude),

PhD

University of Amsterdam
March 2002 Ph.D.
Supervisor: Prof Dr. DH Linszen, Prof Dr. BPR Gersons
Title thesis: Patients’ perspectives; Subjective experiences and attitudes of patients with recent onset schizophrenia

Work experience since graduating

1986-1991 Resident in Psychiatry, PCA Valeriuskliniek, Amsterdam (fixed term, full time)
1991-1992 Resident in Child and Adolescent Psychiatry, Kinderpsychiatrisch Centrum Curium, Oegstgeest (fixed term, full time)
1992-1993 Resident in Social Psychiatry Centrale Riagg Dienst Amsterdam (fixed term, full time)
1993- Consultant Psychiatrist, Senior Lecturer, Zorglijn Vroege Psychose, Divisie Psychiatrie, AMC (tenured, full time)


Brief summary of research over last five years

In the past 5 years L. de Haan focused on subjective experiences on antipsychotic treatment of patients with schizophrenia. Epidemiological and biological factors associated with subjective response to antipsychotic medication were studied. Two randomized controlled trials with subjective response to antipsychotic medication as primary outcome measure were conducted.
Since 2003 L. de Haan is site coordinator in a national multicentre project, since 2010 member of the steering committee: Genetic Risk and Outcome of Psychosis (GROUP). Purpose of this project is to investigate the vulnerability and protective factors (and their interactions) for the development of a psychotic disorder, and the variation in the course of the disorder. A population-based cohort of patients with a recently developed psychotic disorder (n=1000), subjects at risk (brothers/sisters, n=1000), parents (n=1000) and healthy volunteers (n=700) is established. Subjective response to antipsychotic medication is the focus of an add-on study of the GROUP study. Obsessive-compulsive symptoms in patients with psychotic disorders is another focus of the research of L. de Haan. He is co-investigator in a multi-national EU funded study on Gene-Environment interactions in Schizophrenia.
Fundamental and clinical aspects of psychopharmacological influences on craving for cannabis in patients with schizophrenia is a major theme for recently started research projects.

International activities

- Mentor of the Young Investigator Program of the International Congress on Schizophrenia Research
- Expert in MATRA III project (Developing modules social psychiatry in the Czech Republic, project from the Ministry of External Affairs) 2003.

- Reviewer international: Plos one, The Lancet, Archives of General Psychiatry, American Journal of Psychiatry, Schizophrenia Bulletin, Neuropsychopharmacology, Journal of clinical psychiatry, Schizophrenia Research, Psychiatry Research, Psychopharmacology, Clinical Neuropharmacology, PPP Healthcare Medical Trust, Pharmacopsychiatry, International Journal of Psychiatry in Clinical Practice
- Member of the Advisory Board of Psychiatrics

- International invitations:
Five year course of Obsessive compulsive symptoms in first episode schizophrenia. International congress on schizophrenia research, Florence, 15 april 2010
Dopamine and the Subjective experience of patients with Schizophrenia – International congress on schizophrenia research, Colorado Springs, 23 june 2008
Dopamine, Reward and the Subjective experience of patients with Schizophrenia – Concepts and Imaging, CINP, Chicago, 9 – 14 july 2006
Neuroleptic dysphoria - stage of illness and type of medication - International congress on schizophrenia research, Colorado Springs, 29 maart - 2 april 2003
Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia European Regional Congress of WFSBP, Copenhagen, Denmark, 13 – 16 June 2002
How is optimal dosage to be determined? Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized on olanzapine or risperidone - 10th Biennal Winterworkshop on schizophrenia, Davos, 5-11 Februari 2000
Improvement of social functioning after admission of patients with recent onset schizophrenic disorders - Vth Congress World Association for Psychosocial Rehabilitation, Rotterdam, April 23 1996
Duration of untreated psychosis and prognosis - First episode in schizophrenia congress, Amsterdam, 28 November 1996
Delay in intensive psychosocial intervention - First episode in schizophrenia congress, Amsterdam, 29 November 1996

- International collaborations:
Germany, Department of Psychiatry and Psychotherapy, University of Hamburg, Hamburg, Naber D
Canada, Department of Psychiatry, University of Toronto, Kapur S
England, Institute of Psychiatry, London, Kapur S
Canada, McMaster University, Hamilton, Voruganti L, Szechtman H
Canada, Eli Lilly Scarborough, Karagianis JL, MD

Other academic activities
Since 2003 L. de Haan is member of the editorial board of “Tijdschrift voor Psychiatrie” since 2006 citated on medline.
Since 2003 L. de Haan is site-coordinator of the Genetic Risk and Outcome of Psychosis study (GROUP).
Since 2006 L. de Haan is chairman of the site-coordinators of the GROUP study and member of the steering committee of GROUP.
From 2005 – 2009 L. de Haan was chairman of the “Commissie Wetenschap van de Nederlandse Vereniging voor Psychiatrie”.

Involved in the following current PhD projects
1. Mw. L van Nimwegen (AMC) Subjective well-being and craving for cannabis in schizophrenia. Thesis defence 15 October 2008
2. J.M. van Beveren (Erasmus MC) Schizophrenia-associated neural growth factors. Thesis defence: 18 may 2010
3. B. Peters (AMC) White Matters: Diffusion Tensor Imaging in Schizophrenia, Expected date of thesis defence: 7 september 2010
4. E. Barkhof (AMC) Motivational interviewing for non compliance in schizophrenia, Expected date of thesis defence: 2011
5. M.A.M. Boerma (InGeest) Women and recent onset psychotic disorders: estrogens, cognitive functioning, menarche, Expected date of thesis defence: 2012
6. S. Vothknecht (Arkin) Subjective experiences of patients with recent onset psychosis related to antipsychotic medication, Expected date of thesis defence: 2012
7. M. Swets (Arkin) Obsessive-compulsive symptoms in patients with recent-onset schizophrenia and related disorders, Expected date of thesis defence: 2012
8. Mw. W. Hoen (Arkin) Metabolism of fatty acids in patients with recent onset schizophrenia and related disorders, Expected date of thesis defence: 2012
9. Mw. M. C.Klaassen (Rivierduinen) Depressive symptoms in the early course of schizophrenia, Expected date of thesis defence: 2012
10. P.D. Meesters (InGeest) Schizofrenie op oudere leeftijd (SOUL), Expected date of thesis defence: 2011
11. Marise Machielsen (AMC). Het effect van risperidon en clozapine op craving pathways. Een gerandomiseerde dubbel-blind fMRI onderzoek. Expected date of thesis defence: 2011
12. Albertine Scheltema Beduin (AMC). Het effect van clozapine en olanzapine op middelengebruik bij patiënten met een schizofrene stoornis en verslaving. Randomized Olanzapine Clozapine Key Study on Addiction in the Netherlands [ROCKSAN] Expected date of thesis defence: 2012
13. Bouke Sterk (AMC). Tijdige onderkenning psychose en duur onbehandelde psychose Expected date of thesis defence: 2011
14. Sara Dragt (AMC). Cognitieve gedragstherapie bij patiënten met een hoog risico op psychose
Expected date of thesis defence: 2011
15. Oswald Bloemen (AMC). Dopaminerge neurotransmissie bij patiënten met een hoog risico op psychose Expected date of thesis defence: 2011
16. Erik Boot. Dopaminerge neurotransmissie bij patiënten met het Velo Cardio Faciaal Syndroom. Expected date of thesis defence: 2010.
17. Julia Meijer (AMC). Reuk en schizofrenie Expected date of thesis defence: 2012
18. Nikie Korver (AMC). Hechting en psychose Expected date of thesis defence: 2012
19. Eva Velthorst (AMC) Predictie van Transitie naar Psychose
20. Anita Wessels (Dimens) Sport en psychose
21. Mirjam van Tricht (AMC) Neurofysiologische afwijkingen bij schizofrenie
22. N. Dekker (AMC) Cannabis and schizophrenia, patients and siblings, Expected date of thesis defence: 2011
23. Hiske Becker (AMC). Neuropsychologie in de voorspelling van psychose. Expected date of thesis defence: 2011
24. Renate van der Valk (AMC). Trait anxiety and psychosis

Member of the supervising committee
Research in Mentrum on forced psychiatric treatment L. van der Post.
Trimbos research on nurse interventions at suicide: Abandon suicide. E Broers, J van Weeghel.

Reviewer national: Tijdschrift voor Psychiatrie, Maandblad Geestelijke Volksgezondheid, Nederlands Tijdschrift voor Geneeskunde

Organisation:
Chairman Voorjaarscongres van de Nederlandse Vereniging voor Psychiatrie, 2008 Amsterdam
Theme: Preventie (congres 3 days, 2800 participants)
Chairman Voorjaarscongres van de Nederlandse Vereniging voor Psychiatrie, 2007 Maastricht
Theme: Psychiatrie in Europa (congres 3 days, 2500 participants)
Chairman Voorzitter Voorjaarscongres van de Nederlandse Vereniging voor Psychiatrie, 2006 Groningen Theme: Ontwikkeling en levensloop (congres 3 days, 2300 participants)
Chairman Voorjaarscongres van de Nederlandse Vereniging voor Psychiatrie, 2005 Den Haag
Theme: Education Permanente (congres 3 days, 2300 participants)
Chairman: Cursus voor huisartsen Schizofrenie: diagnostiek en behandeling, Champery, 18 jamuari 2002
Coordinator Blok Psychotische stoornissen, Onderwijs aan arts-assistenten in opleiding tot psychiater consortium Noord-Holland, sinds 2000
Coordinator co-schappen Psychiatrie AMC, sinds 1997
Chairman Cursus voor huisartsen,Psychotische stoornissen, Clermont-Ferrand, 4-8 juni 1997
Chairman Symposium voor huisartsen en jeugdartsen,Vroeg herkenning van schizofrenie, Amsterdam, 28 November 1996

Local collaborations:
Department of Nuclear Medicine, AMC, Booij J
Laboratorium Genetische Metabole Ziekten, AMC, Duran R, Wanders R
Department of Radiology, Majoie CBLM, Den Heeten GJ,

National collaborations:
UMC Utrecht, Kahn RS, Cahn W,
UMC Groningen, Wiersma D, Bruggeman R
UMC Maastricht, Van Os, Germeys I
VU Krabbendam L
Erasmus MC, Hengeveld M, Van Beveren N
GGZ Noord Holland Noord, Monden M, Wisman H, Keet R
GGZ Arkin Swets M, Vothknecht S, Schoevers R, Van der Post, Dekker J, Hoen W
GGZ In Geest, Boerma M, Meesters PD, Beekman ATF
GGZ Rivierduinen, Klaassen R
Altrecht, Kleijweg MM
Antonius ziekenhuis Nieuwegein, Lavalaye J
 

Scholarships prizes, and grants

(in collaboration with others or alone)
- Award of the British Medical Association Mental Health Book of Year 1st prize, Marihuana and Madness. D. Castle, R. Murray, editors, Cambridge University Press, Cambridge, 2005, Cannabis abuse and the course of schizophrenia, Linszen DH, Peters B, De Haan L, Pag. 119-126
- Nominated for the best article Tijdschrift voor Psychiatrie, 2006: Resterende neuropsychologische stoornissen, structurele en functionele hersenafwijkingen na langdurig cannabisgebruik, Weeda MR, Peters BD, De Haan L , Linszen DH, Tijdschrift voor Psychiatrie, 2006, 48, 185-193
- Award for the best article Tijdschrift voor Psychiatrie, 2004: Genetisch onderzoek bij schizofrenie: een overzicht. Figee M, Van Amelsvoort T, De Haan L, Linszen DH, Tijdschrift voor Psychiatrie, 2004, 46, 15-26
- Promovendi Primeur Award 2002, De Haan L Beste Presentatie
- Janssen Cilag Schizofrenie Prijs 2002 De Haan L € 10.000
- Aanmoedigingsprijs Ypsilon De Haan L 1994

L de Haan has received (in collaboration with others) the following grants, total amount is mentioned:

- ‘Early detection of psychosis: the efficacy of an early detection program in Amsterdam’
Linszen DH, Van Amelsvoort TA, Becker HE, Birchwood M, Dingemans PM, De Haan L [Principal Investigator], Lester H, Nieman D, Van der Fliert R, € 468.719 ZonMW

- EU European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI), Large Scale Integrating project HEALTH-2009-2.2.1-2: Identifying genetic and environmental interactions in schizophrenia.
Principal Investigator Van Os J.
De Haan L Principal Investigator AMC part
(a.) Projectleader Workpackage Training. AMC part: € 526.286
(b.) Projectmember of workpackage Functional Enviromics € 379.628
(c.) Projectmember Workpackage GxE Prodrome € 115.286
Total AMC part: € 1.021.200

- Genetic Risk and Outcome of Psychosis (GROUP), Project team members: Linszen DH, De Haan L, Kahn RS, Cahn W, Wiersma D, Bruggeman R, Van Os, Krabbendam L, total: € 5.088.420, AMC part: € 1.272.105, ZonMW

- Unrestricted grant pharmaceutical companies for the GROUP project (Eli Lilly Nederland, Dr. Paul Janssen Stichting, AstraZeneca, Bristol Myers Squibb), Project team members: Linszen DH, De Haan L, Kahn RS, Cahn W, Wiersma D, Bruggeman R, Van Os, Krabbendam L, total: € 800.000, AMC part: € 200.000

- Mental illness, genomics and society, Project team members: Meijman FJ, VU University Medical Centre/Metamedica, Kahn RS, Linszen DH, Cahn W, De Haan L, Wiersma D, Bruggeman R, Van Os, Krabbendam L Cornel M, Van Tilburg W, VU University, € 160.000 , AMC part: € 40.000, Funding Centre for Society and Genomics

- Subjective well-being, craving for cannabis and compliance or medication switch in a randomized double blind study with olanzapine or risperidone, De Haan L [Principal Investigator], Project team members: Linszen DH, Van den Brink W, € 180.000

- Placebo and active comparator trial of olanzapine zydis pills used sublingually, P.I.: Karagianis J (Canada) De Haan L [P.I. The Netherlands]: total € 380.000 AMC part: € 20.000

- MIGROUP, samen met, J.P. Selten, R. Schoevers, P.I.: Selten JP Project team members: Havenaar J, Schoevers R, De Haan L, € 50.100

- Effect of different antipsychotic medications on craving and craving related brain activity in patients with schizophrenia and cannabis abuse or dependence:a randomized controlled study comparing clozapine and risperidone De Haan L [Principal Investigator], Linszen DH, Van den Brink W, Veltman D. ZonMW € 353.972

- Multi-Center Studie Clozapine vs olanzapine intervention in patients with schizophrenia and co-morbid substance use, a multi-centre double blind randomized trial (aanvraag 637) , Linszen DH, De Haan L [Principal Investigator], Van den Brink W, Schulte R. ZonMW € 494,056

5.0. In Press

Three year course of clinical symptomatology in young people at ultra high risk for transition to psychosis
Velthorst E, Nieman DH, Klaassen RMC, Becker HE, Dingemans PM, Linszen DH, De Haan L
Acta Psychiatrica Scandinavica in press

Disability in patients clinically at high risk for a psychosis
Velthorst E, Nieman D, Linszen D, Becker H, De Haan L, Dingemans P, Birchwood M, Patterson P, Salokangas R, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Schultze-Lutter F, Klosterkötter J, Ruhrmann S
British Journal of Psychiatry in press

Schizophrenia in later life: one-year prevalence and distribution of age at onset and sex in a catchment area in Amsterdam
Meesters PD, De Haan L, Comijs HC, Stek ML, Eikelenboom P, Smit JP,
Beekman ATF
The American Journal of geriatric psychiatry in press

GWA study data-mining and independent replication identify cardiomyopathy associated 5 (CMYA5) as a risk gene for schizophrenia
Chen X, Lee G, Maher BS, Fanous AH, Chen J, Zhao Z, Guo A, van den Oord E, Sullivan PF, Shi X, Levinso DF, Gejman P, Sanders A, Duan J, Owen MJ, Craddock NJ, C O’Donovan M, Blackman J, Lewis D, Qin W, Schwab S, Wildenauer D, Chowdari K, Nimgaonkar V, Straub R, Weinberger DR, O’Neill A, Walsh D, Darvasi A, Lencz T, Malhotra AK, Rujescu D, Giegling I, Werge T, Hansen T, Ingason A, Nöthen MM, Rietschel M, Cichon S, Djurovic S, Andreassen O, Cantor R, Ophoff R, Corvin A, Morris DW, Gill M, Pato CN, Pato MT, Macedo A, Gurling H, McQuillin A, Pimm J, Hultman C, Lichtenstein P, Sklar P, Purcell S, Scolnick E, St Clai Dr, Blackwood D, the GROUP investigators: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, the International Schizophrenia Consortium, Kendler KS

Three year course of clinical symptomatology in young people at ultra high risk for transition to psychosis
Velthorst E, Nieman DH, Klaassen RMC, Becker HE, Dingemans PM, Linszen DH, De Haan L
In press Acta Psychiatrica Scandinavica

Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode
Van Tricht MJ, Nieman DH, Koelman JHTM, Van der Meer J, Bour LJ, De Haan L, Linszen D
Biological Psychiatry, in press

Emotional Experience and Estimates of D2 Receptor Occupancy in Psychotic Patients Treated with Haloperidol, Risperidone, or Olanzapine: an Experience Sampling Study
Lataster J, van Os J, De Haan L, Thewissen V, Bak M, Lataster T, Lardinois M, Delespaul P, Myin-Germeys, I
The Journal of Clincial Psychiatry, in press

Cannabis use in patients with a first psychotic episode and subjects at Ultra High Risk of psychosis: impact on psychotic- and pre-psychotic symptoms.
Machielsen M, Van der Sluis S, De Haan L
Australian and New Zealand Journal of Psychiatry, in press

Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission
Machielsen M, De Haan L
Psychopharmacol Bull. 2010 In press

Neurocognitive functioning before and after a First psychotic episode: Does psychosis result in cognitive deterioration?
Becker HE, Nieman DH, Wiltink S, Dingemans PM, van de Fliert JR, Velthorst E, De Haan L, van Amelsvoort A, Linszen DH. Psychological Medicine, in press.

Social functioning among older community-dwelling patients with schizophrenia: a review
Meesters PD, Stek M, Comijs HC, De Haan L , Patterson TL, Eikelenboom P, Beekman ATF
The American Journal of geriatric psychiatry in press

Factors associated with weight change during 16 weeks of therapy with sublingual orally disintegrating olanzapine or standard olanzapine tablets: results from exploratory analyses of a randomized, double-blind, clinical trial
Karagianis J, Landry J, Hoffmann VP, Grossman L, De Haan L, Maguire G, Milev R, Holt S
International Journal of Clinical Practice in press


5.1. Publications

- International (refereed) publications

163. The association between social anhedonia, withdrawal and psychotic experiences in general and high-risk populations.
Velthorst E, Meijer C; G.R.O.U.P. Investigators.
Schizophrenia Research 2012 Jul;138(2-3):290-4. Epub 2012 Apr 6

162. The Strauss and Carpenter Prognostic Scale in subjects clinically at high risk of psychosis.
Nieman DH, Velthorst E, Becker HE, de Haan L, Dingemans PM, Linszen DH, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, von Reventlow HG, Morrison A, Schultze-Lutter F, Klosterkötter J, Ruhrmann S; on behalf of the EPOS group.
Acta Psychiatrica Scandinavica 2012 Jul 7. doi: 10.1111/j.1600-0447.2012.01899.x. [Epub ahead of print]

161. Childhood bullying and the association with psychosis in non-clinical and clinical samples: a review and meta-analysis.
van Dam DS, van der Ven E, Velthorst E, Selten JP, Morgan C, de Haan L.
Psychological Medicine 2012 Mar 9:1-12. [Epub ahead of print]

160. Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender
Dekker N, Meijer J, Koeter M, van den Brink W, van Beveren N; GROUP Investigators, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I.
Psychological Medicine 2012, 42, 1903-1911

159. Social Cognitive Impairments and Psychotic Symptoms: What is the Nature of Their Association?
Fett AK, Maat A; GROUP Investigators.
Schizophr Bull. 2011 Jun 22. [Epub ahead of print]

158. Social cognition and quality of life in schizophrenia.
Maat A, Fett AK, Derks E; GROUP Investigators.
Schizophrenia Research 2012 Mar 7. [Epub ahead of print]

157. Intermediate Phenotype Analysis of Patients, Unaffected Siblings, and Healthy Controls Identifies VMAT2 as a Candidate Gene for Psychotic Disorder and Neurocognition.
Simons CJ, van Winkel R; GROUP investigators.
Schizophrenia Bull. 2012 Apr 24.

156. No evidence for familial covariation of neurocognition and negative symptoms in psychotic disorders.
Lataster T, Shazad A, Henquet C, GROUP Investigators.
Schizophrenia Research 2012

155. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective
psychotic illness and their unaffected siblings.
Meijer JH, Dekker N, Koeter MW, Quee PJ, van Beveren NJM, Meijer CM; GROUP Investigators.
Psychological Medicine 2012, 42, 705–716. f Cambridge University Press 2011

154. Cognitive impairment in late life schizophrenia and bipolar I disorder.
Meesters P, Schouws S, Stek M, de Haan L, Smit J, Eikelenboom P, Beekman AJ, Comijs H.
International Journal Geriatric Psychiatry, 2012.

153. Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients.
van Beveren NJM, Buitendijk GHS, Swagemakers S, Krab LC, Röder C, de Haan L, van der Spek P, Elgersma P.
PLoS ONE, 2012 February 7, (2).

152. Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents.
Meijer J, Simons CJ, Quee PJ, Verweij K; GROUP Investigators.
Acta Psychiatrica Scandinavica 2012 Jan;125(1):66-76.

151. Schizophrenia Spectrum Disorders in Later Life: Prevalence and Distribution of Age at Onset and Sex in a Dutch Catchment Area.
Paul D. Meesters, M.D., Lieuwe De Haan, M.D., Ph.D., Hannie C. Comijs, Ph.D., Max L. Stek, M.D., Ph.D., Maureen M.J. Smeets-Janssen, M.D., Ph.D., Marjan R. Weeda, M.D., Piet Eikelenboom, M.D., Ph.D.,
Johannes H. Smit, Ph.D., Aartjan T.F. Beekman, M.D., Ph.D.
American Journal Geriatric Psychiatry 20:1, January 2012

150. Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic
risk for psychosis.
Collip D, Nicolson NA, Lardinois M, T. Lataster, van Os J, Myin-Germeys I; GROUP Investigators.
Psychological Medicine (2011), 41, 2305–2315. f Cambridge University Press 2011

149. The validity of the DSM-IV diagnostic classification system of non-affective psychoses.
Korver-Nieberg N, Quee PJ, Boos HB, Simons CJ; GROUP Investigators.
The Australian and New Zealand journal of psychiatry. 2011 Dec;45(12):1061-8. Epub 2011 Oct 25. PubMed PMID: 22026404.

148. Motivational interviewing and interaction skills training for parents to change cannabis use in young adults with recent-onset schizophrenia: a randomized controlled trial.
Smeerdijk M, Keet R, Dekker N, van Raaij B, Krikke M, Koeter M, De Haan L, Barrowclough C, Schippers G, Linszen D.
Psychological Medicine, 2011 Dec 8:1-10. [Epub ahead of print]

147. Correction: proton magnetic resonance spectroscopy in 22q11 deletion syndrome.
Da Silva Alves F, Boot E, Schmitz N, Nederveen A, Vorstman J, Lavini C, Pouwels P, De Haan L, Linszen D, van Amelsvoort T.
PLOS ONE 2011;ahead of print[ PubMed ]

146. White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia.
Da Silva Alves F, Schmitz N, Bloemen O, van der Meer J, Meijer J, Boot E, Nederveen A, De Haan L, Linszen D, van Amelsvoort T.
Schizophrenia Research 2011;132 (1):75-83[ PubMed ]

145. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder.
Van Winkel R, van Beveren NJ, Simons C; Genetic Risk and Outcome of Psychosis (GROUP) Investigators.
Neuropsychopharmacology. 2011 Nov;36(12):2529-37. doi: 10.1038/npp.2011.141. Epub 2011 Jul 20.

144. Ultra high-risk state for psychosis and non-transition: a systematic review.
Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, De Haan L.
Schizophrenia Research 2011 Oct;132(1):8-17. Epub 2011 Jul 23.

143. Genome-wide association study identifies five new schizophrenia loci.
Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DH, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, De Hert M, Jönsson EG, Bitter I, Pietiläinen OP, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, De Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jürgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lönnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nöthen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Orntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Réthelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CC, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV; Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium.
Nature Genetics 2011 Sep 18;43(10):969-76. doi: 10.1038/ng.940.

142. Factor analysis of the scale of prodromal symptoms: differentiating between negative and depression symptoms
Klaassen RM, Velthorst E, Nieman DH, De Haan L, Becker HE, Dingemans PM, van de Fliert JR, van der Gaag M, Linszen DH.
Psychopathology. 2011;44(6):379-85. doi: 10.1159/000325169. Epub 2011 Aug 17.

141. Ethnicity and baseline symptomatology in patients with an At Risk Mental State for psychosis.
Velthorst E, Nieman DH, Veling W, Klaassen RM, Dragt S, Rietdijk J, Ising H, Wunderink L, Linszen DH, De Haan L, van der Gaag M.
Psychol Med. 2011 Aug 11:1-10. [Epub ahead of print]

140. Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis.
Bloemen OJ, Gleich T, de Koning MB, da Silva Alvis F, De Haan L, Linszen DH, Booij J, van Amelsvoort TA.
Biological Psychiatry. 2011 Jul 1;70(1):e1-2; author reply e3. Epub 2011 Apr 8.

139. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Steinberg S, de Jong S; Irish Schizophrenia Genomics Consortium, Andreassen OA, Werge T, Børglum AD, Mors O, Mortensen PB, Gustafsson O, Costas J, Pietiläinen OP, Demontis D, Papiol S, Huttenlocher J, Mattheisen M, Breuer R, Vassos E, Giegling I, Fraser G, Walker N, Tuulio-Henriksson A, Suvisaari J, Lönnqvist J, Paunio T, Agartz I, Melle I, Djurovic S, Strengman E; GROUP, Jürgens G, Glenthøj B, Terenius L, Hougaard DM, Ørntoft T, Wiuf C, Didriksen M, Hollegaard MV, Nordentoft M, van Winkel R, Kenis G, Abramova L, Kaleda V, Arrojo M, Sanjuán J, Arango C, Sperling S, Rossner M, Ribolsi M, Magni V, Siracusano A, Christiansen C, Kiemeney LA, Veldink J, van den Berg L, Ingason A, Muglia P, Murray R, Nöthen MM, Sigurdsson E, Petursson H, Thorsteinsdottir U, Kong A, Rubino IA, De Hert M, Réthelyi JM, Bitter I, Jönsson EG, Golimbet V, Carracedo A, Ehrenreich H, Craddock N, Owen MJ, O'Donovan MC; Wellcome Trust Case Control Consortium 2, Ruggeri M, Tosato S, Peltonen L, Ophoff RA, Collier DA, St Clair D, Rietschel M, Cichon S, Stefansson H, Rujescu D, Stefansson K.
Human Molecular Genetics. 2011 Oct 15;20(20):4076-81. Epub 2011 Jul 26.

138. The 5-Year Course of Obsessive-Compulsive Symptoms and Obsessive-Compulsive Disorder in First-Episode Schizophrenia and Related Disorders.
De Haan L, Sterk B, Wouters L, Linszen DH.
Schizophrenia Bulletin. 2011 Jul 28. [Epub ahead of print]

137. Social disability at admission for a first psychosis does not predict clinical outcome at 5-year follow-up.
Velthorst E, Nieman DH, Meijer C, Linszen D, De Haan L.
The Journal of Nervous and Mental Disease 2011 Jul;199(7):510-2.

136. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.
Machielsen M, Scheltema Beduin A, Dekker N, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I.
Journal of Psychopharmacology 2011 Jul 18. [Epub ahead of print]

135. Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe.
Rietschel M, Mattheisen M, Degenhardt F; GROUP Investigators; Genetic Risk and Outcome in Psychosis (GROUP Investigators), Kahn RS, Linszen DH, Os JV, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I, Mühleisen TW, Kirsch P, Esslinger C, Herms S, Demontis D, Steffens M, Strohmaier J, Haenisch B, Breuer R, Czerski PM, Giegling I, Strengman E, Schmael C, Mors O, Mortensen PB, Hougaard DM, Orntoft T, Kapelski P, Priebe L, Basmanav FB, Forstner AJ, Hoffmann P, Meier S, Nikitopoulos J, Moebus S, Alexander M, Mössner R, Wichmann HE, Schreiber S, Rivandeneira F, Hofman A, Uitterlinden AG, Wienker TF, Schumacher J, Hauser J, Maier W, Cantor RM, Erk S, Schulze TG; SGENE-plus Consortium; (Only those persons responsible for the samples of Replication 2 are listed), Stefansson H, Steinberg S, Gustafsson O, Sigurdsson E, Petursson H, Kong A, Stefansson K, Pietiläinen OP, Tuulio-Henriksson A, Paunio T, Lonnqvist J, Suvisaari J, Peltonen L, Ruggeri M, Tosato S, Walshe M, Murray R, Collier DA, Clair DS, Hansen T, Ingason A, Jakobsen KD, Duong L, Werge T, Melle I, Andreassen OA, Djurovic S, Bitter I, Réthelyi JM, Abramova L, Kaleda V, Golimbet V, Jönsson EG, Terenius L, Agartz I, Winkel RV, Kenis G, Hert MD, Veldink J, Wiuf C, Didriksen M, Craddock N, Owen MJ, O'Donovan MC, Børglum AD, Rujescu D, Walter H, Meyer-Lindenberg A, Nöthen MM, Ophoff RA, Cichon S.
Molecular Psychiatry. 2011 Jul 12. doi: 10.1038/mp.2011.80. [Epub ahead of print]

134. Auditory ERP components before and after transition to a first psychotic episode.
Van Tricht MJ, Nieman DH, Koelman JH, Bour LJ, van der Meer JN, van Amelsvoort TA, Linszen DH, De Haan L.
Biological Psychology 2011 Jul;87(3):350-7. Epub 2011 Apr 30.

133. Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic
illness. Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD, Kristinsson KT, le Roux L, Gustafsson O, Craddock N, Möller HJ, McQuillin A, Muglia P, Cichon S, Rietschel M, Ophoff RA, Djurovic S, Andreassen OA, Pietiläinen OP, Peltonen L, Dempster E, Collier DA, St Clair D, Rasmussen HB, Glenthøj BY, Kiemeney LA,
Franke B, Tosato S, Bonetto C, Saemundsen E, Hreidarsson SJ; Genetic Risk and Outcome of Psychosis (GROUP), Nöthen MM, Gurling H, O'Donovan MC, Owen MJ, Sigurdsson E, Petursson H, Stefansson H, Rujescu D, Stefansson K, Werge T.
The American Journal of Psychiatry, 2011 Apr;168(4):408-17. Epub 2011 Feb 15. PubMed PMID:
21324950.

132. Factor structure of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) in a large sample of patients with schizophrenia or related disorders and comorbid obsessive-compulsive symptoms.
Boyette L, Swets M, Meijer C, Wouters L, GROUP.
Psychiatry Research 2011 Apr 30;186(2-3):409-13. Epub 2010 Aug 30.

131. Association of treatment delay, migration and urbanicity in psychosis.
Boonstra N, Sterk B, Wunderink L, Sytema S, De Haan L, Wiersma D.
European Psychiatry. 2011 Jun 24. [Epub ahead of print]

130. Social Cognitive Impairments and Psychotic Symptoms: What is the Nature of Their Association? Fett AK, Maat A; Genetic Risk and Outcome of Psychosis (GROUP).
Schizophrenia Bulletin. 2011 June 22. PubMed PMID: 21697150 [Epub ahead of print]

129. Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia.
Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J; Genetic Risk and Outcome of Psychosis (GROUP).
Biological Psychiatry. 2011 Mar 1;69(5):487-94. Epub 2010 Oct 16

128. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-A review of the past decade.
Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, De Haan L.
European Psychiatry. 2011 May 9. [Epub ahead of print]

127. Genome-Wide Analysis Shows Increased Frequency of Copy Number Variation Deletions in Dutch Schizophrenia Patients. Buizer-Voskamp JE, Muntjewerff JW; Genetic Risk and Outcome in Psychosis (GROUP) Consortium, Strengman E, Sabatti C, Stefansson H, Vorstman JA, Ophoff RA.
Biological Psychiatry. 2011 April 12. [Epub ahead of print]

126. Effects of season of birth and a common MTHFR gene variant on the risk of schizophrenia.
Muntjewerff JW, Ophoff RA, Buizer-Voskamp JE, Strengman E, den Heijer M, GROUP Consortium
European Neuropsychopharmacology (2011) 21, 300–305

125. Evidence that Familial Liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. GROUP investigators.
Archives of General Psychiatry 2011 Feb; 68(2):138-47. Epub 2010 Oct 4.

124. Family-based analysis of genetic variation underlying psychosis-inducing effects
of cannabis: sibling analysis and proband follow-up. van Winkel R; Genetic Risk and Outcome of Psychosis (GROUP).
Archives of General Psychiatry, 2011 Feb;68(2):148-57. Epub 2010 Nov 1. PubMed PMID: 21041608.

123. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. `
Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietiläinen OP, Buizer-Voskamp JE, Strengman E, Francks C, Muglia P, Gylfason A, Gustafsson O, Olason PI, Steinberg S, Hansen T, Jakobsen KD, Rasmussen HB, Giegling I, Möller HJ, Hartmann A, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Bramon E, Kiemeney LA, Franke B, Murray R, Vassos E, Toulopoulou T, Mühleisen TW, Tosato S, Ruggeri M, Djurovic S, Andreassen OA, Zhang Z, Werge T, Ophoff RA; GROUP Investigators, Rietschel M, Nöthen MM, Petursson H, Stefansson H, Peltonen L, Collier D, Stefansson K, St Clair DM.
Molecular Psychiatry, 2011 Jan;16(1):17-25. Epub 2009 Sep 29. PubMed PMID: 19786961

122. White-matter markers for psychosis in a prospective ultra-high-risk cohort.
Bloemen OJN, de Koning MB, Schmitz N, Nieman DH, Becker HE, De Haan L, Dingemans P, Linszen DH, van Amelsvoort TAMJ.
Psychological Medicine 2010;40(8):1297-1304

121. Emotional Experience and Estimates of D2 Receptor Occupancy in Psychotic Patients Treated with Haloperidol, Risperidone, or Olanzapine: an Experience Sampling Study
Lataster J, van Os J, De Haan L, Thewissen V, Bak M, Lataster T, Lardinois M, Delespaul P, Myin-Germeys, I
The Journal of Clincial Psychiatry, 2010 Dec 14. [Epub ahead of print]

120. Kraepelin was right: a latent class analysis of symptom dimensions in patients and controls.
Derks EM, Allardyce J, Boks MP, Vermunt JK, Hijman R, Ophoff RA; GROUP.
Schizophrenia Bulletin 2010 Sep 30. [Epub ahead of print]

119. Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness
Quee PJ, Van der Meer L, Bruggeman R, De Haan L, Krabbendam L, Cahn W, Mulder N, Wiersma D, Aleman A
Schizophrenia Bulletin 2011 Jan;37(1):29-37. Epub 2010 Nov 22

118. Off-label second generation antipsychotics for impulse regulation disorders: a review.
Beduin AS, De Haan L.
Psychopharmacol Bull. 2010;43(3):45-81

117. Reply to Fan and Hart.
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, De Haan L.
Psychiatry Research. 2011 Jan 30;191(1):85. Epub 2010 Nov 10

116. Obsessive – compulsive symptoms in first episode psychosis and in subjects at ultra high risk for developing psychosis; onset and relationship to psychotic symptoms.
Sterk B, Lankreijer K, Linszen D, De Haan L.
The Royal Australian and New Zealand College of Psychiatrists. 2010 Nov 18. [Epub ahead of print]

115. Family-based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis: Sibling Analysis and Proband Follow-Up.
Van Winkel R, GROUP Investigators.
Archives of General Psychiatry. Published online 2010 November 1

114. Social functioning among older community-dwelling patients with schizophrenia: a review
Meesters PD, Stek M, Comijs HC, De Haan L , Patterson TL, Eikelenboom P, Beekman ATF
The American Journal of geriatric psychiatry 2010 Oct;18(10):862-78

113. Neurocognitive functioning before and after a First psychotic episode: Does psychosis result in cognitive deterioration?
Becker HE, Nieman DH, Wiltink S, Dingemans PM, van de Fliert JR, Velthorst E, De Haan L, van Amelsvoort A, Linszen DH.
Psychological Medicine, Psychol Med. 2010 Oct;40(10):1599-606. Epub 2010 Feb 5

112. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder.
Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, Georgieva L, Williams NM, Morris DW, Quinn EM, Giegling I, Ikeda M, Wood J, Lencz T, Hultman C, Lichtenstein P, Thiselton D, Maher BS; Molecular Genetics of Schizophrenia Collaboration (MGS) International Schizophrenia Consortium (ISC), SGENE-plus, GROUP, Malhotra AK, Riley B, Kendler KS, Gill M, Sullivan P, Sklar P, Purcell S, Nimgaonkar VL, Kirov G, Holmans P, Corvin A, Rujescu D, Craddock N, Owen MJ, O'Donovan MC.
Mol Psychiatry. 2010 Apr 6. [Epub ahead of print]

111. Disability in people clinically at high risk for a psychosis
Velthorst E, Nieman D, Linszen D, Becker H, De Haan L, Dingemans P, Birchwood M, Patterson P, Salokangas R, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Schultze-Lutter F, Klosterkötter J, Ruhrmann S
British Journal of Psychiatry. 2010 Oct; 197, (4), 278-84

110. Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk
Dragt S, Nieman DH, Veltman D, Becker HE, Van de Fliert R, De Haan L, Linszen DH
Schizophrenia Research. 2010 Sept 29 [Epub ahead of print] PMID: 20884179

109. Symptomatic remission and associated factors in a catchment area based population of older patients with schizophrenia.
Meesters PD, Comijs HC, De Haan L, MD, Smit JH, Eikelenboom P, Beekman ATF, Stek M
Schizophrenia Research. 2010 Sep 29 [PubMed - as supplied by publisher] PMID: 20888190

108. Effect of Early Dysphoric Response and Cannabis Use on Discontinuation of Olanzapine or Risperidone in Patients With Early Psychosis.
Nimwegen-Campailla LV, Beveren NV, Laan W, Brink WV, Linszen D, De Haan L
Pharmacopsychiatry. 2010 Sep 13. PubMed PMID: 20839158


106. Social functioning among older community-dwelling patients with schizophrenia: a review
Meesters PD, Stek M, Comijs HC, De Haan L , Patterson TL, Eikelenboom P, Beekman ATF
The American Journal of geriatric psychiatry, 2010s

105. Expanding the range of ZNF804A variants conferring risk of psychosis.
Steinberg S, Mors O, Børglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Böttcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietiläinen OP, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Athanasiu L, Suvisaari J, Lonnqvist J, Paunio T, Hartmann A, Jürgens G, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Breuer R, Möller HJ, Giegling I, Glenthøj B, Rasmussen HB, Mattheisen M, Bitter I, Réthelyi JM, Sigmundsson T, Fossdal R, Thorsteinsdottir U, Ruggeri M, Tosato S, Strengman E; GROUP, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Walshe M, Bramon E, Vassos E, Li T, Fraser G, Walker N, Toulopoulou T, Yoon J, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Peltonen L, Rujescu D, Collier DA, Stefansson H, St Clair D, Stefansson K
Molecular Psychiatry advance online publication 5 January 2010; doi: 10.1038/mp.2009.149

104. Copy number variations of chromosome 16p13.1 region associated with schizophrenia
Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietiläinen OP, Buizer-Voskamp JE, Strengman E, Francks C, Muglia P, Gylfason A, Gustafsson O, Olason PI, Steinberg S, Hansen T, Jakobsen KD, Rasmussen HB, Giegling I, Möller HJ, Hartmann A, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Bramon E, Kiemeney LA, Franke B, Murray R, Vassos E, Toulopoulou T, Mühleisen TW, Tosato S, Ruggeri M, Djurovic S, Andreassen OA, Zhang Z, Werge T, Ophoff RA; GROUP Investigators, Rietschel M, Nöthen MM, Petursson H, Stefansson H, Peltonen L, Collier D, Stefansson K, Clair DM.
Molecular Psychiatry advance online publication 29 September 2009; doi: 10.1038/mp.2009.101

103. Duration of untreated psychosis and ethnicity
Sterk B, Slief EM, Blankers M, Linszen DH, De Haan L
Schizophr Res. 2010 Aug 17. [Epub ahead of print]

102. Three year course of clinical symptomatology in young people at ultra high risk for transition to psychosis
Velthorst E, Nieman DH, Klaassen RMC, Becker HE, Dingemans PM, Linszen DH, De Haan L
Acta Psychiatrica Scandinavica, 2010

101. An exploratory analysis of factors associated with weight change in a 16 week trial of oral versus orally disintegrating olanzapine: the PLATYPUS study
Karagianis J, Landry J, Hoffmann VP, Grossman L, De Haan L, Maguire G, Milev R, Holt S
International Journal of Clinical Practice, 2010, 64, 11, 1520-1529

100. Cannabis use in patients with a first psychotic episode and subjects at Ultra High Risk of psychosis: impact on psychotic- and pre-psychotic symptoms.
Machielsen M, Van der Sluis S, De Haan L
Australian and New Zealand Journal of Psychiatry, 2010, 44 [8], 721-728

99. Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode
Van Tricht MJ, Nieman DH, Koelman JHTM, Van der Meer J, Bour LJ, De Haan L, Linszen D
Biological Psychiatry, 2010 Epub

98. Diffusion Tensor Imaging in the Early Phase of Schizophrenia: What Have We Learned?
Peters BD, Blaas J, De Haan L
Journal of Psychiatric Research, 2010

97. Dopaminergic modulation of human reward system: a placebo controlled dopamine depletion fMRI study
Da Silva Alves F, Schmitz N, Figee M, Abeling N, Hasler G, Van der Meer J, Nederveen A, De Haan L, Linszen DH, Van Amelsvoort T
Journal of Psychopharmacology, 2010 Jun 8

96. Increased saccadic rate during Smooth Pursuit Eye Movements in patients at Ultra High Risk for developing a psychosis
Van Tricht MJ, Nieman DH, Bour LJ, Boeree T; Koelman JH, De Haan L, Linszen DH
Brain and Cognition 2010 Jun 8. [Epub ahead
of print] PubMed PMID: 20538400

95. Reduced context effects on retrieval in first-episode schizophrenia
Talamini LM, De Haan L, Nieman DH, Linszen DH, Meeter M
Plos One, 2010 Apr 27;5(4):e10356

94. Age at onset of cannabis use is associated with age at onset of high-risk symptoms for psychosis.
Dragt, S. Nieman DH, Becker HE; Van de Fliert R, Dingemans PM, De Haan L, van Amelsvoort TA, Linszen DH. Canadian Journal of Psychiatry, 2010, 55(3): 165-171

93. A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia. Ingason A, Giegling I, Cichon S, Hansen T, Rasmussen HB, Nielsen J, Jürgens G, Muglia P, Hartmann AM, Strengman E, Vasilescu C, Mühleisen TW, Djurovic S, Melle I, Lerer B, Möller HJ, Francks C, Pietiläinen OP, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Walshe M, Vassos E, Di Forti M, Murray R, Bonetto C, Tosato S; Genetic Risk and Outcome in Psychosis (GROUP), Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman
R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I., Cantor RM, Rietschel M, Craddock N, Owen MJ, Peltonen L, Andreassen OA, Nöthen MM, St Clair D, Ophoff RA, O'Donovan MC, Collier D, Werge T, Rujescu D. Hum Mol Genet. 2010 Apr 1;19(7):1379-86. Epub 2010 Jan 12. PubMed PMID: 20071346;
PubMed Central PMCID: PMC2838541.

92. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra high risk for developing psychosis and healthy controls. Korver N, Nieman DH, Becker HE, Van de Fliert JR, Dingemans PM, De Haan L, Spiering M, Schmitz N, Linszen DH. Australian and New Zealand Journal of Psychiatry, 2010 44(3) 230-6

91. Verbal fluency as a possible predictor for psychosis.
Becker HE, Nieman DH, Dingemans PM, van de Fliert JR, De Haan L, Linszen DH.
Eur Psychiatry. [Epub ahead of print] PubMed PMID: 20005685

90. Differences in efficacy on substance abuse between Risperidone and Clozapine supports the importance of differential modulation of dopaminergic neurotransmission.
Psychopharmacol Bull. 2009;42(4):40-52.
Machielsen MW, de Haan L

89. Subjective effects of cannabis before the first psychotic episode.
Peters BD, de Koning P, Dingemans P, Becker H, Linszen DH, De Haan L
Aust N Z J Psychiatry. 2009 Dec;43(12):1155-62

88. Neurocognitive functioning before and after the first psychotic episode: Does psychosis result in cognitive deterioration?
HE Becker, DH Nieman, S Wiltink, PM Dingemans, JR VD Fliert, De Haan L, TA van Amelsvoort, DH Linszen
Psychological Med. 2009

87. Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission
Machielsen M, De Haan L
Psychopharmacol Bull. 2009; 42(4):40-52

86. Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia.
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, De Haan L.
Psychiatry Res. 2009

85. White matter connectivity and psychosis in ultra-high-risk subjects: A diffusion tensor fiber tracking study.
Peters BD, Dingemans PM, Dekker N, Blaas J, Akkerman E, van Amelsvoort TA,
Majoie CB, den Heeten GJ, Linszen DH, De Haan L.
Psychiatry Res. 2009 Nov 30. PubMed PMID: 19954931

84. Implicit and explicit affective associations towards cannabis use in patients with recent-onset schizophrenia and healthy controls.
Dekker N, Smeerdijk AM, Wiers RW, Duits JH, van Gelder G, Houben K, Schippers
G, Linszen DH, De Haan L.
Psychol Med. 2010 Aug;40(8):1325-36. Epub 2009 Nov 17.

83. Remission of schizophrenia psychosis and strong reduction of obsessive-
compulsive disorder after adding clozapine to aripiprazole.
Peters B, De Haan L.
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Sep 17

82. Reasons for Cannabis Use and Effects of
Cannabis Use as Reported by Patients with Psychotic Disorders.
Dekker N, Linszen DH, De Haan L.
Psychopathology. 2009 Sep 15;42(6):350-360

81. Crisis intervention and acute psychiatry in Amsterdam: 20 years of change.
van der Post LF, Jonkers JF, Beekman AT, Mulder CL, De Haan L, Mulder WG,
Schoevers RA, Dekker JJ.
Int J Soc Psychiatry. 2010 Jul 17

80. Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for
structural hyperconnectivity?
Peters BD, De Haan L, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH.
Psychopharmacol Bull. 2009;42(2):75-88

79. Polyunsaturated fatty acids and brain white matter anisotropy in recent-onset schizophrenia: a preliminary study.
Peters BD, Duran M, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH, de Haan L.
Prostaglandins Leukot Essent Fatty Acids. 2009 Jul;81(1):61-3. Epub 2009 May 23

78. Common variants conferring risk of schizophrenia.
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge
T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M,
Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T,
Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D,
Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I,
Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB,
Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R,
Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E,
Kiemeney LA, GROUP, Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de
Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N,
Toulopoulou T, Need AC, Ge D, Lim Yoon J, Shianna KV, Freimer NB, Cantor RM,
Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG,
Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P,
Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA; Genetic Risk and
Outcome in Psychosis (GROUP), Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman
R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I.
Nature. 2009 460, 744-7

77. Prevalence of Psychotic Disorders in patients with an Obsessive-Compulsive Disorder
De Haan L, Dudek-Hodge C, Verhoeven Y, Denys, D
CNS spectrums, 2009, 14(8), 415-417

76. Polyunsaturated fatty acids and brain white matter anisotropy in recent-onset schizophrenia: a preliminary study.
Peters BD, Duran M, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH, de Haan L.
Prostaglandins Leukot Essent Fatty Acids. 2009 Jul;81(1):61-3. Epub 2009 May 23

75. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life.
Staring AB, Mulder CL, Duivenvoorden HJ, De Haan L, Van der Gaag M.
Schizophrenia research, 2009, 113, 27-33

74. Subjective Effects of Cannabis Before the First Psychotic Episode deze staat al genoemd
Peters BD, De Koning P, Dingemans P, Becker H, Linszen DH, De Haan L

73. The prescription of antipsychotic medication to patients at ultra high risk for developing psychosis
Nieman DH, Rike WH, Becker HE, Dingemans PM, Van Amelsvoort TA, De Haan L, Van der Gaag M, Denys DA, Linszen DH
International Clinical Psychopharmacology, 2009, 24, 223-228

72. Preliminary Evidence for Reduced Frontal White Matter Integrity in Subjects at Ultra-High-
Risk for Psychosis
Peters B, Schmitz N, Dingemans P, Van Amelsvoort A, Majoie C, Den Heeten G, Linszen D, De Haan L
Schizophrenia research, 2009, 111, 192-193

71. A Randomized Controlled Trial of the Effect of Sublingual Orally Disintegrating Olanzapine Versus Oral Olanzapine on Body Mass Index: the PLATYPUS Study
Karagianis J, Grossman L, Landry J, Reed VA, De Haan L, Maguire J, Hoffmann VP, Milev R
Schizophrenia research, 2009, 113, 41-48

70. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis
Velthorst E, Nieman D, Becker H, Van de Fliert R, Dingemans P, Klaassen R, De Haan L, Van Amelsvoort T, Linszen D
Schizophrenia Research 2009, 109, 60-65

69. Striatal D2 receptor binding in 22q11 Deletion Syndrome: an [123I]IBZM SPECT study
Boot E, Booij J, Zinkstok JR, De Haan L, Linszen DH, Baas F, Van Amelsvoort TA
Journal of Psychopharmocology 2009

68. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine
or risperidone
Van Bruggen M, Van Amelsvoort T, Wouters L, Dingemans P, De Haan L, Linszen D
Psychoneuroendocrinology (2009, IF: 4.4), 34, 989-995

67. Disruption of the neurexin 1 gene is associated with schizophrenia.
Rujescu D, Ingason A, Cichon S, Pietiläinen OP, Barnes MR, Toulopoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Möller HJ, Hartmann A, Hoffmann P, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Andreassen OA, Djurovic S, Hansen T, Werge T, Melle I, Kiemeney LA, Franke B, Buizer-Voskamp JE, Ophoff RA; GROUP Investigators: Kahn RS, Linszen DH, Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I Rietschel M, Nöthen MM, Stefansson K, Peltonen L, St Clair D, Stefansson H, Collier DA.
Hum Mol Genet. 2009; 18(5):988-96 (IF 7.8)

66. White Matter Fibertracking in First-Episode Schizophrenia, Schizoaffective Patients and Subjects at Ultra-High Risk of Psychosis.
Peters BD, De Haan L, Dekker N, Blaas J, Becker HE, Dingemans PM, Akkerman EM, Majoie CB, van Amelsvoort T, den Heeten GJ, Linszen DH.
Neuropsychobiology. 2008 ; 58(1):19-28. (IF 2.4)

65. Recurrent CNVs disrupt three candidate genes in schizophrenia patients.
Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E; Genetic Risk and Outcome in Psychosis (GROUP) Consortium: Kahn RS, Linszen DH, Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I, Sabatti C, Geurts van Kessel A, Brunner HG, Ophoff RA, Veltman JA.
Am J Hum Genet. 2008 Oct;83(4):504-10. (IF 11.1)

64. Cocaine is a major Risk Factor for Antipsychotic Induced Akathisia, Parkinsonism and Dyskinesia.
Maat A, Fouwels A, De Haan L
Psychopharmacology Bulletin 2008;41(3):5-10 (IF: 1.7)

63. Recurrent microdeletions associated with schizophrenia
Stefansson H, Rujescu D, Cichon S, Pietiläinen OPH, Ingason A, Fossdal A, Steinberg S, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Möller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon T, Di Forti M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Mühleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney LA, Franke B, GROUP Investigators: Kahn RS, Linszen DH, Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I, , Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff R, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein D, Nöthen MM, Peltonen L, Collier D, St Clair D, Stefansson
Nature, 2008; 455(7210):232-6 (IF: 26.7)

62. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.
Van Nimwegen LJ, De Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D.
Can J Psychiatry. 2008 Jun;53(6):400-5. (IF: 2.5)

61. Schizophrenia aetiology: D gene-environment interactions hold the key?
Van Os, Leboyer M, Meyer-Lindenberg A, Stefanis N, GROUP Investigators: Kahn RS, Linszen DH, Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I Arango C, Jones P, Kapur S, Lewis S, Murray R, Owen MJ
Schizophrenia Research, 2008, 102: 21-26

60. The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area.
Van der Post L, Schoevers R, Koppelmans V, Visch I, Bernardt C, Mulder N,
Beekman A, De Haan L, Dekker J.
BMC Psychiatry. 2008 14;8:35 (IF: 2.9)

59. A visual metaphor describing neural dynamics in schizophrenia
Van Beveren N, De Haan L
PlosOne 2008, 3 (7): e2577. doi:10.1371/journal.pone.0002577

58. Obsessive-Compulsive Symptoms in a Randomized, Double-Blind Study With Olanzapine or Risperidone in Young Patients With Early Psychosis.
Van Nimwegen L, De Haan L, van Beveren N, Laan W, van den Brink W, Linszen D.
J Clin Psychopharmacol. 2008 28(2):214-218. (IF: 4.6)

57. Cessation of cannabis use by patients with recent-onset schizophrenia and related disorders
Dekker N, De Haan L, Van den Berg S, De Gier M, Becker H, Linszen D
Psychopharmacology Bulletin 2008; 41:142-53.(IF: 1.7)

56. The revised dopamine hypothesis of schizophrenia: Evidence from pharmacological MRI studies with atypical antipsychotic medication
DaSilva F, Figee M, Van Amelsvoort T, Veltman D, De Haan L.
Psychopharmacology Bulletin 2008;41:121-32. (IF: 1.7)

55. Improvement of subjective well-being and enduring symptomatic remission, a 5 year follow up of first episode schizophrenia
De Haan L, van Nimwegen, T. van Amelsvoort, P. Dingemans, D. Linszen
Pharmacopsychiatry, 2008, 41(4):125-8.1-4. (IF: 3.2)

54. AMPT-induced monoamine depletion in humans: evaluation of two alternative [123] IBZM procedures
Boot E, Booij J, Hasler G, Zinkstok J, De Haan L, Linszen D, van Amelsvoort T.
European Journal of Nuclear Medicine and Molecular Imaging 2008; 35(7):1350-6. (IF: 4.0)

53. The Catechol-O-Methyltransferase Gene and Obsessive-Compulsive Symptoms in Patients with Recent-Onset Schizophrenia
Zinkstok J, van Nimwegen L, van Amelsvoort T, De Haan L, Abdulkadir M, Baas F, Linszen D.
Psychiatry Research, 2008, 15, 157:1-8

52. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
Karagianis J, Poole Hoffmann V, Arranz B, Treuer T, Maguire GA, De Haan L, Chawla B
Human Psychopharmacology: Clinical and Experimental 2008, 28 (2) 214-218 (IF: 2.4)

51. Hepatic insulin resistance in antipsychotic naive patients with schizophrenia, a detailed study of glucose metabolism with stable isotopes.
Van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, De Haan L,
Becker H, van Amelsvoort T, Ackermans MT, Fliers E, Serlie MJ, Sauerwein HP.
J Clin Endocrinol Metab. 2008, 93: 572-577 (IF: 5.8)

50. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up
De Haan L, van Amelsvoort T, Dingemans P, Linszen D
Pharmacopsychiatry. 2007 Nov;40(6):264-8. (IF: 3.2)

49. Catechol-O-methyltransferase gene and obsessive-compulsive symptoms in patients with recent-onset schizophrenia: Preliminary results.
Zinkstok J, Van Nimwegen L, Van Amelsvoort T, De Haan L, Yusuf MA, Baas F, Linszen D.
Psychiatry Res. 2008, 157:1-8 (IF: 2.3)

48. Disrupted Dopaminergic Neurotransmission in 22q11 Deletion Syndrome.
Boot E, Booij J, Zinkstok J, Abeling N, De Haan L, Baas F, Linszen D, van Amelsvoort T.
Neuropsychopharmacology.2008, 1252-1258 (IF: 5.9)

47. Effects of a functional COMT polymorphism on brain anatomy and cognitive function in adults with velo-cardio-facial syndrome.
Van Amelsvoort T, Zinkstok J, Figee M, Daly E, Morris R, Owen MJ, Murphy KC, De
Haan L, Linszen DH, Glaser B, Murphy DG.
Psychol Med, 2008,38,89-100 (IF: 3.8)

46. Motivational Interviewing in psychotic disorders
Barkhof E, De Haan L, Meijer KJ, Fouwels AJ, Keet IPM, Hulstijn KP, Schippers GM, Linszen DH
Current Psychiatry Reviews, 2006 (IF: 1.10)

45. Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients
De Haan L, Hoogenboom B, Beuk N, Wouters L, Dingemans P, Linszen D
Psychopharmacology Bulletin, 2006, 39, 25-30 (IF: 1.43)

44. Schizophrenia-associated neural growth factors in peripheral blood. A review
Van Beveren, NJM Van der Spelt, De Haan L, Fekkes,
European Neuropsychopharmacology, 2006, 16, 469-480 (IF: 3.51)

43. The five-factor model of the Positive and Negative Syndrome Scale I: Confirmatory factor analysis fails to confirm 25 published 5-factor solutions
Van der Gaag M, Cuijpers A, Hoffman T, Remijsen M, Hijman R, De Haan L, Van Meijel B, Van Harten P, Valmaggia L, De Hert M, Wiersma D
Schizophrenia Research, 2006, 85, 273-279 ( IF: 4.31)

42. The five-factor model of the Positive and Negative Syndrome Scale II: A ten-fold cross-validation of a revised model Schizophrenia Research
Van der Gaag M, Hoffman T, Remijsen M, Hijman R, De Haan L, Van Meijel B, Van Harten P, Valmaggia L, De Hert M, Cuijpers A, Wiersma D
Schizophrenia Research, 2006, 85, 280-287 (IF: 4.31)

41. Early Withdrawal in a Double-Blind Randomized Clinical Trial with Olanzapine and Risperidone Performed in Adolescents with First Psychosis
Van Nimwegen L, De Haan L
Psychophathology, 2006, 39, 158 (IF: 0.81)

40. Feelings of comfort, self-confidence and safety are related to dopamine D2 receptor occupancy by conventional and new generation antipsychotics
De Haan L, Lavalaye J, Booij J, Linszen D
American Journal of Psychiatry, 2005, 162, 1544-1545 (IF: 7.61)

39. Subjective experiences during dopamine depletion
De Haan L, Booij J, Lavalaye J, Van Amelsvoort T, Linszen D
American Journal of Psychiatry, 2005, 162, 1755 (IF: 7.61)

38. Olanzapine Treatment of Residual Positive and Negative Symptoms
De Haan L, Van Beveren N
American Journal of Psychiatry, 2005, 162: 1392-1393 (IF: 7.61)

37. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia
De Haan L, Booij J, Lavalaye J, Van Amelsvoort T, Linszen D
Psychopharmacology, 2006, 183, 500-505 (IF: 3.99)

36. Modelling the treated course of schizophrenia: Development of a Discrete Event Simulation Model
Heeg BMS, Buskens E, Knapp M, VanCuijpers A, Aalst G, Dries PJT, De Haan L, Van Hout BA
PharmacoEconomics, 2005, 23, 17-33 (IF: 2.20)

35. Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders
De Haan L, Hoogenboom B, Beuk N, Van Amelsvoort T, Linszen D
The Canadian Journal of Psychiatry, 2005, 50 ,519-524 (IF: 2.18)

34. Adolescence, schizophrenia and drug abuse: a window of vulnerability.
Van Nimwegen L, De Haan L, Van Beveren N, Van den Brink W, Linszen D
Acta Psychiatryca Scandinavia, 2005, 427: 35-42 (IF: 2.97)

33. Weight loss after switching from conventional olanzapine to orally disintegrating olanzapine tablets
De Haan L, Van Amelsvoort T, Rosien K, Linszen D
Psychopharmacology, 2004, 175: 389-390 (IF: 3.99)

32. Obsessive-Compulsive Disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders
De Haan L, Oekeneva A, Van Amelsvoort T, Linszen D
European Psychiatry, 2004, 19, 524 (IF: 1.27)

31. Elevated homocysteine levels in schizophrenia
De Haan L, Van Amelsvoort T, Linszen D
American Journal of Psychiatry, 2004, 161, 1131-1132 (IF: 7.61)

30. Risperidone-induced leucopenia and neutropenia: a case report
Sluys M, Güzelcan Y, Casteelen G, De Haan L
European Psychiatry, 2004, 19, 117 (IF: 1.27)

29. Olanzapine vs haloperidol for treatment of schizophrenia
De Haan L, Van Beveren N
JAMA, 2004, 291, 1065 (IF: 23.33)

28. Pericardial and bilateral pleural effusion associated with clozapine treatment
Boot E, De Haan L, Guzelcan Y, Scholte P, Assies H
European Psychiatry, 2004, 19, 65-66 (IF: 1.27)

27. Opinions of mothers towards the first psychotic episode and the start of treatment of their child
De Haan L, Welborn K, Krikke M, Linszen D
European Psychiatry, 2004, 19: 226-229 (IF: 1.27)

26. Early intervention in first epsiode psychosis and schizophrenia: a critical period for patients, families, and professionals
Linszen D, De Haan L, Van Amelsvoort T
Advances in Schizophrenia and Clinical Psychiatry, 2004, 1:11-15 (IF: 1.27)

25. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics; Clinical implications of neuroimaging
De Haan L, Lavalaye J, Van Bruggen M, Van Nimwegen L, Booij J, T van Amelsvoort, Linszen DH
The Canadian Journal of Psychiatry, 2004, 49: 290-296 (IF: 2.18)

24. Overview of neuropathological theories of schizophrenia: from degeneration to progressive developmental disorder
De Haan L, Bakker JM
Psychopathology, 2004, 37: 1-7 (IF: 0.81)

23. School performance in secondary education shows no decline before the onset of a first episode of psychosis in schizophrenia.
van der Gaag M, Wolthaus J, De Haan L, Wykes T
Journal of Mental Health, 2003, 12: 585- 594 (IF: 1.82)

22. Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication
De Haan L, Linszen DH, Lenior ME, Doderlein de Win E, Gorsira R
Schizophrenia Bulletin, 2003, 29: 341-348 (IF: 2.87)

21. Suicide risk in placebo versus the active treatment in placebo-controlled trials for schizophrenia
Storosum JG, Van Zwieten BJ, Wohlfarth T, De Haan L, Khan A, Van den Brink W
Archives of Psychiatry, 2003, 60: 365-368 (IF: 11.21)

20. Subjective experience and D2 receptor occupancy in patients with schizophrenia, treated with low dose Olanzapine or Haloperidol; a randomized double-blind study
De Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans P, Linszen D
American Journal of Psychiatry, 2003, 160: 303-309 (IF: 7.61)

19. Attitudes of Patients towards the First Psychotic Episode and the Start of Treatment
De Haan L, Peters B, Dingemans P, Wouters L, Linszen D
Schizophrenia Bulletin, 2002, 28(3): 431-442 (IF: 2.87)

18. Priorities and satisfaction on the help needed and provided in a first episode of psychosis
A survey in five European Family Associations
De Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L
European Psychiatry, 2002, 17: 425-433 (IF: 1.27)

17. Obsessive-Compulsive Symptoms during treatment with olanzapine and risperidone, a prospective study of 113 patients with recent-onset schizophrenia or related disorders
De Haan L, Beuk N, Hoogenboom B, Dingemans PMAJ, Linszen DH
The Journal of Clinical Psychiatry, 2002, 63: 104-107 (IF: 5.04)

16. Comparable Dopamine 2 receptor occupancy
De Haan L, Van Amelsvoort T
American Journal of Psychiatry, 2002, 159, 2118 (IF: 7.61)

15. Informed consent from behaviourally disturbed patients
Storosum JG, van Zwieten BJ, De Haan L
The Lancet, 2002, 359, 83 (IF: 23,41)

14. Psychometric properties of the Subjective Well-being under Neuroleptics scale (SWN) and the Subjective Deficit Syndrome Scale (SDSS)
De Haan L, Weisfelt M, Dingemans PMAJ, Linszen DH, Wouters L
Psychopharmacology, 2002, 162:24-28 (IF: 3.99)

13. Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder
Jonkers F, De Haan L
Psychopharmacology, 2002, 162: 87-88 (IF: 3.99)

12. Risperidone may induce mania
Güzelcan Y, De Haan L, Scholte WF
Psychopharmacology, 2002, 162: 85-86 (IF: 3.99)

11. Preferences for treatment during a first psychotic episode
De Haan L, van Raaij B, van den Berg R, Jager M, Houweling P,
Stockmann M, Delsing P, Linszen D, Peters B, Wouters L
European Psychiatry, 2001, 16: 83-89 (IF: 1.27)

10. Social functioning and the course of early-onset schizophrenia. Five-year follow-up of a psychosocial intervention
Lenior ME, Dingemans PMAJ, Linszen DH, De Haan L, Schene AH
British Journal of Psychiatry, 2001, 179: 53-58 (IF: 4.61)

9. Dr. De Haan and colleagues reply to Bressan et al.: Dopamine D2 receptor blockade in schizophrenia
De Haan L, Lavalaye J, Linszen DH, Dingemans PMAJ, Booij J
American Journal of Psychiatry, 2001, 158: 972 (IF: 7.61)
8. Interaction of olanzapine with fluvoxamine
De Jong J, Hoogenboom B, Doude van Troostwijk L, De Haan L
Psychopharmacology, 2001, 151: 219-220 (IF: 3.99)

7. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized on olanzapine or risperidone
De Haan L, Lavalaye J, Linszen DH, Dingemans PMAJ, Booij J
American Journal of Psychiatry, 2000, 157:1019-1020 (IF: 7.61)

6. Duration of untreated psychosis and the long-term course of schizophre¬ni¬a
De Haan L, van der Gaag M, Wolthaus J
European Psychiatry, 2000, 15: 264-267(IF: 1.27)

5. Massive increase in serum creatine kinase (CPK) during olanzapine and quetiapine treatment, not during treatment with clozapine
Boot E, De Haan L
Psychopharmacology, 2000, 150: 347-348 (IF: 3.99)

4. Clozap¬ine and obsessions in pa¬tients with recent onset schi¬zophrenia and other psychotic disorders
De Haan L, Linszen DH, Gorsira R
The Journal of Clinical Psychiatry, 1999, 60:364-365 (IF: 5.04)

3. Early intervention, social functioning and psychotic relapse of patients with recent-onset schizophrenic disorders
De Haan L, Linszen DH, Gorsira R
International Clinical Psychopharmacology, 1998, 63-66 (IF: 2.75)

2. Early intervention, untreated psychosis and the course of early schizophrenia
Linszen DH, Lenior ME, De Haan L, Dingemans PMAJ, Gersons BPR
British Journal of Psychiatry, 1998, 84-89 (IF: 4.61)

1. Early detection and intervention in schizophrenia
Linszen DH, Dingemans PMAJ, Lenior ME, Scholte WF, De Haan L, Goldstein MJ
International Clinical Psychopharmacology, 1998, 31-34 (IF: 2.75)

National (refereed) journals

52. Vrouwen, schizofrenie en oestrogeen; neurobiologische hypothesen en interventiestudies
Boerma MAM, Van der Stel JC, Van Amelsvoort T, Linszen DH, De Haan L
Tijdschrift voor Psychiatrie 52 (2010) 4, 235-244

51. Mulder CL, van der Gaag M, Bruggeman R, Cahn W, Delespaul PA, Dries P, Faber
G, De Haan L, van der Heijden FM, Kempen RW, Mogendorff ES, Slooff CJ, Sytema S,
Wiersma D, Wunderink L, van Os J.
Routine Outcome Monitoring for patients with severe mental illness: a consensus document.
Tijdschr Psychiatr. 2010;52(3):169-79

50. Bewegen. [Editorial]
de Haan L
Tijdschr Psychiatr. 2009;51(5):275-7

49. Veranderingen in crisisinterventie en acute psychiatrie; Amsterdamse consulten in 1983 en 2005
Van der Post L, Dekker J, Jonkers J, Beekman A, Mulder C, De haan L, Mulder W, Schoevers R
Tijdschrift voor psychiatrie, 51 (2009) 3, 139 - 150

48. 25 years antipsychotics: back to the future?
Denys D, de Haan L
Tijdschr Psychiatr. 2008;50(13):105-9

47. Preventie en behandeling van somatische complicaties bij antipsychoticagebruik
Cahn W, Ramlal D, Bruggeman R, De Haan L, Scheepers FE, van Soest MM, Assies J, Slooff CJ
Tijdschrift voor Psychiatrie 50 (2008) 9, 579-591

46. Voorkom! [Editorial]
De Haan L.
Tijdschr Psychiatr. 2008; supplement Voorjaarscongres Nederlandse Vereniging voor Psychiatrie

45. Alledaagse vragen en wetenschap [Editorial]
De Haan L.
Tijdschr Psychiatr. 2007;49(11):785-8.

44. [Adolescence, schizophrenia and drug abuse: interactive vulnerability. A hypothesis]
van Nimwegen L, De Haan L, van Beveren N, van den Brink W, Linszen D.
Tijdschrift voor Psychiatrie. 2007;49:169-78

43. Probleeminventarisatie vanuit clienten met een psychose: toepasbaarheid van de Canadian Occupational Performance Measure (COPM)
Teunissen S, Bolten M, De Wilde O, De Haan L
Rehabilitatie, 2007, 1: 35-40

42. Ontwikkeling van psychopathologie [Editorial] [Development of psychopathology]
De Haan L
Tijdschrift voor Psychiatrie. 2006, 48:359-60

41. Boekbespreking: Murphy KC, Scambler PJ: Velo-cardio-facial syndrome: a model for understanding microdeletion disorders
De Haan L
Tijdschrift voor Psychiatrie, 2006, 48, 574

40. Klinische respons op antipsychotica al binnen 24 uur
Dekker N, De Haan L
Tijdschrift voor Psychiatrie, 2006, 48, 242

39. Effectiviteit van antipsychotica bij patiënten met chronische schizofrenie
Schulte PFJ, De Haan L
Tijdschrift voor Psychiatrie, 2006, 48, 243-244

38. Resterende neuropsychologische stoornissen, structurele en functionele hersenafwijkingen na langdurig cannabisgebruik
Weeda MR, Peters BD, De Haan L , Linszen DH
Tijdschrift voor Psychiatrie, 2006, 48, 185-193

37. Het optimale niveau van dopaminerge neurotransmissie
De Haan L
Nederlands Tijdschrift voor Geneeskunde, 2005, 149, 1721-1722

36. Psychose en intellectuele prestatie
Van Nimwegen L, De Haan L
Tijdschrift voor Psychiatrie, 2005, 47, 558

35. De “delayed-onset hypothese” van het effect van antipsychotica: getoetst en verworpen.
Dekker N, De Haan L
Tijdschrift voor Psychiatrie, 2004, 46, 781

34. Loont het om nieuwe-generatie antipsychotica te gebruiken ter voorkoming van terugval bij schizofrenie?
De Haan L
Maandblad Geestelijke Volksgezondheid, 2004, 59, 852-855

33. Boekbespreking: Eling P, de Haan E, Hijman R, Schmand B: Cognitieve neuropsychiatrie
De Haan L
Tijdschrift voor Psychiatrie, 2004, 46, 442-443

32. Mannen met schizofrenie waarderen geur op een afwijkende wijze
De Haan L
Nederlands Tijdschrift voor Geneeskunde, 2004, 148, 544

31. Relevantie van het metabolisme van homocysteine voor de behandeling van schizofrenie
De Haan L, Güzelcan Y
Tijdschrift voor Psychiatrie, 2004, 46, 93-99

30. Genetisch onderzoek bij schizofrenie: een overzicht.
Figee M, Van Amelsvoort T, De Haan L, Linszen DH
Tijdschrift voor Psychiatrie, 2004, 46, 15-26

29. Boekbespreking: Schothorst PF, Emck C, Hop J: Jongeren met psychotische stoornissen, behandeling in een zorglijn.
De Haan L
Maandblad Geestelijke Volksgezondheid, 2003, 58: 972-974

28. Recensie: Solms, M. & Turnbull, O. The brain and the inner world. An introduction to the neuroscience of subjective experience.
De Haan L
Tijdschrift voor Psychiatrie, 2003, 45: 382

27. Dysconnectiviteit bij schizofrenie: afwijkingen in de witte stof van de hersenen
Peters BD, De Haan L, Linszen DH
Tijdschrift voor Psychiatrie, 2003, 45: 507-515

26. Dopamine, importantie en psychose
De Haan L, Kapur S
Maandblad Geestelijke Volksgezondheid, 2003, 58: 228-235

25. Boekbespreking: Aalsvoort, van der L.Met gezond verstand. Herstel van schizofrenie langs de natuurlijke weg.
De Haan L
Maandblad Geestelijke Volksgezondheid, 2003, 58: 306-308

24. Antwoord aan Verhoeven en Tuinier: schizofrenie en het 22q11 deletie syndroom
Vorstman JAS, Van Amelsvoort T, Güzelcan Y, De Haan L, De Ranitz AGS, Udink ten Cate FEA, Van Schaik P, Kahn RS, Linszen DH, Beemer FA
Nederlands Tijdschrift voor Geneeskunde, 2003, 44, 318

23. Cognitie, subjectieve ervaring, dopamine en antipsychotica
De Haan L
Tijdschrift voor Psychiatrie, 2002, 44, 759-766

22. Het 22q11 deletie syndroom en schizofrenie
Güzelcan Y, Van Amelsvoort T, De Haan L, Linszen DH, van Schaik P
Nederlands Tijdschrift voor Geneeskunde, 2002, 43, 2019-2021

21. Klinische consequenties van interactie tussen olanzapine en fluvoxamine
de Jong J, Hoogenboom B, Doude van Troostwijk L, De Haan L
Tijdschrift voor psychiatrie, 2002, 44, 703-707

20. De "schizofrenie" ontmanteld reactie op het artikel van P. Vlaminck
De Haan L
Maandblad Geestelijke volksgezondheid, 2002, 57: 659-660

19. Dopamine receptorbezetting door antipsychotica: een overzicht van SPECT en PET onderzoek
Lavalaye J, De Haan L, Linszen DH
Tijdschrift voor Psychiatrie, 2002, 44: 39-44

18. Neurobiologische hypothesen over de pathogenese van schizofrenie. Van degeneratie tot progressieve ontwikkelingsstoornis
Bakker JM, De Haan L
Tijdschrift voor Psychiatrie, 2001, 43: 21-29

17. Sociaal functioneren en het beloop van recent onstane schizofrenie. Een vervolgstudie over de eerste vijf jaar
Lenior ME, Dingemans PMAJ, Linszen DH, De Haan L, Schene AH
Tijdschrift voor Psychiatrie, 2001, 43: 219-232

16. Rehabilitatie van klassieke antipsychotica, een overzicht van meta-analyses
De Haan L, Van Bruggen M, Lavalaye J, Scholte WF, Wouters L, Storosum J, Linszen DH
Tijdschrift voor psychiatrie, 2001, 43: 259-264

15. Het beloop van schizofrenie gedurende vijf jaar na een eerste opname in de westerse wereld, een meta-analyse
De Haan L, Timmer T, Linszen DH, Wouters L, Lenior ME
Tijdschrift voor Psychiatrie, 2001, 43: 559-565

14. Vrouwen met schizofrenie: onderzoeksbevindingen en implicaties voor de behandeling
Peters E, De Haan L
Tijdschrift voor psychiatrie, 2001, 43: 639-644

13. Recensie: Scheepers F: The effects of atypical antipsychotics in the brain of schizophrenic patients
De Haan L
Maandblad Geestelijke volksgezondheid, 2001, 12, 1204-1205

12. Recensie: Harrison, P.J., & Roberts, G.W. (red.) The neuropathology of Schizophrenia
De Haan L
Tijdschrift voor Psychiatrie, 2001, 43, 834-835

11. Dwangsymptomen bij schizofrenie: aanwijzingen voor een aparte groep
Beuk N, De Haan L
Tijdschrift voor Psychiatrie, 2000, 42: 347-351

10. Effectiviteit van individuele psychotherapie bij schizofrenie. Een overzicht van recent onderzoek
De Haan L, Bakker JM
Tijdschrift voor Psychiatrie, 2000, 42: 751-758

9. Duur onbehandelde psychose en beloop van schizofrenie
De Haan L, Bottelier M
Tijdschrift voor Psychiatrie, 1999, 239-243

8. Psychosebehandeling met een lage dosering D2-antagonist
De Haan L, Maksmovic I
Tijdschrift voor Psychiatrie, 1999, 287-291

7. Verbetering van therapietrouw bij de behandeling van schizofrenie patienten met antipsychotica
De Haan L, Bremmer M
Tijdschrift voor Psychiatrie, 1999, 665-669

6. Reactie op "Comorbiditeit van psychiatrische stoornissen in de Nederlandse bevolking…" betreffende de gevoeligheid van de CIDI voor psychotische stoornissen
Dingemans PMAJ, De Haan L, Linszen DH
Tijdschrift voor Psychiatrie, 1999, 41:58-61

5. Regionale aanpak van initiele niet-affectieve psychosen (Reactie op Vlaminck)
Linszen DH, De Haan L, Scholte WF
Maandblad Geestelijke Volksgezondheid, 1999; 10:1061-1066

4. Subjectieve ervaringen van patiënten met schizo¬fre¬nie gerelateerd aan behan¬deling met antipsychotica
Ten Brink C, De Haan L, Kne¬gtering H
Tijdschrift voor Psychiatrie, 1998, 40: 238-245

3. Vroegtijdige intensieve interventie, sociaal functioneren, psychoserecidief en suicide bij patienten met recent onstane schizofrenie en verwante stoornissen
De Haan L, Linszen DH, Gorsira R
Tijdschrift voor Psychiatrie, 1997, 24-36

2. Gestructureerd klinisch interview voor de positieve en negatieve syndroom schaal (SCI-PANSS)
Linszen D, De Haan L, Kuipers T, Dingemans P
Academisch Medisch Centrum, Divisie Psychiatrie, 1994, Amsterdam

1. Systeemconsultatie op een opname afdeling
Maillette de Buy Wenniger WF, De Haan L
Tijdschrift voor psychotherapie, 1992; 18: 2-11

Books or contributions to books

Brochure: Voor het eerst een psychose
De Haan L, Stavenuiter B, Stockmann M, Vlaminck P
38 pagina's
Ypsilon, 2009

Preventie en behandeling van somatische complicaties bij antipsychoticagebruik 2009
Cahn W, Ramlal D, Bruggeman R, De Haan L, Scheepers FE, Van Soest MM, Assies J, Slooff C
In: Complicaties bij behandeling van mensen met een psychose
Slooff C, Withaar F, Van der Gaag M
Koninklijke van Gorcum
Pag 503-523

Psychosen bij jeugdigen
De Haan L, Becker H
In: Leerboek voor kinder- en jeugd psychologie en psychiatrie
Dorelijer T, Huisman J, Vermeiren R, Boer F, De Haan E, Red
Pag 385-394

Medicamenteuze behandeling van psychotische stoornissen
De Haan L, Bruggeman R
In: Zorg rondom schizofrenie, Van Meijel B, Kuipers T, red
Pag 39-57
Bohn Stafleu van Loghum, 2006

Medewerker Pinkhof Geneeskundig woordenboek

The catechol-O-methyltransferase gene and schizophrenia.
Zinkstok J, van Amelsvoort T, De Haan L, Baas F, Linszen D.
Chapter in “Trends in Schizophrenia Research” edited by Mary V. Lang, pp. 45-78COMT gene and schizophrenia

Mijn eten is vergifitigd door de duivel
Dekker N, De Haan L
In: Probleemgeorienteerd denken in de Psychiatrie Van Balkom T, Hengeveld MW red
Pag 249- 256
De Tijdstroom, Utrecht, 2005

Sinds ik die pillen slik zijn mijn benen zo onrustig
Dekker N, De Haan L
In: Probleemgeorienteerd denken in de Psychiatrie Van Balkom T, Hengeveld MW red
Pag 315- 323
De Tijdstroom, Utrecht, 2005

Psychotische stoornissen
De Haan L, Kahn R
In: Leerboek Psychiatrie Hengeveld MW, Van Balkom T red
Pag 217- 232
De Tijdstroom, Utrecht, 2005

Cannabis abuse and the course of schizophrenia
Linszen DH, Peters B, De Haan L
Pag. 119-126
In: Marihuana and Madness. D. Castle, R. Murray, editors
Cambridge University Press
Cambridge, 200
Awarded the British Medical Association Mental Health Book of Year 1st prize

Subjectieve ervaring en antipsychotica
Pag 171- 183
De Haan L
In: Jaarboek voor psychiatrie en psychotherapie 2003-2004
Schene AH, Boer F, Heeren TJ, Henselmans HWJ, Sabbe B, Van Weeghel J (red)
Bohn Stafleu Van Loghum
Houten/Mechelen 2003

Co-operation in case of imminent relapse
De Haan L, Scholte WF
In: Community care and psychiatric rehabilitation
Van Weeghel J (red)
Sphere, Kiev Ukraine 2002

Psychose, informatie voor clienten, famlie en andere betrokkenen
Lid van de adviescommissie
Brochure Trimbos-instituut, Utrecht, 2002

Breaking the silence. Carers' views on the help given during the first episode of psychosis, a European perspective
De Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L
Publication of EUFAMI, Madrid, 2001 (The European Federation of Associations of people with a Mental Illness)

Die hilfsangebote bei einer ersten psychotischen episode aus der sicht der betreuende angehorigen. Eine Europaische studie.
De Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L

Anghorigas synpunkter pa den hjalp som givits vid forsta psykosepiod. Ett Europeiskt perspektiv
De Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L

El punto de vista delcuidador sobre la ayuda proporcionada en un primer episodio de psicosis. Una perspectiva Europea
De Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L

Patients’ perspectives, subjective experiences and attitudes of patients with recent onset schizophrenia
De Haan L
Thesis, University of Amsterdam, Amsterdam, 2001

Het belang van hospitalisatie bij een eerste psychotische episode
Pag 137-146
De Haan L
In: Schizofrene stoornissen
Peuskens J, De Clerq M (red)
Academia Press, Gent 1999

Antipsychotica
Pag 47-61
De Haan L
In: Gezinsbegeleiding bij psychotische patienten
Dingemans PMAJ, de Pater-Zijlstra MA (red.)
Bohn Stafleu Van Loghum, Houten/Diegem 1998

Brochure: Voor het eerst een psychose
De Haan L, Stavenuiter B, Stockmann M, Vlaminck P
38 pagina's
Ypsilon, 1998

Samenwerken bij dreigende terugval
Pag 203-211
De Haan L, Scholte WF
In: Onderzoek van Schizofrenie: implicaties voor de behandeling
Dingemans PMAJ, van der Bosch R, Kahn R, Schene AH (red)
Bohn Stafleu Van Loghum, Houten 1995


Other: Abstracts

Subjective Experience and Dopamine D2 Receptor Occupancy in Patients treated with Antipsychotics:
Clinical Implications
De Haan L
The International Journal of Neuropsychopharmacology, 2006, 9, sp76.05

Obsessive Compulsive Symptoms in a Randomized Double Blind Study with Olanzapine or Risperidone in Young
Patients with Recent-onset Schizophrenia or Related Disorders.
Van Nimwegen L, De Haan L, Van Beveren N, Laan W, Van den Brink W, Linszen D
Schizophrenia Research, 2006, 69, 99-100

Subjective Well-being and Craving for Cannabis in First Psychosis, a Randomized Double Blind
Comparison of Olanzapine vs Risperidone
Van Nimwegen L, De Haan L, Van Beveren N, Laan W, Van den Brink W, Linszen D
Schizophrenia Research, 2006, 69, 141

MATCH: The effect of motivational interviewing on adherence to antipsychotic treatment in schizophrenia
Barkhof E, Meijer CJ, De Haan L, De Sonneville LJM, Linszen D
Schizophrenia Research, 2006, 69, 100-101

The COMT gene and OCS in patients with recent onset schizophrenia
Baas F, Zinkstok J, Nimwegen L, Van Amelsvoort T, De Haan L, Linszen D.
Schizophrenia Research, 2006, 69, 188

A three year follw-up of OCD and OCS in 148 patients with a first episode of schizophrenia, schziophreniform
or schizoaffective disorder: aggression and substance abuse
De Haan L, Van Amelsvoort T, Dingemans P, Linszen D
Schizophrenia Research, 2006, 69, 232

Dopaminergic neurotransmission in 22Q11deletion syndrome before and after dopamine depletion
Boot E, Booij J, Zinkstok J, De Haan L, Linszen D, Abeling N, Van Amelsvoort T
Schizophrenia Research, 2006, 69, 271

Can long term critical period interventions in the early phase of schizophrenia like disorders prevent deterioration
Linszen D, De Haan L, Dingemans P, Wouters L
Schizophrenia Research, 2006, 69, 7

Opinions of mothers towards the first psychotic episode and the start of treatment of their child
De Haan L, Welborn K, Krikke M, Linszen D
Schizophrenia Research, 2004, 67, 33

Early and 3-year sustained intervention in first episode schizophrenia: relapse, stabilization and its predictors
Linszen DH, Wouters L, Dingemans PMAJ, De Haan L, Nieman D
Schizophrenia Research, 2004, 67, 18

Confirmatory factor analysis of the positive and negative symptom scale
Van der Gaag M, Cuijpers A, Wiersma D, De Haan L, Hijman R, Van Harten P, Van Meijel B, De Hert M, Arends J
Schizophrenia Research, 2004, 67, 72-73

Subjective reasons for cannabis use and prodromal symptoms in recent-onset schizophrenia and in a general population
Peters BD, De Koning PP, De Haan L, Linszen DH
Schizophrenia Research, 2004, 67, 219

Reduced white matter integrity in recent-onset schizophrenia as assessed with diffusion tensor imaging
Peters BD, Vlieger E, De Haan L, Majoie CB, Den Heeten GJ, Linszen DH
Schizophrenia Research, 2003, 204-205

Treatment reluctance in first episode schizophrenia: Lack of insight, non-compliance and cannabis abuse predict bad outcome after eighteen months intervention
Linszen DH, De Haan L, Dingemans P, Van Bruggen M, Hofstra N, Van Engelsdorp H, Ter Smitten M
Schizophrenia Research, 2003, 325

Psychometric properties of the Subjective Well-being under Neuroleptics scale (SWN) and the Subjective Deficit Syndrome Scale (SDSS)
De Haan L, Weisfelt M, Dingemans PMAJ, Linszen DH, Wouters L
Schizophrenia Research, 2001, 49: 282

Obsessions in pa¬tients with schi¬zophrenia during treatment with clozapine
De Haan L, Linszen DH, Gorsira R
Psychosis and Schizophrenia, 2001, 1, 9 (extended abstract)

How is optimal dosage to be determined? Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized on olanzapine or risperidone
De Haan L, Lavalaye J, Linszen DH, Dingemans PMAJ, Booij J
Schizophrenia Research, 2000, 41: 26 (oral presentation at the Biennal Winterworkshop on schizophrenia in Davos)

Attitudes of patients concerning the first psychotic episode and the start of treatment
De Haan L, Peters B, Dingemans PMAJ, Wouters L, Linszen DH
Schizophrenia Research, 2000, 41: 227

Obsessive-Compulsive Symptoms during treatment with olanzapine and risperidone, indication of differences in the long-term. Preliminary results from a prospective study
De Haan L, Beuk N, Linszen DH, Dingemans PMAJ
Schizophrenia Research, 2000, 41: 191

Early intervention and the course of recent onset schizophrenia
Linszen DH, Dingemans PMAJ, Lenior ME, De Haan L, Scholte WF
European Psychiatry, 1998, S12
 

Research programmes

Recent onset schizophrenia

Psychosis, Variation, Phase, Profile

Needs, circum¬stances and characteristics of people with psychotic disorders differ substantially. In research we need to capture this variation in phase and profile.
We focus on patients with recent onset psychotic disorders and their variation - in therapeutic and subjective response on antipsychotic treatment, - co-morbidity and - cognitive and social functioning.
These variations are thought to be partly related to differences in dopaminergic neurotransmission.
Increased striatal dopamine synthesis and dopamine reactivity to stress is related to dysregulated salience attribution and thereby psychotic symptoms. Modulation of dopaminergic neurotransmission by antipsychotic medication and illicit drugs affects symptoms and wellbeing.

The three main strategic research objectives of the Early Psychosis Department are:
1. Finding brain and behavioral characteristics of specific disturbances in early psychotic disorders.
a. Identify the relationship between neural activity and specific disturbances in psychotic disorders.
b. Identify genetic and environmental factors associated with variation in early psychotic disorders.
c. Identify biological markers in patients with psychotic disorders.
2. Define the developmental trajectories around onset of psychotic disorders to determine when and how to intervene.
3. Develop better interventions directed at the diverse needs, circum¬stances and characteristics of people with early psychotic disorders.
 

Faculty
Prof. dr. L. de Haan

Postdocs
Dr. N.J.M. van Beveren MD (Erasmus MC)
Dr. N. Dekker MD
Dr. R.M.C. Klaassen MD
Dr. N. Korver-Nieberg
Dr. M.W.J. Machielsen MD
Dr. P.D. Meesters MD
Dr. C.J. Meijer PhD
Dr. J.H. Meijer MD
Dr. D.H. Nieman
Dr. L.J.M. van Nimwegen MD
Dr. B.D. Peters MD
Dr. M.J. van Tricht (Arkin)
Dr. E. Velthorst MSc

PhD Students
Drs. H.E. Becker MD
T.J. Burger
N. Cakici
F.A. van Dijk
Drs. P. Doedens
R.M. van Eck MD (Arkin)
J.M. Hagen
S. Medema
Drs. F.J. van der Meer
F.L. Oosterwijk
K. Pos
Drs. G. van Rooijen
Drs. B. Sterk MD
Drs. A. Sutterland MD
Drs. M. Swets MD
A.M. Tedja
R. Van der Valk MSc
J.M. Vermeulen MD

Other research related activities
  • Membership of medical or scientific committee, Nederlandse Vereniging voor Psychiatrie, Voorzitter Commissie Wetenschappelijke Activiteiten
  • Board of directors / Trustees / Supervisory board, Genetic Risk and Outcome of Psychosis
  • Membership of editorial board / Editorship, TIJDSCHRIFT VOOR PSYCHIATRIE
Current research funding
  • AMC
  • Amsterdam Neuroscience
  • Europese Unie
  • King's College London
  • Parnassia Groep
  • ZonMw